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Abstract 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Main site 
of infection are the lungs, but infection of other organs can occur in later stages. First line 
therapy includes antibiotic therapy using a combination of three out of four drugs (rifampicin, 
isoniazid, ethambutol, and pyrazinamide), for a period of at least 26 weeks. In the case of 
rifampicin, fairly high daily doses of 10 mg/KGBW (600 mg max.) are to be administered, 
which often times is accompanied by unwanted side effects that might not only affect the 
patient´s overall status, but could also compromise compliance and adherence to the 
therapeutic regimen. In order to achieve therapeutically effective concentrations at the site of 
infection (the lungs) whilst minimizing systemic exposure to avoid unwanted side effects, 
inhalable antibiotic therapy is desirable. Much effort has already been made to develop 
respirable dry powder dosage forms of rifampicin, and spray drying was shown as suitable 
method to produces rifampicin particles with favorable aerosol performance. Two solvent free 
polymorphs as well as several solvates are described in literature. This work systematically 
investigated aerosol properties of formulations spray dried from solutions and suspension of 
rifampicin in common solvents, in order to assess if different (pseudo-) polymorphs show 
suitability for a potential aerosol therapy. In a first study, formulations spray dried from 
ethanol, methanol, isopropyl alcohol, acetone, dichloromethane, and water were manufactured 
and assessed for their aerodynamic (NGI), as well as their solid state (XRPD) properties. 
Suitable candidates were found in samples spray dried from ethanol, methanol, and water, 
yielding three crystalline and one amorphous formulation. Additionally an amorphous 
reference formulation showing the characteristic shape of collapsed spheres, often seen when 
spray drying solutions, was manufactured. Selected formulations were repeated and 
investigated more closely with special focus on crystallographic properties or mechanism of 
particle formation in the case of crystalline, or amorphous formulations respectively. All 
formulations investigated in the second study showed good aerosol properties with fine 
particle fractions (FPF, being the fraction of the dose with an aerodynamic diameter ≤ five 
µm, which is indicative for lung deposition) of about 40%, but one formulation spray dried 
from aqueous solutions of rifampicin in water showed excellent aerosol properties with FPFs 
as high as 90%. Crystallographic studies showed that suspensions spray dried from water are 
most likely a member of an isostructural series of solvates that was firstly described as 
rifampcin pentahydrate. Contrary, samples spray dried from ethanol and methanol were 
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shown to be members of a common isostructural series, but could not clearly be allocated to 
other (pseudo-) polymorphs already reported in literature. In order to investigate the 
mechanism of particle formation when spray drying samples from watery or 
isopropylalcoholic solutions, drying kinetics of individual droplets were investigated using an 
acoustic levitator. It was found that in watery solution rifampicin displays early crust 
formation, which detaches from the liquid core that eventually is removed from the system. 
As a consequence remaining particles consist of the highly collapse shell only, creating a 
powder of low density with excellent aerosol properties. 
For efficient formulation design, it is highly desirable to develop suitable in vitro tools being 
predictive of in vivo performance of the formulation. It is known from literature that 
aerodynamic diameters smaller than five µm are indicative for lung deposition, but standard 
in vitro test methods as for example the NGI, which are designed to provide a suitable test 
system in an QC environment, fail to provide accuracy in full dose assessment necessary. 
Amongst others, lack of physiological relevance of the NGIs induction port, has been 
identified as a reason for this. Much effort has already been made to develop more biorelevant 
deposition models, but limited information on the impact of modifications of the IP on aerosol 
data using the NGI is available. Additionally, approaches most intensely investigated 
represent idealized physiological conditions of an averaged patient collective, which is a 
reasonable approach in many applications, but a more dynamic model might be desirable to 
investigate lung deposition in special patient populations (e.g. children or patients with 
pathophysiological alterations) or to investigate fundamental mechanisms of particle 
deposition in the relevant regions. In this study we presented a modified induction port to be 
used with the NGI that was manufactured based on geometries (trachea) derived from a 
computer tomographic scan of a patient, and 3D printed using FDM technique. In a first study 
it was investigated which types of aerosol formulations are critical in terms of tracheal 
deposition, by assessing the aerodynamic properties of preparations of salbutamol, formulated 
as pressurized metered dose inhaler (pMDI), dry powder inhaler, and solution for 
nebulization, respectively. Additionally, the impact of using a valved holding chamber was 
investigated. It was found that using the modified induction port offered no additional 
information in the case of the dry powder, and nebulizer formulation. Contrary, the pMDI 
formulation showed increased deposition, which consequently translated into a lower FPF, 
which was found to correlate better to in vivo data reported in literature. In a second study, 
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additional pMDI formulations, which were selected on availability of in vivo data of lung 
deposition in literature, were assessed and results of in vitro / in vivo (IVIVC) correlation 
were found more accurate than ones obtained using the regular induction port, which is 
monographed in the European and United States pharmacopoeia. Additionally, another 
modified induction port was manufactured to get a more accurate understanding of the factors 
responsible for increased tracheal deposition in certain formulations, and it was confirmed 
that adding physiologically more accurate geometries to the induction port is beneficial for 
IVIVC. It was concluded that besides a physiologically relevant trachea, the next model 
should also include more biorelevant mouth/throat region, as this was found relevant in 
certain formulations.  
The novel induction port was also used to estimate in vivo performance of the rifampicin 
formulations investigated. Though increased deposition in the induction port, which 
correlated to a decrease in expected lung deposition, was found, differences were found at a 
magnitude, which probably cannot be resolved in an in vivo setting. Thus good to excellent 
aerosol performance achieved could translate into good performance in vivo. 
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1 Introduction and theoretical background 
 
1.1 Physiology of the respiratory tract  
Similarly, to most other terrestrial vertebrate species, humans regulate their blood oxygen and 
carbon dioxide level by proactive exchange of the atmospheric gas phase over a perfused, 
permeable membrane. Due to this constant exchange, a gradient of gas concentrations in 
blood and atmosphere is maintained, which facilitates passive diffusion of oxygen and carbon 
dioxide molecules into, or from blood circulation respectively. Gas exchange occurs in a 
distinct organ called the lungs, which are part of the respiratory tract. The respiratory tract can 
be subdivided into the upper and the lower respiratory tract. The upper respiratory tract is 
formed by oral and nasal cavities, pharynx, and larynx. The lower respiratory tract consists of 
the trachea, bronchi, and lungs. Main function of the upper respiratory tract is to condition the 
air inspired, which includes adaptation of gas to body temperature, as well as humidification, 
and purification by removal of e.g. dust or other particles. Moving to the lower respiratory 
tract, inspired gas firstly passes the trachea, which is a tubular membrane surrounded by 
cartilaginous rings, connecting larynx and the lungs. At its proximal end, the trachea 
subdivides into the primary bronchi, which are two branches supplying the left and right lung 
respectively. The bronchial system divides another 22 times until bronchioles terminate into 
alveolar sacs. Based on its physiological function, the bronchial system can be subdivided 
into two zones. The main physiological purpose of the conducting zone, which comprises of 
the first 16 generations of bronchi and terminal bronchioles, is to conduct gases inspired to the 
deep lungs. In the respiratory zone, which comprises of the remaining 7 generations of 
respiratory bronchioles as well as alveolar ducts and alveoli, gas exchange occurs. Alveoli are 
terminal cavities, where mainly type I pneumocytes and endothelial cells of the supplying 
capillary system form a thin barrier between the ambient atmospheric gas and the blood (the 
blood-gas-barrier), which typically is as low as 500 nm thick. Other cell types present in the 
alveolar epithelium include type II (= granular) pneumocytes whose main function is the 
secretion of surfactant, as well alveolar macrophages, lymphocytes, and mast cells, which are 
part of the immune system. Due to the high number of subdivisions in the bronchial system, 
about 3 x 108 alveoli are present, this gives rise to a high surface area of about 70 m2, 
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available for gaseous diffusion. The lungs are located inside the pleural sac in the chest. They 
are passively inflated by contraction of muscles of respiration (mainly the diaphragm, which 
divides thoracic and abdominal cavities), expanding the volume of the thoracic cavity, which 
is connected to the parietal pleura of the pleural sac. Upon relaxation of the muscles, 
exhalation occurs passively. Forced exhalation is facilitated by contraction of abdominal wall 
muscles. The total volume of the lungs is about 6000 mL, the tidal volume is the volume 
exchanged during a regular breathing cycle; approximately 500 mL. As a typical breathing 
frequency at rest would be 0.2 Hz (i.e. 12 cycles per min.), the total volume of the lungs is 
exchanged once each minute. If needed, the inspirational volume can be increased by another 
3000 mL (= inspiratory reserve volume) and 1200 mL can be exhaled upon forced expiration 
(expiratory reserve volume) [1,2].  
 
1.2 Pathophysiology of the respiratory tract 
Most common pathophysiological conditions of the respiratory tract are associated with 
infections of the upper airways that are usually caused by virus infections, sometimes with the 
occurrence of secondary bacterial infections. Though having a high prevalence, these 
infections do not often require causal therapeutic intervention and so will not be discussed 
further here. Following, selected indications for inhalable therapy as well as general 
approaches for treatment will be briefly discussed.  
 
1.2.1 Asthma 
Asthma is an inflammatory disease of the respiratory tract that is characterized by hyper 
reactivity of the bronchial system. Typically, patients suffer from reoccurring episodes of 
dyspnoea, which is related to bronchoconstriction, oedema in the airways, increased secretion 
of viscous mucus, or in most cases a combination of these causes. According to its genesis, it 
can be classified as allergic or intrinsic asthma. In allergic asthma, hyper reaction is triggered 
by exogenous stimuli (e.g. pollen) that causes an allergic reaction, which in many cases is 
immunoglobulin E (IgE) mediated. With disease progression, asthma inducing stimuli might 
become unspecific, which is related to a general proceeding of hyper reactivity and might be 
amplified by a positive feedback mechanism involving the vagus nerve. In contrast, intrinsic 
3 
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asthma is not initially based on specific exogenous stimuli, but rather shows the unspecific, 
vagus mediated, mechanism. Intrinsic asthma attacks can be triggered by several factors 
including, for example: cold air, tobacco smoke, exercise, or dust [2]. Besides training and 
education as well as precise assessment and monitoring of the patient’s state, control of 
environmental factors, and control of comorbid conditions affecting the asthma, 
pharmacotherapy is important to successfully treat asthma. Substances used in 
pharmacotherapeutic treatment can be divided into two distinct classes: Long term control 
medications, which are used to maintain control and prevent exacerbations, and immediate 
relief medications, which are used to treat acute symptoms occurring. Table 1 gives an 
overview on drug classes used in asthma therapy. Depending on the severity of the asthma, 
different combinations of aforementioned drug classes can be applied according to an 
escalation scheme [3]. Due to the complexity of the disease, detailed information on 
interventions and escalation stages will not be provided here and the reader is kindly referred 
to the relevant guidelines. 
Table 1. Overview on drug classes used in asthma therapy. 
 
Substance class Example substance
Long - term mediction Corticosteroids Budesonide
Beclomethasone dipropionate
Fluticasone propionate
Mometasone furoate
Ciclesonide
Long acting  2 agonists Salmeterol xinafoate
Formoterol fumarate dihydrate
Immunomodulators Methotrexate
Omalizumab
Leukotriene modifiers Montelukast
Zafirlukast
Methylxanthines Theophylline
Mast cell stabilizers Cromolyn sodium
Nedocromil
Quick - relief medication Anticholinergics Ipratropium bromide
Short acting  2 agonists Salbutamol sulfate
1
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1.2.2 Chronic obstructive pulmonary disease (COPD) 
COPD is a chronic disease of the respiratory tract that is mainly characterized by restricted 
airflow caused by abnormalities of (small) airways and/or alveoli (emphysema). Other 
symptoms associated with COPD are dyspnoea, hypoxia, chronic cough, inflammation, and 
sputum production. The main causes for COPD are reported as exposure to noxious gases and 
particles (e.g. tobacco smoke, as well as indoor or outdoor air pollution), genetic 
predisposition, or comorbidity (e.g. asthma, bronchitis), and infections [4]. Clinically, 
persistent airflow restrictions are assessed by means of spirometry and a forced expiratory 
volume as a one second (FEV1)/forced vital capacity (FVC) ratio, and a value of <0.7 post 
bronchdilatator exposition is understood as confirmative for COPD. For effective COPD 
therapy, smoking cessation is essential. Pharmacotherapeutic interventions may provide 
reduction of symptoms (at rest or upon exercise), as well as frequency and severity of 
exacerbations. However, as of now, there is little supporting positive evidence of 
pharmacotherapeutics affecting the long-term decline of lung function. Table 2 gives an 
overview on drug classes used in COPD treatment. Additionally, depending on degree of 
severity of hypoxia, oxygen therapy might be indicated for use. Similarly to asthma, COPD is 
a highly complex disease and the reader is kindly referred to the respective guideline, for 
example “The Global Initiative for Chronic Obstructive Lung Disease” [5], that provides 
additional information for dosing regimen, escalation stages etcetera. 
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Table 2. Overview on drug classes used in COPD therapy. 
 
1.2.3 Infectious diseases 
As previously mentioned, viral infections of the upper airways with or without bacterial co-
infections are the most common pathophysiological condition and usually require no causal 
therapy. In more severe cases, systemic antibiotic therapy can be indicated if bacterial co-
infections can be confirmed. In contrast, infections (bacterial or viral) of the lower respiratory 
tract may cause severe complications with a broad variety of clinical symptoms, for example, 
inflammation of the lung tissue (oedema), respiratory distress, or sepsis. In case of bacterial 
infections of the lungs, inhalable antibiotic therapy is desirable but as of now, only a few 
formulations have been approved. Most antibiotics available as inhalable formulations, i.e. 
aztreonam (monobactam antibiotic) and tobramycin (aminoglycoside antibiotic) are approved 
only for the treatment of cystic fibrosis associated pseudomonas aeruginosa infections. 
Additionally, colistin (ploymyxin E) is approved for treatment of acute or chronic pulmonary 
infections with gram-negative bacteria, but its clinical use is mainly limited to treatment of 
chronic cystic fibrosis associated pseudomonas infections. Aztreonam is available as solution 
for nebulization only; only in recent years have dry powder formulations of colistin 
Substance class Example substance
Corticosteroids Budesonide
Beclomethasone dipropionate
Fluticasone propionate
Mometasone furoate
Ciclesonide
Long acting  2 agonists Salmeterol xinafoate
Formoterol fumarate dihydrate
Short acting  2 agonists Salbutamol sulfate
Fenoterol hydrobromide
Anticholinergics Ipratropium bromide
Aclidinium bromide
Tiotropium
Methylxanthines Theophylline
Aminophylline
Phosphodiesterase four inhibitors Roflumilast
1
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(Colobreathe®, Turbospin® DPI) and tobramycin (TOBI®, Podhaler® DPI) become 
available. Besides formulations approved for the pulmonary route, several injectable 
antibiotic (amikacin, amphotericin B, ceftazidime, gentamicin) formulations applied using 
nebulizers have been used “off-label” in clinical practice [6], which highlights the need of a 
higher number of commercially available inhalable antibiotics.  
1.2.4 General considerations 
Delivery of active pharmaceutical agents to the respiratory system is not only appropriate for 
local treatment of respiratory diseases such as asthma, COPD, or infections, but may also be 
suitable for systemic drug delivery, for example in the delivery of peptides or proteins such as 
insulin [7], or rescue medication for e.g. pain therapy [8]. Due to the high surface area 
available and the small dimensions of the diffusion barrier, rapid and complete absorption of 
the drug administered is possible. Additionally, the absence of degrading enzymes (e.g. 
proteases) and systemic distribution (without the first-pass effect of the liver) is likely to 
result in higher bioavailabilities, when compared to oral administration of active 
pharmaceutical ingredients (APIs) [9]. To ensure deposition in the desired target area, 
therapeutic aerosol particles must fulfill certain requirements. Most relevant here is the 
aerodynamic diameter. It is defined as the equivalent diameter of the unit density sphere 
showing the same settling velocity as the particle of interest. Equation 1 shows the most 
general case of the relationship of aerodynamic diameter (dae) and geometric diameter (dgeo), 
particle (ρp) and reference particle density (ρae), Cunningham slip correction factors for 
sample (Cp) and reference (Cae) particle diameters, and a shape correction factor (χ).  
 
!!" = !!"# ρ!!!χρ!"!!" 
Equation 1. Relation of dae to dgeo [10]. 
 
In the case of a density unit sphere per definition ρp= 1 g/cm3, χ= 1, and Cp/Cae= 1 is true. 
Cunningham slip correction factors are used to compensate for non-continuum effects 
occurring at high Knudsen numbers. Knudsen numbers are dimensionless factors relating the 
particle diameter to its mean free path length in the system [11]. Equation 1 implies that dae of 
a particle can effectively be manipulated by changing its geometrical diameter, density, or 
7 
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shape. It is generally assumed that particles showing an aerodynamic diameter of one to five 
µm are suitable for deposition in the lower respiratory tract [12,13]. Five distinct mechanisms 
triggering particle deposition can be identified: impaction, sedimentation, diffusion, 
interception, and electrostatic precipitation [14]. Impaction describes separation of the aerosol 
particle from the air stream upon changes in the motion vector of the airflow field. Due to the 
particle’s momentum it undergoes radial acceleration and might separate from the airflow and 
impact onto the walls of the flow path defining structure (e.g. trachea or bronchi). 
Sedimentation of particles occurs due to gravitational pull and becomes more effective in the 
lower respiratory tract, where particle velocities are low. Diffusion of particles predominantly 
occurs in the lower respiratory tract as well and is caused by Brownian motion of sub-micron 
particles. Thus, sedimentation and diffusion are competing processes, and predominance of 
one over the other is mainly depending on particle mass. At settling velocities lower than 
0.001 cm/s, which is equivalent to a unit density sphere equivalent diameter of about 0.5 µm, 
diffusion becomes predominant. Interception describes particle surface interactions of fibrous 
particles and the extent of deposition by interception depends on the length of the fiber. As 
therapeutical aerosols usually exhibit a more spherical morphology, deposition by interception 
in this context plays a negligible role. Importantly, this mechanism is highly relevant for 
toxicological evaluation of those fibrous materials (e.g. asbestos). Electrostatic precipitation 
might occur if particles demonstrate high electric mobility. Charged particles induce image 
charges on the airway surfaces, which triggers separation from the air stream. This effect 
occurs, for example upon in situ formation of dry particles from aqueous droplets, but has low 
relevance in equilibrated systems [14]. Figure 1 gives an overview on the extent of particle 
deposition via impaction, sedimentation, and diffusion as a function of particle diameter of 
unit density spheres. This figure illustrates that particle deposition of pharmaceutical aerosols 
in the lungs only appears in the size range of about one to five µm. The upper limit is defined 
by the maximum dae suitable for passing the upper airways and the lower limit is defined by 
deposition efficiency of the particles. If particles do not deposit, their exhalation is to be 
assumed. It is also shown that deposition efficiency increases at dae lower than 0.1 µm. 
However, these low diameter powders are extremely cohesive and, as of now, of little 
relevance when considering deposition mechanisms. Figure 2 depicts typical sites of 
deposition, related to dae. 
 
8 
1. Introduction and theoretical background 
 
 
Figure 1. Deposition frequencies as function of dae. Modified from [15]. 
 
Figure 2. Sites of deposition related to dae. Modified from [16]. 
Diffusion	 Diffusion	and	
sedimenta.on	
Sedimenta.on	
and	impac.on	
Par.cle	diameter	[µm]	
De
po
si.
on
	[	
]	
0.01	 0.1	 1	 10	
1.0	
0.5	
0	
Impaction 
Sedimentation 
Diffusion 
d a
e	
[µ
m
]	
100	
10	
1	
0.1	
9 
1. Introduction and theoretical background 
 
Since the site of deposition in the airways is related to dae, aerosols for different indications 
might have different requirements. For example for asthma therapy, targeting to the bronchi 
and bronchioles is desired; In this case larger particles could be needed compared to those for 
systemic treatment, where particles need to be targeted to alveoli (in order to be absorbed 
across a high surface area). 
 
1.3 Aerosol therapy 
1.3.1 Dry powder inhalation devices 
Dry powder inhalers (DPIs) are designed to reproducibly deliver a predefined dose of a drug 
to the small airways and alveolar region of the lung. It is well reported that particles with a 
mass median aerodynamic diameter (MMAD) of one to five µm are effectively deposited at 
aforementioned sites [17]. The MMAD of a particle depends on its geometrical diameter, 
density, and morphology with these properties generally being manipulated during the 
manufacturing process [18]. Due to interparticulate forces (i.e. mechanical interlocking, 
capillary, electrostatic, and van der Waals forces [19]) micronized powders are very 
adhesive/cohesive; spontaneously forming agglomerates. The extent of the partial and 
consequently of the combined forces is dependent on powder properties such as: particle size, 
morphology, shape, and chemical properties [20], as well as environmental factors like 
relative humidity [21]. Since the extent of agglomeration negatively affects the fraction of the 
inhaled powder, which is within the respirable range [22], these agglomerates must be 
effectively deagglomerated prior to or during the processes of aerosolization and inhalation 
[23]. DPIs that utilize a patient’s inspiratory airflow to provide the required energy to 
overcome the aforementioned interparticulate forces are known as passive devices, whereas 
those that utilize other sources of energy are referred to as active devices. One advantage of 
utilizing a patient’s inspiratory airflow as the main source of energy is that such devices are 
breath actuated; this inherently avoids the need to synchronize the actuation and inspiration 
maneuver by the patient. The downside of this approach is that devices currently available 
show a device-specific airflow resistance, and this often demands a relatively high inspiratory 
effort [24], which might be a potential hurdle for patient populations suffering from 
obstructive airway diseases such as asthma or COPD, the elderly, or very young [25]. The 
extent of lung deposition is also dependent on the individual patient’s inspiratory flow rate 
10 
1. Introduction and theoretical background 
 
causing a potential inter-patient variability in the dose effectively delivered [26]. Another 
critical factor affecting the reproducibility of doses delivered by multidose inhalers is dose 
metering. While single dose and multi-unit dose devices use pre-metered powders packed into 
blisters or capsules, bulk powder bed multidose inhalers use powder reservoirs so that the 
dose to be delivered has to be separated from the bulk material prior to actuation [27]. For 
both types of devices, suitable powder flow properties are essential, either for accurate dosing 
or emptying of the single-dose container entirely. Since flow properties of micronized 
powders are often poor, most formulations consist of physical blends of drug particles with 
larger carrier particles such as lactose (30-90 µm), to aid de-agglomeration and powder flow 
[28]. In light of the aforementioned considerations, the ideal DPI would reproducibly deliver 
an accurate dose, regardless of a patient’s condition. Clinically, it may also be advantageous if 
the device is breath actuated, easy, and safe to use, offers some type of control feedback 
mechanism (related to efficacy), and has an accurate dose counter. The dose counting 
mechanism is a standardized requirement that serves to help patients to track whether doses 
have been administered appropriately, and when to replace the device at a suitable time 
[29,30]. Single use disposable DPIs have to meet different requirements than reusable ones. 
But the need for an effective dose metering system is however, negated. Since the disposable 
DPI itself can be packed and sealed, it is therefore not exposed to direct environmental 
conditions such as humidity, so there may be no need to ensure a high level of protection of 
the drug within the DPI. Patients potentially using disposable DPIs cannot be expected to be 
familiar with medical inhalation devices, so it is preferable to keep operation of the device as 
simple as possible. Visible or audible control feedback mechanisms would be a great benefit 
to naive patients. Of course, it is compulsory for disposable devices to meet all the 
requirements necessary to ensure a safe therapy (i.e., dose accuracy and reproducibility) [31]. 
Figure 3 shows a schematic drawing of a typical single unit dose DPI. 
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Figure 3. Schematic diagram of a DPI device of the Aerolizer type (Breezhaler). 
1.3.2 Pressurized metered dose inhaler (pMDI) 
In contrast to passive DPI devices, pMDIs utilize propellant gases as main source of energy to 
form a respirable aerosol. As minimal requirements, they consist of an aluminum container 
that holds the drug formulation, a metering valve, and an actuator [32]. The active ingredient 
is typically formulated as solution, or suspension of micronized particles in a liquefied 
propellant. Over a relevant temperature range, propellants must liquefy at moderate pressures, 
which are typically less than 500 kPa for a pure propellant, or mixtures of propellants. 
Additionally, they are required to be physically and chemically compatible with the API and 
other excipients, nonflammable, and nontoxic [33]. 
Starting from the mid 1990s, chlorofluorocarbon (CFC) propellants, previously used in pMDI 
formulation design, were replaced by non ozone layer depleting hydrofluoroalkanes (HFA); 
as requested in the Montreal Protocol of 1987 [34]. Besides re-formulating already approved 
products, this transition also demanded modifications of the pMDI parts used, as HFA 
propellants show different physicochemical properties, such as polarity and vapor pressure, 
when compared CFCs [34,35]. The change to use HFAs instead of CFC propellants also 
offered new opportunities, leading to a new generation of pMDI products that exhibited better 
performance in terms of fine particle fractions (FPF) generated, when compared to their CFC 
containing predecessors. Besides the active ingredient and the propellant, HFA pMDI 
formulations may include surfactants and solubilizing excipients such as ethanol [35]. By 
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design, the drug containing HFA formulation is stored within an aluminum canister, onto 
which the metering valve is crimped. Aluminum is the material of choice as it fulfills all 
requirements that need to be met since it is sufficiently robust to hold the propellant system 
pressure, impervious, light protective, and chemically inert. Additionally, surface 
modifications can be used to chemically and physically stabilize the formulation, thereby 
minimizing container/drug interactions [36]. As reproducible dose delivery is essential, the 
metering valve is one of the most critical parts of the pMDI assembly. Doses metered are in 
the range of 25 - 100 µL and shaking of the devices prior to actuation by the patient is 
required to ensure accurate and reproducible metering and drug delivery. Consequently, 
applicable doses are limited to about 200 µg per actuation for suspension based inhalers 
whereas investigational solution based pMDIs are reported to deliver up to 1.5 mg per 
actuation [37,38]. The basic principle of operation is that prior to actuation the metering 
chamber displays an open orifice, establishing a connection to the reservoir so that it can be 
filled gravimetrically. Upon actuation, this connection closes and another valve, establishing a 
connection to an expansion chamber, opens. Now exposed to atmospheric pressure, the 
metered dose of the API containing propellant formulation flash evaporates, creating the 
therapeutic aerosol when exiting from the actuator nozzle [39]. Comparably to DPI 
formulations, suspension based pMDI formulations must de-agglomerate prior to (shaking) or 
during actuation, to ensure that the aerodynamic particle size distribution (aPSD) is within the 
desired range. APSDs of solution based pMDIs are correlated to the PSD of the initial 
droplets generated, which can be effectively influenced by the geometry of the nozzle used 
and the dimensions of the actuator nozzle path [35,40]. Expansion of the propellant and 
evaporation of other included liquid excipients (e.g. EtOH) does not occur isothermically, 
thus decreasing the temperature of the aerosol plume. This reduction in temperature 
phenomenon, known as “Freon effect” was reported to induce bronchoconstriction in some 
patients, which compromises their compliance [41]. Additionally, synchronization of the 
actuation and inhalation maneuver has been shown to be challenging to certain patient sub-
populations [29,39]. The use of valved holding chambers (VHC), spacer devices extending 
the distance from the actuator nozzle to the patient, addresses both issues, but suffers from 
diminished therapeutically effective doses due to electrostatic interactions of the aerosol 
particles with the wall of the spacer, as well as somewhat unwieldy and erroneous handling by 
the patient [42]. Another approach to overcome the need to actuate and inspire simultaneously 
is the addition of breath actuated valves to the pMDI assembly. The Autohaler® (3M 
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Pharmaceuticals, St. Paul, MN, USA) for example, must be primed prior to inhalation by 
lifting a leaver and actuates automatically upon detection of inspiratory flow as low as 30 
L/min. Actuation of the airflow triggered valve creates a clicking sound, which serves as 
positive feedback control that the dose was inhaled correctly [43]. Modern pMDI devices also 
incorporate an accurate dose counter, which enables the patient to keep track on when to 
discard and replace the prescribed medication [39]. Since pMDIs as well as multi use DPIs, 
are intended for everyday patient use, equivalent requirements are important for an “ideal” 
device. These criteria include: accurate and reproducible delivery of a predefined dose, 
audible or visible feedback mechanisms and a robust mode of application (e.g. breath 
actuation) to verify and assure that the dose was inhaled correctly, as well as a reliable dose 
counting mechanism. Figure 4 shows a schematic diagram of a pMDI. 
 
 
Figure 4. Schematic diagram of a pMDI. Modified from [31]. 
1.3.3 Nebulizer 
Nebulizer devices are capable of aerosolizing a drug containing formulation (a solution, an 
emulsions, or suspensions) in order to create a therapeutic mist that can be inspired by a 
patient [44]. Since nebulizers are active devices, correct inhalation requires only little 
inspiratory effort when compared to DPIs. Another benefit is that no complex 
actuation/inhalation maneuver is necessary, making nebulizers the first choice for patients 
with impaired function: physically restricted patients (such as the elderly or very young 
patients), or those with obstructed airways [45]. Commercially available nebulizers can be 
assigned into two general categories for aerosol generation. In the first instance, jet nebulizers 
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utilize compressed air or oxygen, which is provided by a compressor unit, to aerosolize the 
drug containing formulation in a two fluid atomizer [45]. Product feed occurs passively 
utilizing Bernoulli´s principle, whereby a gas flow is applied through a small orifice and a 
negative pressure is created in an adjacent feed tube that provides a pressure gradient 
sufficiently high to convey the formulation to the atomization zone where droplets are broken 
down by turbulent rupture and secondary decay [45,46]. In contrast, ultrasonic nebulizers (or 
vibrating mesh nebulizers) operate independently from a compressed air source using a 
piezoelectric crystal oscillating at high frequencies (1-3 MHz) to generate the aerosol [46]. In 
comparison to pMDI or DPI formulations, formulations for jet nebulization usually are more 
facile in development and a wide range of drug substances have been investigated, so 
nebulized formulations may provide quicker access and higher stability of investigational 
therapies in clinical testing [47–50]. However, performance of most nebulizers used is 
considerably lower than that achieved by pMDI or DPI devices, often not exceeding a FPFtotal 
of about 10% as the majority of the dose is retained within the device itself [51,52]. It is also 
problematic that deposition rates are highly influenced by the patient´s breathing pattern 
[53,54], and that a large fraction of the dose is lost when exhaling [51]. To address this issue 
so called breath enhanced nebulizers (see Figure. 5) have been introduced. The enhanced 
nebulizer uses the patient´s inspirational airflow to create a negative pressure which aids in 
promoting aerosol generation and reduces losses upon expiration thus generating higher FPFs 
[55]. Another approach to address this problem is to couple vibrating mesh nebulizers to 
diagnostic tools and microprocessors. Smart nebulizers determine the patient´s individual 
breathing pattern and actuate only during the early phases of inspiration. Additionally 
formulation specific characteristics can be incorporated which can lead to an improved 
aerosol generation characteristics [56], consequently generating higher FPFs.  
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Figure 5. Schematic diagram of a breath enhanced jet nebulizer. Modified from [57]. 
1.3.4 Overview on approved inhalable drugs in Germany  
A broad range of different inhalable preparations are approved and marketed in Germany. 
Main indications are asthma and COPD. Table 3 gives an overview on dry powder 
preparations and Table 4 gives an overview of pMDIs approved in Germany. These lists are 
based on online research using the Gelbe Liste Pharmindex database [58], and searching for 
the respective dosage form. Since nebulized formulations are not the focus area of the 
research presented in these studies, they will not be discussed further. 
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Table 3. Overview on DPIs approved in Germany. 
 
Substance Product name Manufacturer mdrug/dose [µg] DPI Indication
Salbutamol sulfate Salbu Easyhaler Orion Pharma (200 / 400) Easyhaler COPD
Ventilastin MEDA 100 Novolizer Asthma / COPD
Cyclocaps Salbutamol PB Pharma 400 Cyclohaler COPD
Salmeterol xinafoate Serevent GSK 50 Diskus Asthma
Salmeterol xinafoate Seretide GSK 50 / (250 / 500) Diskus Asthma
Fluticasone propionate Rolenium Elpen Pharma 50 / (250 / 500) Elpenhaler Asthma / COPD
Atmadisc GSK 50 / (100 / 250 / 500) Diskus Asthma
Tiotropium bromide Spiriva BI 18 Handihaler COPD
Braltus TEVA 10 Zonda COPD
Umeclidinium bromide Incruse GSK 50 Ellipta COPD
Umeclidinium bromide Anoro GSK 50 / 22 Ellipta COPD
Vilanterol GSK
Aclidinium bromide Bretaris Astra Zeneca 322 Genuair COPD
Aclidinium bromide Eklira Astra Zeneca 322 Genuair COPD
Aclidinium bromide Brimica Astra Zeneca 322 / 12 Genuair COPD
Formoterol fumarate Duaklir Astra Zeneca 322 / 12 Genuair COPD
Beclometasone dipropionate Cyclocaps Beclometason PB Pharma (100 / 200 / 400) Cyclohaler Asthma
Beclomet Easyhaler Orion Pharma (100 / 200 / 400) Easyhaler Asthma
Beclometasone dipropionate Kantos Chiesi 100 / 6 Nexthaler Asthma
Formoterol hemifumarate Foster Chiesi 100 / 6 Nexthaler Asthma
Budesonide Cyclocaps Budesonid PB Pharma 100 / 200 / 400 / 600 / 800 Cyclohaler Asthma / COPD
Budesonid Easyhaler Orion Pharma 100 / 200 / 400 Easyhaler Asthma
Miflonide Novartis 200 / 400 Cyclohaler Asthma
Budecort MEDA 200 / 400 Novolizer Asthma
Novopulmon MEDA 200 / 400 Novolizer Asthma
Pulmicort Astra Zeneca 200 / 400 Turbohaler Asthma
Budesonide Duoresp TEVA (160 / 320) / (4.5 / 9) Spiromax Asthma
Formoterol hemifumarate Symbicort Astra Zeneca (80 / 160 / 320) / (4.5 / 9) Turbohaler Asthma
Fluticasone propionate Flutide GSK 50 / 100 / 250 / 500 Diskus Asthma
Fluticasone furoate Relvar GSK 50 / 100 / 250 / 500 Diskus Asthma
Vilanterol
Formoterol hemifumarate Cyclocaps Formoterol PB Pharma 12 Cyclohaler Asthma
Foradil Hexal 12 Cyclohaler Asthma / COPD
Oxis Astra Zeneca 12 Turbohaler Asthma / COPD
Formatris MEDA (6 / 12) Novolizer Asthma / COPD
Formotop MEDA (6 / 12) Novolizer COPD
Glycopyrronium bromide Seebri Novartis 44 Breezehaler COPD
Tovanor Novartis 44 Breezehaler COPD
Glycopyrronium bromide Ultibro Novartis 44 / 85 Breezehaler COPD
Indacaterol Ulunar UCB 44 / 85 Breezehaler COPD
Xoterna Kohl Pharma 44 / 85 Breezehaler COPD
Indacaterol Onbrez Novartis 150 / 300 Breezehaler COPD
Mometasone furoate Asmanex MSD 200 / 400 Twisthaler Asthma
Tobramycin TOBI Novartis 2800 Podhaler Cystic fibrosis with
P. Aeruginosa infection
1
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Table 4. Overview on pMDIs approved in Germany. 
 
Substance Product name Manufacturer mdrug/dose [µg] Formulation Indication
Beclometasone propionate Beclohexal Hexal 100 solution Asthma
Beclo Sandoz Hexal 100 solution Asthma
Berotec N BI 100 solution Asthma
Junik Infectopharm 100 solution Asthma / COPD
Junik Autohaler Infectopharm (50 / 100) solution Asthma / COPD
Ventolair Autohaler TEVA (50 / 100 / 250) solution Asthma / COPD
Sanasthmax Chiesi (50 / 250) solution Asthma / COPD
Arobec IVAX Pharma (50 / 100) solution Asthma
Beclometason CT TEVA (50 / 100 / 200) solution Asthma
Beclometason Ratiopharm (50 / 100 / 250) solution Asthma
Beclometasone propionate Foster Chiesi (100 / 200) / 6 solution Asthma / COPD
Formoterol hemifumarate Formodual Kohlpharma 100 / 6 solution Asthma / COPD
Inuvair Chiesi 100 / 6 solution Asthma / COPD
Kantos Chiesi (100 / 200) / 6 solution Asthma / COPD
Budesonide Budiair Chiesi 200 solution Asthma / COPD
Ciclesonide Alvesco Astra Zeneca (80 / 160) solution Asthma
Fenoterol HBr Dosberotec Kohlpharma 100 solution Asthma / COPD
Fluticasone dipropionate Flutihexal Hexal (125 / 250) suspension Asthma
Flutide GSK (50 / 125) suspension Asthma / COPD
Fluticasone dipropionate Flutiform Mundipharma (50 / 150) / 5 / not reported solution Asthma
Formoterol hemifumarate A↵era Mundipharma 250 / 10 / not reported solution Asthma
Na-Cromoglicate
Formoterol hemifumarate Foradil Hexal 12 solution Asthma
Forair Chiesi 12 solution Asthma
Ipratropium Br Atrovent N Axicorp 20 solution Asthma / COPD
Ipratropium Br Ipratropiumbr. Hexal Axicorp 20 solution Asthma / COPD
Reproterol Aarane N Sanofi (500)/(1000) suspension Allergic Asthma
Na-Cromoglicate Allergospasmin N MEDA (500)/(1000) suspension Allergic Asthma
Salbutamol sulfate Bronchospray novo Infectopharm 100 suspension Asthma / COPD
Bronchospray Autohaler Infectopharm 100 suspension Asthma / COPD
Salbuhexal Hexal 100 suspension Asthma / COPD
Salbutamol Sandoz Hexal 100 suspension Asthma / COPD
Salbulair N Autohaler TEVA 100 suspension Asthma / COPD
Salbulair N Easi-Breathe TEVA 100 suspension Asthma / COPD
Sultanol GSK 100 suspension Asthma / COPD
Salbutamol 1A 100 suspension Asthma / COPD
AL
Ratiopharm
Stada
Salmeterol xinafoate Salmeterol Hexal Hexal 25 suspension Asthma
Serevent GSK 25 suspension Asthma
Salmeterol Seretide GSK (25) / (125 / 250) suspension Asthma
Fluticasone dipropionate Serkep Mylan (25) / (125 / 250) suspension Asthma
Atmadisc GSK (25) / (50 / 125) suspension Asthma
Viani GSK (50) / (250) suspension Asthma
2
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1.4 Aerosol analysis  
1.4.1 The Cascade impactor (CI) 
As described in the previous sections, knowledge of aerodynamic aerosol properties is 
essential to evaluate the performance of an inhalable product. Aerosol impactor analysis 
continues to be the most important method for characterizing inhalable formulations. The 
United States Pharmacopoeial (USP) Convention and the European Pharmacopoeia (Ph.Eur.) 
describe four different types of impaction methods: Andersen Cascade Impactor (Apparatus 
1/3/D), Marple-Miller Impactor (Apparatus 2), Multi-stage Liquid Impinger (Apparatus 4/C) , 
and Next Generation Pharmceutical Impactor (NGI, Apparatus 5/E). Additionally, the Ph.Eur. 
describes a simple twin stage impinger test (Apparatus A). Each test method is designed to 
provide quality assurance for industrial manufacturing environments by providing highly 
standardized and robust tests to assess aerosol characteristics [59]. 
Shortly after the commercial distribution of the first pMDI in 1955 by Riker Laboratories 
(Loughborough, Leicestershire, UK), the first particle sizing method was introduced to assure 
reproducible quality. Here, scattering of an incident light beam on the test aerosol was used to 
calculate the PSD [60]. This method, which is still in use today, shows fundamental 
limitations; since it is not the aerodynamic, but the geometric diameter of the particles that 
was determined. As discussed earlier, not only the geometric diameter, but also particle 
density and shape are crucial for its aerodynamic behavior. Thus, this method can be helpful 
in providing quality control (QC) data on batch-to-batch variability, if the particles assessed 
show identical solid-state properties. In 1958, the first cascade impaction device was designed 
by Andersen to collect and sample viable airborne particles. It featured a six stage vertical 
design that allowed particle collection by inertial deposition. In this device, the test aerosol is 
supplied into the inlet of the cascade impactor and classified in six consecutive stages. Each 
stage consists of a plate, showing perforations that from stage to stage differ in size and 
number, and a petri dish holding an agar gel, onto which the particles (in this case bacterial 
spores) impact. Particle classification occurs by inertial impaction, which is facilitated by 
increasing acceleration of the particles due to increasing jet velocities generated in the nozzles 
[61]. As characteristic aerodynamic cut-off sizes can be attributed to each stage, this device is 
capable of determining the aPSD of an aerosol sample. The first application of CI analysis on 
pharmaceutical aerosols was reported by Polli et al. in 1969 [62]. Two years later in 1971, an 
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eight stage version of the Andersen cascade impactor (ACI Mark I) was introduced for 
pharmaceutical aerosol analysis by Riker Laboratories. Over the years, several different 
designs of CIs including the Multi-stage Liquid impinger or the Marple-Miller impactor were 
developed and described. They were designed specifically for pharmaceutical applications, 
providing higher resolution in the relevant size range with simplified product recovery. In the 
1990s, a consortium comprising of representatives of all major laboratories associated with 
inhalable product testing was recruited in order to develop a novel cascade impaction device 
based on experience gained using earlier models, which was intended to provide a highly 
standardized, versatile, and reproducible test method [10]. Table 5 shows essential 
requirements for this device (NGI), as defined by the consortium. 
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Table 5. Requirements defined as essential characteristics for the NGI. From [10]. 
 
Essential requirement
1 Automatable, but suitable for manual operation
2 Operates over a range of flow rates 30 - 100 L/min
3 Calibration data for the flow rates of 30 - 100 L/min are available
4 Capable of fully characterizing the ”less than 10 µm” cloud size range
5 Needs right number of stages at right cut-o↵s (independent of flow rate);
minimum of 5 stages 0.5 - 5 µm, one stage between 5 and 10 µm plus
high capacity stage at 10 µm or higher (pre-separator)
6 The stages will be followed by a micro-orifice collector that is 90% e cient
for particles larger than or equal to 0.2 mm aerodynamic diameter
7 E ciency curves for stages must be appropriate; GSD for all stages similar;
overlap between stages is minimized
8 Deposition profile una↵ected by stage loadings (up to 10 mg)
9 Operates using defined entry conditions
10 The empty volume of the impactor must be no more than 1.5 L, measured from
the inlet of the USP/EP inlet to the exit of the impactor body, including the pre-separator
11 Low wall losses; not more than 5% on any stage and not more than 5% total on all stages
12 Good drug recovery (mass balance)
13 No bounce/re-entrainment
14 Capable of being grounded; una↵ected by static
15 Physically robust
16 Constructed using inert/robust materials (can use common solvents)
17 Good accuracy and precision (65%)
18 Operator independent (no statistical di↵erence between results
between independent laboratories)
19 Acceptable to regulators/Pharmacopoeia
20 Designed and manufactured to ISO 9000 or equivalent
21 Applicable to all single shot inhaled delivery systems (MDIs, DPIs, aqueous inhalers)
22 Easy to qualify and validate in the laboratory
23 Fast; cycle time of less than 30 min for manual determinations
2
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Not all requirements discussed are critical to the performance of the NGI, and focus was also 
put on user convenience and cost efficiency. At the end of the development phase, the 
consortium presented a CI with a horizontal design, comprising of seven stages and a terminal 
high efficiency collector (Micro orifice collector, MOC). It also includes an USP/Ph.Eur. 
compliant induction port (IP), as well as a preseparator unit to remove coarse carrier particles, 
if needed. To ensure narrow distributions around the nominal stage cut off, nozzles were 
designed in a way that they would fulfil requirements, which had been investigated 
empirically [63–66] with the following specifications: a) exhibiting a Reynolds number of 
500-3000, b) a nozzle to plate distance should be between 1-10 times the dimension of the 
nozzle diameter, and c) limited cross flow (i.e. limiting the interaction of airflow traversing 
from the inner most nozzles across flow paths of the outer nozzles). Each impaction stage 
particle size cut off was designed to be equally distant on a logarithmic scale [10]. Circular 
stage nozzles and flow paths connecting the stages are arranged in a horizontal alignment and 
are incorporated into the lid of the device. Particles deposit into individual cups, which are 
inserted into a tray in the bottom part of the device, which facilitates easy removal for product 
recovery and subsequent quantification (Figure. 6).  
 
Figure 6. Schematic drawing of one NGI stage. Modified from [67]. 
Due to the function of the MOC, a terminal filter stage is redundant in most cases. Initially, 
the NGI was calibrated for functionality over the airflow range of 30-100 L/min, this was later 
was extended to operate from 15-100 L/min in order to make it suitable for analysis of 
nebulized formulations. Figure 7 shows a schematic picture of the NGI in open and closed 
position. 
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Figure 7. Schematic drawing of the NGI. Modified from [67]. 
Below is a brief description of the experimental procedure for aerosol characterization for a 
typical DPI formulation: 
 
1. Determination of the flow rate to generate a pressure drop of 4 kPa across the DPI. 
2. Optional coating of collection cups with typically silicone oil or glycerol (in order to 
minimize potential particle reentrainment).  
3. Filling 15 mL of recovery solvent into the preseparator.  
4. Assembling the cascade impactor. 
5. Adjustment of flow rate through the impactor inlet (e.g. USPIP) to flow rate determined in 
Step 1, above. 
6. DPI priming. 
7. Connection of the DPI using a suitable mouthpiece (premanufactured generally using an 
airtight silicone material). 
6. Actuation of the DPI into the CI for the duration it takes to draw 4 L of gas through the 
device.  
7. Confirmation of sonic flow over the device.  
8. If necessary, repetition of Steps 4-6 until a quantifiable dose is deposited, but max. n= 10. 
9. Disassembly of the device and recovery of impacted powders following actuation of the 
DPI  using a suitable solvent, as well as collection of the solution from the preseparator and 
washing using a suitable solvent. 
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10. Determination of the mass of powder deposited at the individual stages, preseparator, IP, 
and the DPI device. 
11. Statistical evaluation of the results including: 
11.1. Plotting relative frequencies of powder deposition over stages. 
11.2. Plotting cumulative frequencies of MOC to S1 over in-stage cut off values at the given 
flow rate used. If determined at the inlet of the device, flow rate must be corrected according 
to Equation 2, as pressure drops over the DPI and the impactor change the actual total flow 
over the system. !!"# = !!"!!!! − ∆!  
Equation 2. Correction of flow rate over the test system with: Qout= mass flow at outlet, Qin= 
mass flow at inlet, p0= atmospheric pressure, and ∆p= pressure drop over the test system. 
 
11.3. Linearization of cumulative distribution by probit transformation of y axis (i.e. 
cumulative frequency). 
11.4.1. Linear regression model of the data set obtained in Step 11.3. 
11.4.2. Evaluation if assumption of log-normal distribution is valid.  
11.5. Determination of MMAD and GSD using the linear regression model obtained in 11.4. 
11.6. Determination of FPFs and ED. 
 
A detailed description of the experimental procedure can be found in the USP General 
Chapters <601> [68], or Ph.Eur. 2.9.18 [67]. 
1.4.2 Modified induction ports for CI analysis 
As discussed in the previous section, CI experiments as monographed in USP and Ph.Eur. 
provide highly standardized testing for QC and industrial manufacture. However, each test 
fails to make precise predictions of in vivo behavior of formulations tested. From the clinical 
and basic science perspective it is highly desirable to develop test systems that deliver a high 
grade of in vitro/in vivo correlation (IVIVC). Along with other considerations, the following 
limitations for impactors have been identified: simplification of the patient’s breathing 
behavior [69], simulation of poor device utilization [70], and particle bounce [71]. 
Furthermore, simplification of physiological conditions found in the upper respiratory tract 
[72] has been identified as major issue for IVIVC. The IP monographed in the USP and 
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Ph.Eur. is a simple tube of uniform cross sectional diameter with a 90° bend, which is 
intended to represent the throat and upper airways [73]. It is commonly assumed that large 
particles as well as large agglomerates can impact in the upper regions of the human 
respiratory tract. This being the case, this already ’removed’ fraction of the dose would not be 
available to become therapeutically effective in the deep lung. Depending on the nature of the 
API used, it is possible that an increase in the occurrence of unwanted side effects could result 
from this upper airway deposition. Much effort has been made to improve IVIVC by 
replacing the standard USP IP with an IP that better represents physiological conditions. 
Advanced mouth/throat (MT) models have been generated from casts [74–76] or through the 
use of magnetic resonance/computer tomographic (MRT/CT) imaging techniques [77,78]. 
Prototype models have been prepared using resin, rubber, or fiber glass [75–77], as well as 
rapid prototyping techniques, such as fused deposition modeling (FDM) [78]. Most of these 
studies offer fundamental mechanistic insight, but provide little information on how alteration 
of the IP influences the outcome of cascade impaction experiments, which are considered as 
method of choice in formulation and device development [79]. Specifically, these studies 
have not highlighted which characteristics make a given formulation susceptible to divergent 
results. As benchtop size 3D printing devices have become more readily accessible, 3D 
printing technologies have gained great attention over the past few years. In the 
pharmaceutical field, an interesting area of research has grown involving 3D printing related 
to personalized medicine. In this area, 3D printers have been used to manufacture highly 
customized dosage forms [80]. Development of a novel modified IP (mIP) based on CT scans 
using 3D printing FDM technology will be presented in Chapter 3. This chapter also includes 
an evaluation of the mIP and will discuss it in context of the previous work conducted on this 
topic. 
1.4.3 Additional tests to characterize inhalable pharmaceutical preparations 
Additional tests to ensure quality of inhalable products include determination of dose stability 
over the life cycle of a device or stress tests under non-standardized conditions (e.g. elevated 
RH or temperature), as well as performance testing after storage. As these tests are 
predominantly relevant for commercial development and manufacture, they will not be 
discussed here. 
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1.5 Systematic review on experimental tuberculosis therapy using inhalable dry 
powders of RF 
1.5.1 Introduction  
 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. M. 
tuberculosis is a gram-negative bacterial species of the ubiquitous mycobacteriaceae family, 
showing slow growth (generation time is typically about 24 hours), complex cell envelopes, 
and intracellular pathogenesis. Depending on the patient’s immune status, it may remain 
dormant for several years, which leads to delayed development of clinical symptoms [81]. 
Main site of infection are the lungs, though infections can secondarily spread to other organs 
(e.g. liver), and eventually generalize. Characteristic symptoms after lung infection, which 
typically occurs after exposition to bacteria conveying aerosols, include cough, fever, and 
hemoptysis, as well as anorexia and weight loss [82]. In 2016, approximately 10 million cases 
of TB were registered, making it the 9th leading cause of death globally and the leading cause 
of death from a single infectious agent [83]. Standard therapies of drug susceptible strains 
include administration of four first line antibiotics i.e. rifampicin (Rifampin, RF), isoniazid, 
ethambutol, and pyrazinamide over a period of at least 26 weeks [84]. In case of RF the 
recommended daily dose is per oral administration of 10 mg per kilogram bodyweight 
(KGBW), but 600 mg maximum. Continuous administration of high doses of RF is often 
accompanied with unwanted side effects, including: rash, pruritus, urticaria, induction of 
transaminases, as well as more severe incidents as thrombocytopenia, or kidney failure [85]. 
Due to the therapeutic burden, and since the regimen has to be followed strictly over a long 
period of time, patient’s adherence is often poor - especially when it comes to the treatment of 
latent (i.e. clinically inapparent) tuberculosis [86]. Due to the high volume of distribution of 
approximately 1 L/KGBW [85], application of high doses is necessary to achieve 
concentrations at the site of infection which are sufficiently high to become therapeutically 
effective. Additionally, M. tuberculosis survives and replicates after phagocytosis. 
Phagocytosis actually protects the bacteria from antibacterial drugs present in the lung tissue; 
a compound problem that is exacerbated by cellular encapsulation [87]. So, in addition of 
delivering a drug dose that is sufficiently high to efficiently inhibit free bacteria, it would also 
be advantageous to demonstrate proactive targeting to phagocytes [88]. To limit the total drug 
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exposure and therefore the therapeutic burden it is desirable to develop a dosage form that is 
suitable for direct application to the site of infection, i.e. the lungs.  
 
RF is a semi-synthetic antibiotic drug that was first reported in 1966 by Maggi et al. In this 
original publication, it was synthesized by reacting 3-formyl rifamycin SV with 1-amino-4-
methylpiperazine, yielding an orange to red crystalline powder, when recrystallized from 
acetone. RF is described as slightly soluble in water at pH higher than six, with increased 
solubility at lower pHs. Additionally, it is soluble in most organic solvents [89]. Two solvent-
free polymorphs (F-I and F-II) as well as numerous stoichiometric hydrates and solvates are 
reported in literature [90–96]. F-II is a metastable form that transitions into F-I by consecutive 
melting and recrystallization at a temperature of about 190 °C [90,97]. RF is reported to be 
fairly stable at neutral pH but tends to oxidize to RF-quinone in basic environments, which 
can effectively be prevented by adding ascorbic acid. In acidic environments, hydrolysis to 3-
formyl-rifamycin SV occurs, which tends to precipitate [89]. In vivo, RF is mainly 
metabolized by cytochrome P-450 (CYP) mediated deacetylation to 25-deacetyl-RF and 
shows induction of the CYP superfamily enzymes, which lowers its oral bioavailability from 
about 90% to 70% after three weeks of therapy [85]. 
 
In order to successfully develop a pulmonary therapeutic form of RF, not only the general 
requirements for inhalable dosage forms as discussed in Section 1.3.1 must be met (i.e. 
aerosolizability, reliability of dosing etc.), the unique physicochemical properties of RF mean 
that there has to be an increased focus on long term stability, related to chemical and solid 
state properties. Additional requirements depend on the therapeutic strategy intended and 
might demand utilization of sophisticated manufacturing techniques and excipients, if for 
example, alveolar macrophage targeting is desired. However, since most high TB burden 
countries are of low income, or developing countries [83], therapy cost effectiveness is 
paramount. Thus, estimated production costs for the formulation, the DPI device type, and 
cold-chain transportation must be considered when evaluating novel formulation approaches. 
These additional aspects will not be elaborated further in this review; being beyond its scope. 
The focus of this review is to give an overview of RF pulmonary dry powder formulations 
developed and tested, as well as a presentation of the device types used in these studies, this 
will provide an in-depth evaluation of aerosol properties reported. 
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1.5.2 Results 
A literature search of the PubMed [98] database was conducted on 05-10-18 and returned 228 
results. Figure 8 gives an overview on processing of primary results in a modified PRISMA 
scheme [99]. Figure 9 gives an overview on articles reporting formulation development with 
and without aerosol testing per year. Figure 10 provides an overview on formulation strategies 
investigated per year. 
 
 
Figure 8. Overview on data processing using a modified PRISMA scheme. 
92 records comply with 
inclusion criteria = full text 
articles assessed
53 articles reporting aerosol 
testing
Primary PubMed search:
228 records
136 records did not comply 
with inclusion criteria  
39 articles did not report 
aerosol testing
36 studies investigating DP 
formulations
1 study investigating pMDI 
formulations
16  studies investigating 
nebulized formulations
26 RF only 7 combined therapy
3 studies investigating 
insufflated formulations
33 studies investigating DP 
formulations dispensed 
from DPI
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Figure 9. Overview of publications with and without aerosol testing per year. 
 
Figure 10. Overview of publications per year sorted by drug delivery system. 
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1.5.3 Discussion  
1.5.3.1 Utilized Dry powder inhalation devices 
Various dry powder inhalation devices used in these studies are reviewed here. Each of the 
capsule based single unit dose inhalers used in the studies, will be briefly summarized.  
 
Handihaler® 
 
The Handihaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany) is a capsule based 
DPI device showing high intrinsic resistance of 5.1 × 10!!(√!"# ∗!"#)/!  [100]. For dose 
application, the mouthpiece must be tilted back and a size three capsule is to be inserted into 
the capsule compartment. Prior to inhalation, the device must be primed by pushing in a 
button, which triggers the puncture of the capsule by two pins. Upon inhalation, the capsule 
assumes a spinning motion, which facilitates ejection and de-agglomeration of the dry powder 
from the capsule. The capsule is kept within its compartment (see Figure 11) by a metal grid 
that is inserted in the bottom end of the mouthpiece. Upon inhalation, the capsule makes a 
whirring sound that serves as positive feedback control for correct inhalation. 
 
Figure 11. Schematic drawing of the Handihaler. 
Capsule 
compartment 
Button 
Dust cap 
Mouthpiece 
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Aerolizer® / Lupihaler® / Plastiape RS01 / Osmohaler® / Cyclohaler®  
 
The Aerolizer (Novartis, Basel, Switzerland), Lupihaler (Lupin Ltd., Mumbai, India), RS01 
(Plastiape, Sirone, Italy), Osmohaler (Pharmaxis Ltd, New South Wales, Australia), and the 
Cyclohaler (PB Pharma, Meerbusch, Germany) devices are members of a DPI device family 
with highly similar designs using the same de-agglomeration technology. Note that Plastiape 
is not a pharmaceutical company but is specialized in the production of plastic packaging, 
medicinal devices, and nonpackaging based products. Two different makes showing different 
intrinsic resistances of the device are marketed: one low resistance make with a nominal 
airflow of 100 L/min which is reported to correspond to an intrinsic resistance of 1.8 × 10!!(√!"# ∗!"#)/! [101] and another intermediate resistance make, generating the 
pressure drop of 4 kPa at 65 L/min, which corresponds to an intrinsic resistance of 3.1 × 10!!(√!"# ∗!"#)/! [102]. Similarly to the Handihaler, for dose application the 
mouthpiece must be tilted back and a size three capsule is inserted (see Figure 12). 
Additionally, the capsule orientation in this device family is horizontal, whereas it is kept in 
vertical position in the Handihaler device. To prime the device, two buttons located opposite 
and on each side of the device are pushed, this triggers capsule puncture by either two 
opposing single pins, or opposing four pin configurations. Upon inhalation air is drawn 
through tangential slits in the device housing causing the capsule to spin; facilitating ejection 
and de-agglomeration of the dry powder. Similarly to the Handihaler, a plastic mesh holds the 
capsule in place. A whirring sound created by the swirling capsule also serves as audible 
feedback control. 
 
Figure 12. Schematic drawing of the Cyclohaler. 
Mouthpiece 
Capsule 
compartment 
Buttons 
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Rotahaler® 
 
The Rotahaler device (currently Cipla, Mumbai, India, developed by Glaxo, London, UK) 
shows a distinct release mechanism of the powder from the capsule, when compared to the 
Handihaler or Aerolizers. Capsules are not punctuated. Instead, the bottom and top part of the 
capsule are separated, releasing the dry powder. Separation of capsule halves is triggered by 
consecutive insertion of the capsule into the device and twisting of its lower part. A flap that 
is connected firmly to the bottom part of the device, hits the lower half of the capsule upon 
rotation, opening it up by the shear force applied. Upon inhalation a vortex is created in the 
main compartment of the inhaler, facilitating de-agglomeration and aerosolization of the 
powder. A mesh is located in the lower part of the mouthpiece in order to retain the capsule 
within the compartment. The inhaler is made out of transparent plastic, so that correct 
inhalation can be confirmed visually. Pressure drop of 4 kPa is achieved at an airflow rate of 
45 L/min [103], which corresponds to an intrinsic resistance of 4.4 × 10!!(√!"# ∗!"#)/!. 
A schematic drawing of the Rotahaler can be found in Figure 13. 
 
 
Figure 13. Schematic drawing of the Rotahaler. 
Grid 
Capsule chamber 
Main 
compartment 
Mouthpiece 
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Revolizer® 
 
The Revolizer device is another single unit dose DPI marketed by Cipla. Its engine resembles 
the one used in the Handihaler. Similarly, a size three capsule is inserted into a vertical 
capsule compartment and a grid is inserted into the lower part of the inhalation channel in 
order to retain the capsule within the chamber. Upon inhalation, the capsule spins, ejecting 
and aerosolizing the dry powder. Significant differences are observed, compared to previously 
described designs. Priming of the device does not occur by pushing a button in order to 
puncture the capsule, but the punctuation mechanism is connected to the mouthpiece, which is 
to be tilted back in order to insert the capsule (see Figure 14). When placing the mouthpiece 
in the closed position, two pins that are triggered by a spring mechanism automatically pierce 
the capsule. Similar to the Rotahaler it has a high airflow resistance generating a pressure 
drop of 4 kPa at 44 L/min [103], which corresponds to an intrinsic resistance of 4.5 × 10!!(√!"# ∗!"#)/!. 
 
 
Figure 14. Schematic drawing of the Revolizer. 
Jethaler® 
 
The Jethaler (Unisia Jecs Corp. (Hitachi), Isesaki, Japan) (see Figure 15) is another single unit 
dose capsule-based device with a distinct engine for powder de-agglomeration. Priming of the 
device occurs by pushing in a button in order to pierce the capsule using two pins. Upon 
inhalation, the powder is ejected from the size two capsule and the subsequently generated 
aerosol plume is directed into a mixing chamber that resembles a jet-mill. Here, particles 
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collide, which is thought to aid de-agglomeration, before being released into the inhalation 
channel. Unfortunately, since only limited information about this device is available, no 
further description can be provided. 
  
 
Figure 15. Schematic drawing of flow paths inside the Jethaler device. Redrawn from [104]. 
Turbospin® 
 
Developed and marketed by PH&T (Milan, Italy) this single unit dose inhaler is based on the 
Spinhaler device, which was launched by Fisons (Ipswich, UK) in 1969. This inhalation 
device is distinctively different from the Spinhaler, though the principle of operation, i.e. 
ejection and aerosolization of the dry powder from a spinning capsule, as well as the overall 
design was maintained. In the Spinhaler device, the capsule holder was found on top of a 
rotor, which set the capsule into spinning motion upon inhalation [105]. In contrast, the 
capsule spinning in the Turbospin device is induced by airflow path design (see Figure 16). 
To apply a dose, the patient is required to unscrew the mouthpiece, insert a size two capsule 
into the capsule chamber, and re-attach the mouthpiece. The capsule is primed by depressing 
a plunger at the rear end of the device, which triggers puncturing of the capsule by two pins. 
Upon inhalation, air is drawn through tangential slits, causing the capsule to spin. Whilst 
spinning, the capsule produces a whirring noise that again serves as control for correct 
inhalation. The same technology has also been applied to the Podhaler ® device (also PH&T), 
which is an optimized version of the Turbospin. A pressure drop of 4 kPa is achieved at a 
flow rate of about 71 L/min, which corresponds to an intrinsic resistance of 2.8 × 10!!(√!"# ∗!"#)/! [106]. 
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Figure 16. Schematic drawing of the Turbospin device. 
1.5.3.2 Dry powder formulations of Rifampicin  
 
Different approaches to formulate RF into respirable dry powders have been investigated and 
reported over the past 15 years. In the next part of this overview, studies published that 
include aerosol testing will be briefly discussed and presented for excipient classes and are 
laid out chronologically within the respective sections. Table 6 gives an overview of studies 
discussed in this chapter, as well as FPFtotals achieved in each respective study. 
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Table 6. Overview on studies discussed. 
 
 
RF formulations including poly-(D,L-lactic-co-glycolic acid) (PLGA) and poly-(D,L-lactic 
acid) (PLA). 
 
PLGA is a synthetic, yet biocompatible and biodegradable copolymer, which has been widely 
used as structural polymer in micro- and nanoparticle preparation and is approved for human 
therapy by the US Food and Drug Administration (FDA) [107]. Different qualities of PLGA 
vary in monomer ratio, where lactic to glycolic acid ratios of 50:50 and 75:25 are most 
commonly used. Kinetic of hydrolytic degradation in biological relevant environment is 
strongly depending on the monomer ratio, and higher lactic acid content leads to slower 
degradation [108]. Also depending on the monomer ratio, PLGA shows differing degrees of 
crystallinity, where PLA homopolymers tend to be more crystalline than PGA ones. In the 
amorphous state, copolymers show a glass transition in the range of 36-68 °C [109].  
Author Year DPI used Test system (flow rate) FPF Reference
RF only formulations [ ] [ ] [ ] [L/min] [%] [ ]
PLGA (/ PLA) Sethuraman and Hickey 2002 Handihaler ACI (60 / 90) 45 [110]
Coowanitwong et al. 2008 Cyclohaler ACI (28.3) 23 - 68 [111]
Sung et al. 2009 Plastiape ACI (28.3) 36 - 68 [112]
Ohashi et al. 2009 Jethaler ACI (28.3) 35 [113]
Son and McConville 2012 Aerolizer NGI (60) 24 - 45 [114]
Lipids Changsan et al 2008 unknown ACI (60) 32 - 67 [117, 118]
Kumar et al. 2013 Rotahaler ACI (28.3) 68 [119]
Manca et al. 2014 Turbospin NGI (70) 50 [120]
Patil et al. 2015 unknown ACI (60) 26 [121]
Singh et al. 2015 Turbospin NGI (70) 50 [122]
Maretti et al. 2016 Plastiape ACI (60) 9 - 70 [123, 124]
Srichana et al. 2016 novel DPI ACI (60) 37 [125]
Chitosan Kundawala et al. 2014 unknown ACI (60) 55 - 62 [127]
Pai et al. 2016 Lupihaler ACI (28.3) > 25 [128]
Rawal et al. 2017 unknown ACI (unknown) 33 [129]
Carbohydrates Mizoe et al. 2007 Jethaler ACI (28.3) about 35 [130]
Vadakkan et al. 2015 unknown ACI (60) 63 - 78 [131]
Goyal et al. 2015 / 16 unknown ACI (5) not reported [132, 133]
Garg et al. 2015 unknown ACI (5) not reported [134]
Mesoporous silica Mohseni et al. 2015 Cyclohaler ACI (50) 46 [135]
Excipient free Son and McConville 2011 Aerolizer / Handihaler NGI (60) 37 - 64 [91]
Parikh, Patel, and Dalwadi 2014 unknown ACI (unknown) 46 [136]
Rawal et al. 2017 Turbospin ACI (30) 23 - 29 [137]
Combined formulations
RF, isoniazid, pyrazinamide Chan et al. 2013 Aerolizer MSLI (100) 46 [138]
RF, colistin Zhou et al. 2014 Aerolizer MSLI (100) 80 - 90 [139]
Wang et al. 2016 Osmohaler NGI (100) 69 - 73 [140]
RF, colistin, meropenem, tigecycline Lee et al. 2016 Aerolizer NGI (60) 54 - 68 [141]
RF, isoniazid Kadota et al. 2017 Aerolizer ACI (28.3 / 60) 3 - 53 [142]
RF, kanamycin Momin et al. 2018 Aerolizer NGI (100) 69 - 78 [143, 144]
1
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Sethuraman and Hickey were the first to investigate aerosol performance of RF/PLGA 
microparticles (MPs) in 2002 [110]. In this study, PLGA (75:25) microspheres were prepared 
by a solvent evaporation technique, jet milled, and blended with lactose monohydrate or 
maltodextrin carrier particles. As a control, RF was jet milled and blended with carrier 
particles. Dry powder blends were dispensed from the Handihaler device and aerosol 
properties were assessed using an 8-stage MKII ACI at flow rates of 60 and 90 L/min. The 
main focus of the study was assessment of surface properties of the active and carrier particles 
in order to deduce a descriptive factor that would allow prediction of dispersibility/aerosol 
properties from surface energies. FPFs of jet milled RF-PLGA particles were found in the 
range of three to 13% and the best aerosol performance was achieved using sieved lactose 
monohydrate at a flow rate of 90 L/min. Control formulations were found to perform 
significantly better, yielding FPFs of about 45%, determined at 90 L/min. It should be 
mentioned that the Handihaler is a high resistance device, and that USP/Ph.Eur. compliant 
testing would have required lower flow rates of about 40 L/min, so it is to be expected that 
FPFs reported would not be achieved in an in vivo setting.  
 
Another study, published by Coowanitwong et al., reported the preparation of PLGA and PLA 
MPs using a spray drying method, in order to achieve modified release [111]. Different ratios 
of RF with PLA and PLGA, as well as a control formulation containing RF only were 
dissolved in dichloromethane (DCM) and subsequently spray dried. Besides characterization 
of aerosol properties, resultant powders were tested for in vitro dissolution characteristics, in 
vitro macrophage toxicity, and in vivo pharmacokinetic profiles. Dry powders were dispensed 
from a Cyclohaler device and tested using a 28.3 L/min 8-stage MKII ACI. Resulting FPFs 
were found to be 55-68% and 23-34% for PLA and PLGA microparticles, respectively. 
Interestingly, powders were not filled into size three capsules but placed in the capsule 
chamber of the device, allowing higher doses per actuation to be dispersed. Also in this study, 
non-ideal aerosol testing conditions were applied, as testing was conducted using the 28.3 
L/min ACI, which is more suitable for pMDI than DPI testing; especially when taking into 
account that the Cyclohaler generates a pressure drop of 4 kPa at about 65 or 110 L/min, 
depending on which model had been used. Additionally, the system actuation occurred for 
one minute, which is an about five-fold time increase compared to USP/Ph.Eur. standards. 
Furthermore, there was no stage coating in the study, serving to decrease the comparability 
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between test runs. However, FPFs of more than 60% are notably high. On the other hand, 
incomplete drug release from the MPs, especially at higher polymer concentrations, as well as 
limited drug loading, lower the dose effectively to be delivered. Interestingly, relative 
bioavailability of PLA MPs after intratracheal instillation in rats showed a strong decrease 
(compared to RF only MPs), which might be indicative of macrophage uptake. However, no 
additional experiments to exclude other mechanisms discussed were conducted. 
 
A study published in 2009 by Sung et al. [112] investigated in vitro and in vivo performance 
of PLGA (50:50) nanoparticles (NPs) incorporated into leucine MPs. Porous MPs of RF in 
leucine were prepared as control formulation. NPs were prepared by emulsification/solvent 
evaporation and subsequently spray dried with leucine and additional RF. The reference 
formulation was prepared by co-dissolving RF and leucine in EtOH/water with subsequent 
spray drying. Particles obtained showed spherical NP agglomerates or corrugated porous 
particles respectively. Aerosol testing was performed after dispensing from an unspecified 
Plastiape device using the 28.3 L/min 8-stage ACI. Nano- in microparticle formulations were 
found to yield FPFs of 36-45% whereas the control formulation showed a fairly high FPF of 
68%. However, drug loading of the reference formulation was only determined to be 
approximately 40%. In vitro dissolution studies showed fast but incomplete release. In vivo 
studies investigating pharmacokinetic profiles of inhalable, as well as i.v. and p.o. 
administered reference formulations showed fast onset and prolonged RF exposition in the 
case of inhalable formulations assessed. Additionally, it was shown that the RF NP 
formulations were effectively retained within the lungs. 
 
Another study investigating nano- in microparticular formulations of RF was released in 2009 
by Ohashi et al. [113]. Here, nanoparticles composed of RF and PLGA (50:50) were 
incorporated into mannitol MPs, using a spray drying method facilitating one step in situ 
preparation and encapsulation of NPs by means of a four fluid nozzle. Additionally, another 
microparticulate formulation of RF and mannitol was prepared for in vivo uptake studies. As a 
reference, RF/PLGA MPs were prepared using a two-fluid nozzle. Particles obtained show 
spherical morphology with a smooth, or corrugated surface for nano- in micro- and 
microparticles respectively. For aerosol testing (RF/mannitol microparticles were not assessed 
in this study), powder samples were dispensed from a Jethaler device and analyzed using a 
28.3 L/min 8-stage ACI, and both formulations tested showed FPFs of approximately 35%. In 
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vitro macrophage uptake of nanoparticles was shown in a cell culture study, using NR8383 rat 
macrophage cells. In vivo deposition and macrophage uptake was investigated after 
intratracheal insufflation of test formulations, in which RF was substituted by indocyanine 
green, by fluorescence imaging. It was shown that PLGA microparticles were removed from 
the lower regions of the lung within one hour, which was attributed to mucociliary clearance. 
Contrary, microcarriers of mannitol were shown to dissolve and release PLGA NPs, which 
were found to be persistent in the lungs and were taken up by macrophages. 
 
A different approach was reported by Son and McConville in 2012 [114]. In this study PLGA 
and PLA were not used as matrix forming polymer but to coat RF MPs, which had been 
recrystallized from EtOH, in order to achieve sustained release. Coating was achieved by co 
spray drying suspensions of RF in EtOH and solutions of PLA or PLGA (75:25) in DCM 
using a three-fluid nozzle. Reference formulations of RF dihydrate (suspension in EtOH, also 
see section discussing excipient free formulations) and amorphous RF/PLGA or PLA 
(dissolved in DCM) matrix MPs were produced by spray drying, using a two-fluid nozzle. For 
aerosol testing, powders were aerosolized using the Aerolizer DPI and classified by NGI at 60 
L/min. Formulations containing polymer yielded FPFs in the range from 24-45%, whereas the 
crystalline, uncoated reference performed significantly better yielding 70% of fine particles. It 
is to be mentioned that the Aerolizer device generates a pressure drop of 4 kPa at about 110 
L/min, which limits comparability of the results to other studies and might actually 
underestimate powder performance in an in vivo setting. Dissolution studies confirmed 
sustained release for polymeric formulations, and extent of retardation was found more 
pronounced in the case of PLA, when compared to the PLGA particles. In case of the PLGA 
particles, coated formulations showed slower release, whereas PLA coated MPs showed 
opposite behavior. Crystalline formulations prepared were found stable upon storage for six 
months, whereas amorphous formulation showed certain degradation. 
 
Lipid formulations of RF 
 
Another class of excipients that has widely been used to produce micro- and nano- carrier 
systems, are lipids. The term ‘lipid’ includes a wide range of hydrophobic biomolecules e.g. 
mono-, di-, and triglycerides, fatty acids, steroids, and waxes [115]. Phospholipids, e.g. 
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phosphatidylcholine, display the ability to form bilayers in aqueous environment, which is 
due to polar and non-polar entities within the molecule. This can be utilized to form uni-, 
oligo-, or multilamellar liposomes, and number of lamellae can effectively be controlled 
during manufacture. Here, phospholipid bilayers form spherical vesicles that encapsulate an 
aqueous core. Hydrophilic drugs can be incorporated into the liquid core while hydrophobic 
drugs can be incorporated into the bilayers. In order to modify properties such as membrane 
fluidity, other lipid excipients, e.g. cholesterol, can be incorporated into the membrane [116]. 
Solid lipid micro-/nanoparticles can be obtained by using solid lipids, e.g. Na-stearate, and 
may offer certain advantages for the formulation including sustained release [115]. Excipients 
used commonly are of biological origin but fully synthetic qualities are available in many 
cases. 
 
The first study investigating aerosol properties of RF loaded liposomes was published in 2008 
by Changsan et al. [117]. Blank liposomes, which consisted of different ratios of cholesterol 
and phosphatidylcholine, were prepared using a film rehydration method and loaded with RF. 
Liposomes produced were in the size range of 220-260 nm and showed drug encapsulation 
efficiencies of 30-50%. To generate aerosolizable powders, the selected liposome formulation 
was freeze dried, and included the addition of different carbohydrates (trehalose, lactose, and 
mannitol) that acted as cryoprotecting and matrix forming excipients. Six week storage 
stability of RF was investigated for the liposome powders and suspensions, as well as a 
control solution of RF at 4 °C and ambient temperature. Unless subjected to cooling, freeze 
dried test formulations were found to be unstable, with an approximate 20% reduction in drug 
content. All other formulations showed significant decrease in drug content regardless the 
storage conditions. Aerosol testing was conducted by dispensing the dry powder formulations 
from an unspecified DPI device, analyzing the resulting aerosol using a 60 L/min ACI. 
Unfortunately, not only the DPI specifications, but also the exact make of the ACI remain 
unclear, as size cut-offs reported and stage set up do not match expectations, assuming device 
manufacture according to critical dimensions as specified in USP or Ph.Eur. FPFs achieved 
are reported as 32, 28, and 67% for formulations containing trehalose, lactose, and mannitol 
respectively. A single dose for each formulation assessed, was reported to deliver 50 µg of 
RF, which might be insufficient for effective TB treatment. In a second publication by this 
group, liposomes previously described were investigated in terms of lung epithelial and 
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alveolar macrophage cell toxicity, using an in vitro cell culture model [118]. It was concluded 
that the liposomes produced were non-inflammatory and non-toxic. 
 
In 2013, Kumar et al. reported manufacture and assessment of cationic lipopolymeric 
nanomicelles composed of RF and stearic acid, which was covalently conjugated with 
polyethylenimine (SABPEI) [119]. RF and SABPEI were dissolved in DCM/MeOH and 
spray dried under an inert nitrogen atmosphere, using a two-fluid nozzle. Amongst other tests, 
resultant powders were assessed for physical characteristics, in vitro drug release, loading 
efficiency, and aerosol properties. Aerosol properties were determined using an 8-stage ACI 
at a flow rate of 28.3 L/min. Dry powders were dispensed from a Rotahaler device and the 
assembly was actuated for one minute. It was reported that only particles deposited on the 
stages were included for determination of the FPF, which was defined as the relative 
deposition on S2-S5. FPF of the test formulation was reported as 68%, which was probably 
over estimated, due to the fact that only an unspecified fraction of the bulk sample was 
considered for analysis. It should be mentioned that SEM images also showed a binary blend 
of the spray dried product with lactose monohydrate carrier particles, and lactose 
monohydrate is listed in the materials section but was never referred to again in any method. 
Unfortunately, due to poor methodology, the aerosol testing reported was impossible to 
evaluate. Drug loading efficiency of the spray dried powders was found to be 99% yielding 
particles with approximately 50% w/w API content. Dissolution studies showed a more rapid 
release from the test formulation, when compared to bulk RF control powder. However, it 
should be noted that dissolution experiments were carried out in non-sink conditions, so this 
may have affected the overall drug release characteristics. 
 
A different approach to increase aerosolizability of RF loaded liposomes was reported by 
Manca et al. in 2014 [120]. Here, liposomal vesicles composed of phosphatidylcholine, 
hydrogenated phosphatidylcholine, and cholesterol were hydrated in an aqueous dextrose 
solution, sonicated using an ultrasonic probe, and surface modified with chitosan and 
carrageenan. Suspensions of liposomes obtained were then spray dried with lactose and 
calcium carbonate to produce inhalable dry powders. For aerosol testing, doses of 3 mg of dry 
powders were filled into size two gelatine capsules and aerosolized using the Turbospin 
device. Aerosol assessment was conducted using the NGI at a flow rate of 70 L/min. 
Uncoated liposomes showed insufficient aerosol properties, whereas surface modified 
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formulations were found to perform significantly better, yielding FPFs of about 50%. 
Additionally, cell uptake and toxicity of liposomal formulations was assessed in an in vitro 
cell culture model, using A549 alveolar epithelial cells. It was found that liposomes were less 
toxic (MTT assay) to this cell line when compared to suspensions of free RF and were 
internalized by the cells, which was assessed by fluorescence labelling and confocal laser 
scanning microscopy (CLSM).  
 
In 2015, another study investigating RF loaded liposomes for pulmonary delivery was 
published by Patil et al. [121]. In this study, different liposomal formulations were freeze 
dried using sucrose as a cryoprotectant and analyzed for aerosol properties, in vitro drug 
release, in vitro anti-microbial activity, solid state properties, and in vivo pharmacokinetics 
after intratracheal or peroral instillation. Liposomes consisting of cholesterol and lecithin 
were prepared using a thin film hydration method. Aerosol assessment of the optimized 
formulation is reported, but unfortunately it is unclear what exact method was used, as 
description indicates consecutive use of a 60 L/min ACI and an unspecified three stage glass 
impinger. It is also unclear which device was used for dry powder aerosolization. However, it 
is reported that the optimized formulation yielded a FPF of 26%, which is fairly low in 
comparison to FPFs achieved in other studies already discussed that use liposomal 
formulations. In vitro activity testing indicated higher efficiency than free RF but lower 
efficiency than control groups (free ciprofloxacin 10.0 µg/mL and free streptomycin 7.5 
µg/mL). In vivo data suggests an increase in bioavailability after administration via the 
pulmonary route. It is to be mentioned that interpretation of results presented in this study is 
highly compromised by inaccurate description of the methods as well as poor data 
presentation. 
 
Manufacture and assessment of RF loaded lipid microspheres was reported by Singh et al. in 
2015 [122]. RF and soybean phospholipids (Lipoid S75, Lipoid, Ludwigshafen, Germany) 
were dissolved in DCM, spray dried, and then analyzed for physicochemical and aerosol 
properties as well as in vivo pharmacokinetics at the target organ, and deposition. Aerosol 
testing was conducted using an 8-stage ACI, operated at 28.3 L/min. Powders were 
aerosolized from an unknown, apparently capsule based, DPI. FPF, defined as the cumulative 
mass recovered from S2-S7 divided by the mass initially loaded into the capsule, was reported 
as 78%, which is somewhat confusing, as cumulative device (determined indirectly via 
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emitted fraction (EF) of 80%), s0 (approx. 5%), and s1 (approx. 8%) deposition are reported 
as approx. 33%. EF was defined as relative mass in the capsule prior to and after actuation, 
which actually over predicts the EF, as powder adhering to the device was ignored. 
Additionally, IP and preseparator deposition were not reported, which compromises 
evaluation of the data presented. In animal experiments using rats, test (lipid microspheres 
suspended in saline) and reference formulations (RF suspended in saline) were applied using a 
jet nebulizer and selected organs (lungs, heart, liver, kidneys, spleen) were harvested at pre-
set time points. The authors concluded an eightfold increase in relative RF lung deposition for 
the lipid microsphere formulations, which was based on evaluation of the AUC determined in 
lung tissue. However, this method of extraction from the recovered tissues was not reported 
and one might suspect that not only the amount of RF released was analyzed, but also RF still 
entrapped within the microspheres, which would not be subject to systemic distribution and 
elimination. Neither in vitro drug release nor in vitro cell uptake was determined, so the only 
valid conclusion drawn from this experimental setup was that the lipid microspheres persisted 
in the lungs. Transferability of this study to a proposed dry powder application is limited, as 
surface properties of hydrated microparticles are expected to differ significantly from dry 
microparticles, which would need time for equilibration at the site of action.  
 
The first study investigating aerosol performance of formulations comprising solid lipid 
nanoparticles (SLNP) was reported in 2016 by Maretti et al. [123]. SLNPs were manufactured 
by dissolving RF in stearic acid with the application of heat and emulsifying the lipid phase in 
an aqueous solution of sodium taurocholate using ultra sonification. The resultant particles 
were purified by dialysis and subsequently freeze dried, using mannitol or trehalose as a 
cryoprotectant. A two level full factorial design of experiments (DoE) approach was 
conducted to investigate and optimize formulation and process characteristics. Aerosol testing 
was conducted using an abbreviated ACI setup (fast screening imapctor, Copley scientific, 
Nottingham, UK) consisting of two stages separating aerosols into two, i.e. coarse and fine, 
particle fractions. The CI was operated at 60 L/min. Powders where filled into size three 
HPMC capsules and aerosolized using the Plastiape RS01 device. It is unclear, if the 100 
L/min or 65 L/min make of the device was used, so this experimental setup might actually 
underestimate in vivo aerosol performance. Using this experimental setup, FPFs of 9-70% 
were achieved. The main conclusion after evaluation of the DoE data was that rapid freezing 
in combination with sample dilution provides process conditions that permit omission of the 
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cryoprotectant. Omission of the cryoprotectant was considered to be beneficial for the 
feasibility in pulmonary therapy. Another study, published by the same group in 2017, 
investigated mannosylated SLNP with a slightly different composition [124]. Here, 
cholesteryl myristate mixed with either palmitic acid or tripalmitin was melted with RF and 
emulsified into aqueous solutions of either sodium taurocholate or sodium taurocholate with 
methyl α-D-mannopyranoside. Resulting SLNP suspensions were then freeze dried using 
optimized conditions determined in the previous study. Amongst other tests, formulations 
investigated were assessed for in vitro cell toxicity and particle uptake (J774 murine 
macrophage cells), and aerosol properties. Aerosol properties were determined using the NGI. 
Dry powders were filled into size three capsules and dispensed from the Plastiape RS01 
device, which required a flow rate of 60 L/min to generate the required pressure drop of 4 kPa 
in order to comply with USP and Ph.Eur. requirements. One might assume that this make of 
the DPI was also used in the previous study. Though achieving high EFs (>89%) for all 
formulations, FPFs in this study were found to be fairly low (3-25%), which was attributed to 
the cohesiveness of the formulations. Furthermore, functionalized SLNPs were found to be 
taken up more rapidly by macrophages, though the overall extent, after 6 hours was found to 
be identical to the control group. 
  
A highly interesting study published by Srichana et al. in 2016 reports human in vivo 
toxicological data after administration of RF loaded lipid microparticles using a novel DPI 
device [125]. To manufacture respirable particles, soy bean lecithin and cholesterol were 
dissolved in a mixture of ethanol and water (2:1). After lecithin/cholesterol dissolution, 
mannitol spheres of 2 µm as well as RF were added, which yielded a suspension of the 
mannitol spheres in the hydroalcoholic solution. The suspension was then spray dried. 
Powders were filled into size three capsules and dispensed from a novel low intrinsic 
resistance 1.0 × 10!!(√!"# ∗!"#)/! DPI device. Not much information is provided about 
the device but apparently it utilized a capsule opening mechanism similar to that of the 
Rotahaler, and its design included a mesh at the inlet of the mouthpiece. Aerosol testing was 
conducted using an 8-stage ACI at a flow rate of 60 L/min. The FPF for the RF formulation 
was determined as 37% and the MMAD was approximately three µm. During in vivo 
assessment of the formulation using data gathered from 39 participants, no intervention 
related adverse effects were observed. Also, blood marker levels were comparable for all 
groups, indicating good short-term tolerability of inhaled RF. 
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RF formulations including chitosan 
 
Chitosan is a biopolymer that is obtained after the hydrolytic deacetylation of chitin (poly-(N-
acetyl-D-glucosamine)), which can be extracted from, e.g. crustacean shells. Depending on 
the degree of deacetylation as well as molecular weight, different chitosan properties can be 
obtained (e.g. viscosity, acidity, or solubility). With the protonation of free amino groups, 
chitosan shows increased solubility in acidic environments and is capable of forming salts. 
Thus, aqueous solubility is also strongly depending on the ion strength of the solvent [126]. 
Nanoparticles formed from chitosan typically show a positive zeta potential. 
 
The first study providing aerosol data with chitosan containing microparticles was published 
in 2014 by Kundawala et al. [127]. Particles were manufactured as follows: RF was dissolved 
in EtOH before adding a watery solution of ascorbic acid and chitosan, which was 
precipitated by adding pentasodiumtriphosphate (TPP). Leucin and lactose were added as 
structural excipients before spray drying the suspension obtained. Resultant powders were 
characterized by determination of solid-state properties, drug loading/encapsulation 
efficiency, particle sizing, aerosol testing, and in vitro dissolution. Additionally, 
pharmacokinetics was studied post intratracheal insufflation into rats. Particles produced, 
showed a corrugated spherical shape, when analyzed using a scanning electron microscope 
(SEM). Aerosol testing was conducted using an 8 stage ACI at a flow rate of 60 L/min and 
powders were dispensed from an unspecified, capsule based DPI. FPFs reported are in the 
range of 55-62%. In this publication, FPF was determined by relating the cumulative mass 
recovered from all stages to the total mass recovered, which was likely to over predict actual 
aerosol performance. As only characteristic numbers (i.e. MMAD, GSD, FPF, and EF) were 
reported, evaluation of results presented is somewhat compromised. However, low MMADs 
of about three µm indicate the potential to obtain suitable aerosol properties. In vitro release 
studies conducted in pH 7.4 phosphate buffer showed sustained release for all formulations. It 
should be mentioned that the solubility of chitosan is pH dependant, so different release 
kinetics might be expected upon release at the target site. In vivo studies assessing RF blood 
levels after peroral or pulmonary application, verified delayed onset and longer plasma half-
life for the test formulations, which was attributed to sustained release from the delivery 
system.  
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Pai et al. published another study investigating respirable chitosan particles in 2016 [128]. 
Chitosan MPs were prepared in a similar way as previously discussed but were not 
incorporated into leucine/lactose particles, but formulated as binary blend with lactose 
monohydrate. To briefly summarize, chitosan and RF were dissolved in 0.1 N acetic acid and 
chitosan was cross-linked/precipitated using TPP. Resultant suspension was then spray dried, 
and the dry powder obtained was blended with lactose carriers. Characterization included 
solid state and aerosol characterization, in vitro dissolution testing, in vitro macrophage 
uptake, and in vivo toxicity studies of MP suspensions. Aerosol characterization was carried 
out using a 28.3 L/min ACI. Dry powders were dispensed using the Lupihaler device. FPFs 
obtained were found to be below 25%, which might partially be attributed to the low 
operational flow rate of the ACI, which is insufficient for the Lupihaler to perform properly. 
In vitro dissolution studies showed modified release for some formulations but proper 
evaluation of the release properties was compromised by the premature termination of the 
experiment. In vivo toxicity assessment showed good short-term tolerability of the MPs. 
 
In 2017 Rawal et al. investigated in vitro and in vivo performance of chitosan nanoparticles 
[129]. In this study, chitosan nanoparticles were prepared using a method similar to the ones 
previously described, involving dissolution of chitosan and RF in acetic acid, followed by 
chitosan crosslinking and precipitation using TPP. In contrast to previous studies, inhalable 
particles were obtained by freeze drying the resulting suspensions, and lactose was used as 
cryoprotectant. Formulations were optimized in terms of size and drug loading. The optimized 
formulation was then blended with coarse lactose carriers. Characterization included 
determination of solid state properties as well as in vitro dissolution, aerosol, stability, and 
cell toxicity testing using J774 murine macrophages. Additionally, in vitro acute toxicity and 
pulmonary pharmacokinetic studies were conducted, using rats. Aerosol testing was 
conducted using an ACI of unknown specification. Also the DPI device used, remains 
unclear. Aerosol data of one optimized formulation only was reported with a FPF of 33%. 
Due to the fact that not much information about the device and operating conditions, as well 
as only MMAD, FPF, and GSD are provided, proper evaluation of the aerosol performance is 
compromised, but the results presented appear to align with studies previously discussed. 
Also, results from dissolution and cell culture studies are in line with previous publications 
showing sustained release and low cell toxicity. In vivo studies comparing the test formulation 
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to a binary blend of micronized RF and a perorally instilled RF solution, showed prolonged 
persistence of RF in the lungs in the case of the NPs. However, the method of pulmonary 
application is not reported and application of more than 300 mg/KGBW seems fairly high, but 
probably was found necessary due to the low drug loading of 13% w/w. 
 
Carbohydrates 
 
Besides sugars, carbohydrates used in the studies presented include a wide variety of mono- 
oligo-, or polymeric sugar derived excipients like sugar alcohols, cyclodextrins, or alginate. 
Sugars and sugar alcohols typically have applications as matrix forming excipients to 
incorporate free drug or for example, nanoparticles. In contrast, cyclodextrins are used as 
solubility enhancers that also might act as structural excipients. Another interesting field of 
application investigated is the utilization of carbohydrate excipients, such as mannan or guar 
gum, to proactively target microparticles to alveolar macrophages by means of mannose 
receptor mediated internalization.  
 
Co spray drying of RF and mannitol solutions, using a four fluid nozzle, was investigated by 
Mizoe et al. in 2008 [130], and presented a one step approach to incorporate RF into mannitol 
microspheres. It should be mentioned that this study was conducted by the same group that 
later had published another study, previously discussed in the PLGA section [113]. 
Manufacture of MPs was executed by dissolving RF in a mixture of acetone and ethylacetate, 
which was then co spray dried with a solution of mannitol in water. Both feed solutions were 
supplied to different channels of the four-fluid nozzle. In order to achieve sustained release 
from the particles additional batches containing lipids were prepared. However, the sustained 
release batches were not subjected to aerosol or solid-state characterization and were only 
used for in vivo experiments. SEM images probably show collapsed spheres, but in depth 
evaluation is compromised by insufficient image quality. Aerosol testing was conducted using 
an eight stage ACI at a flow rate of 28.3 L/min and dry powders were dispensed using the 
Jethaler device. Samples characterized showed moderate to low inhaler, and moderate 
preseparator deposition. IP deposition was found to be fairly high (about 30-35%). S2-S7 
deposition was in the range of 35-43% indicating acceptable overall performance. In vivo 
studies investigating pharmacokinetics after intratracheal administration showed rapid onset 
and elimination of RF from the blood, which was attributed to a low residence time of RF-
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mannitol MPs in the lungs. To overcome this issue, additional formulations containing lipids 
were investigated but this altered strategy was found to have little effect on the outcome. The 
second study of that group [113] mentioned earlier in this paragraph was conducted to 
overcome this issue by adding PLGA to the microspheres.  
 
An interesting study on the synthesis, characterization, and toxicological evaluation of a novel 
lipopolysaccharide, intended for use as matrix forming polymer for inhalable MPs, was 
published by Vadakkan et al. in 2015 [131]. Stearyl amine was grafted onto dextran with two 
different degrees of substitution, and resulting lipopolysaccharides, were formulated into RF 
loaded MPs, using a spray drying method. One formulation with unmodified dextran was 
sprayed as reference. Distribution and toxicity of the grafted polymers was investigated in 
vivo using rats as well as in in vitro cell culture studies using THP-1 (human monocytic) cells. 
Aerosol testing was conducted using an eight stage ACI at a flow rate of 60 L/min. Powders 
were dispensed from an unknown inhaler. FPFs were determined as 63%, 75%, and 78% for 
the dextran and low and high degree of substitution particles, respectively. Unfortunately, the 
authors fail to provide full deposition data including DPI and IP deposition (use of a 
preseparator unit is not mentioned), which would have been desirable to strengthen the 
excellent results reported. Interestingly, drug loading was limited to 25% and it would have 
been highly interesting to see how the particles might have performed at higher drug loading. 
In vitro and in vivo toxicity experiments indicated biocompatibility but divergent results 
regarding toxicity were obtained from in vivo and in vitro experiments. In vivo studies showed 
a certain degree of pathological alteration of the target issue, which was attributed to the long 
residence time of the particles in the lungs. However, these results could not be confirmed in 
vitro. 
 
In 2015 and 2016, Goyal et al. published results of two studies investigating chitosan, 
mannan, guar gum, and guar gum decorated chitosan nanoparticles that were incorporated 
into mannitol/leucine MPs by spray drying, in order to obtain a respirable formulation [132]. 
Firstly, chitosan, guar gum, and mannan nanoparticles loaded with RF were prepared using 
the ionic gelation method, already described in the chitosan section above, antisolvent 
precipitation, or spray drying respectively. In an additional second step, mannitol and leucin 
were added to the nanoparticulate suspension, which was subsequently spray dried. Samples 
were characterized for their solid state properties, in vitro dissolution, aerosol performance, 
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and AJ774 macrophage toxicity and uptake, as well as in vivo lung deposition and 
pharmacokinetics. Additionally, efficacy of the formulations was tested using an in vivo 
infection model (2016 study [133]). It should be mentioned that all experiments were also 
carried out using isoniazid, but these results are not discussed here as they are outside the 
scope of this text. Aerosol testing was conducted using an ACI that was coupled to a jet mill 
collection vessel at a flow rate of 5 L/min, dispensing 2 g of sample from an unknown device. 
The method reported is not easily understood and obviously deviates from the standard 
procedure of aerosol characterization using cascade impactors, which may have highly 
compromised evaluation of the results, if they were presented. Only MMADs (i.e. missing 
FPF, GSD, and ED) being in the range of 1.2-1.9 µm were reported, this was found to be 
insufficient for valid scientific evaluation. Nonetheless, in vivo γ-scintigraphic studies showed 
inhomogenous lung deposition, since different formulations applied seem to accumulate at 
different locations. This was evaluated as beneficial in the 2015 publication, as one ‘target’ 
spot was identified as region with the highest prevalence of lesions associated with TB, but 
targeting could not be confirmed in the 2016 study, where a similar formulation accumulated 
elsewhere. In vitro macrophage cell uptake assay showed equivalence in uptake of chitosan, 
guar gum, and guar gum decorated chitosan nanoparticles after eight hours, whereas mannan 
nanoparticles showed slightly lower uptake, over the same period. Interestingly, uptake after 
eight hours was found significantly lower than after 2 or 4 hours in the case of mannan 
nanoparticles, which had not been commented. Decorated chitosan, guar gum and mannan 
nanoparticles were found to be taken up more rapidly, which was associated to receptor 
mediated phagocytosis. Minor increase in the uptake of guar gum decorated nanoparticles 
over chitosan nanoparticles was found in the 2016 study. In vitro dissolution studies showed 
sustained release at a similar degree of retention for all formulations. In vivo infectious 
disease model indicated superior performance of guar gum decorated chitosan nanoparticles 
over chitosan nanoparticles and free drugs respectively. 
 
In 2015, Garg et al. investigated feasibility of RF loaded alginate nanoparticles for pulmonary 
application [134]. Alginate particles, prepared by an ionotropic gelation technique, were 
loaded with RF or isoniazid and subsequently spray dried, incorporating mannitol and leucine 
as structural excipients. Samples were characterized for their solid state properties, in vitro 
dissolution, aerosol testing, and cell toxicity, as well as in vivo lung distribution and organ 
pharmacokinetics. Aerosol testing was carried out using an ACI coupled to a jet mill 
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collection vessel at a flow rate of 5 L/min. The DPI device used was not reported, but the 
sample size was 2 g. Limitations of this type of experimental setup have already been 
discussed in the previous paragraph. MMADs of test formulations were found to be “ranging 
from 1 to 2 µm”, from which the authors deduced preferred deposition in the posterior part of 
the lungs. In vitro dissolution studies confirmed sustained release for both formulations. In 
vivo lung deposition studies showed accumulation of the formulation in a specific lung 
location, which is in accordance with other results already discussed (see previous paragraph, 
2016 study). In vitro toxicity studies showed good tolerability of alginate nanoparticles. In 
vivo pharmacokinetic studies showed sustained release and increased bioavailability for both 
nanoparticulate formulations. 
 
 
Mesoporous silica 
 
One study published in 2015 by Mohseni et al. reported the investigation of mesoporous silica 
aggregates as a potential carrier system for RF [135]. Here, in-house synthesized mesoporous 
particles were passively loaded with RF and spray dried under various conditions, using a half 
factorial design DoE approach. Particles were assessed for solid state characteristics, as well 
as in vitro dissolution, and aerosol performance. Aerosol performance was determined using 
the ACI at 50 L/min after dispensing dry powders from the Cyclohaler device. It should be 
mentioned that using the ACI a 50 L/min flow rate is unusual and does not comply with the 
USP or Ph.Eur., as calibration at that flow rate is not fully established. MMAD of all 
formulations investigated were used as responses in the DoE, which must be considered as 
inadequate as MMAD is not always correlated to deagglomeration and aerosolization of a 
given formulation, and can give no information about the actual efficiency of said 
formulation. Particles of small geometric diameter might display very small MMADs for 
example, but might be highly cohesive and so may not be easily deagglomerated, which could 
lead to impaction in the upper airways. Bearing in mind that one of the main reasons for 
inhalable RF therapy development is to reduce systemic exposure in order to avoid unwanted 
side effects, FPF would have been the more appropriate response parameter. Unfortunately, 
incomplete aerosol data was reported for only one formulation (which should be expected to 
be the optimized formulation); indicating an FPF of 46% and an EF of 83%. Despite this 
being a decent result, one might assume that the actual potential of the formulation might not 
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have been realized, and that using the Cyclohaler at a standardized flow rate equivalent to a 
pressure drop of 4 kPa for the device could have yielded higher FPFs. On the other hand, 
higher airflow velocities could induce higher triboelectric charges, so one must conclude that 
this study could have been more meaningful, if data acquired would have been processed in a 
more adequate way.  
 
Excipient free formulations 
 
The following section describes formulation strategies that do not involve the use of 
excipients, and are aimed at maximizing drug loading of a respirable formulation. Since drug 
dose quantities that can effectively be aerosolized are limited, high potency formulation 
approaches (i.e. high API loading) may be desirable unless efficient drug targeting to the site 
of infection (e.g. alveolar macrophages) is involved. Excipients often times are found to be 
necessary to produce fine powders that are easily de-agglomerated, or might aid proactive 
uptake of the API by macrophages. Excipient free approaches usually involve effective 
particle engineering by for example, spray drying or other suitable techniques. 
 
The first study reporting an excipient free formulation of inhalable RF MPs was published by 
Son and McConville in 2011 [91]. RF was recrystallized from anhydrous ethanol and the 
resulting suspension was subsequently spray dried, using a two fluid nozzle. As a reference, 
another formulation yielding amorphous RF particles was spray dried from a solution of RF in 
DCM. Samples were assessed for solid state properties and stability, as well as in vivo 
dissolution and aerosol testing. SEM images showed flake like crystals and corrugated 
spheres for the test and reference formulations respectively. Aerosol testing was carried out 
using the NGI at a flow rate of 60 L/min. Dry powders were aerosolized using either the 
Handihaler, or Aerolizer device. FPFs of test formulation dispensed from the Handihaler 
device at capsule loading of 7, 15, and 30 mg were found to be 59%, 64%, and 60% 
respectively. Performance with the Aerolizer device was slightly higher, generating a FPF of 
69%. The control formulation showed FPFs of 51% and 37% using the Handihaler and 
Aerolizer devices, respectively. It should be mentioned that the aerosol analysis at a flow rate 
of 60 L/min was a deviation from standard USP and Ph.Eur protocol, as the Handihaler and 
Aerolizer devices generate a pressure drop of 4 kPa at flow rates of about 40 L/min and 110 
L/min respectively. Interestingly the test formulation was found to perform better on the 
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Aerolizer, whereas the reference formulation displayed better performance on the Handihaler, 
which was due to pronounced powder retention within the capsule. It was hypothesized that, 
being a high resistance device, more energy was imparted to aid de-agglomeration using the 
Handihaler at given flow rate, which suited better de-agglomeration in the case of the 
reference formulation. Contrary, larger apertures in the capsule after punctuation with the 
Handihaler would facilitate premature ejection of powder agglomerates, in case of the test 
formulation. Dissolution testing was conducted using a novel test method for aerosols, which 
had previously been developed by the same group, where powder samples are recovered from 
the NGI stages (particularly S3) and subjected to dissolution experiments, and immediate 
release was shown for both formulations. Crystals obtained were characterized as RF-
dihydrate, which was based on thermogravimetric analysis. Formation of a co-crystalline 
system was also indicated by XRPD and DSC analyses. However, no identifying assay (e.g. 
Karl Fisher titration) was conducted to confirm that loss on drying observed was actually 
caused by evaporation of water from the crystals. Stability studies conducted at ambient 
conditions over a period of 9 months confirmed chemical stability of the test sample, whereas 
the reference was found to show pronounced degradation. 
 
Another study conducted by Parikh, Patel, and Dalwadi in 2014 reported in vivo assessment 
of the amorphous reference formulation of the study previously discussed [136]. Manufacture 
of amorphous RF particles was facilitated by spray drying solutions of RF from DCM. 
Samples were characterized for in vitro dissolution and aerosol properties, as well for in vivo 
pharmacokinetics after intratracheal and peroral administration. Aerosol characterization was 
carried out using an 8-stage ACI at unknown flow rate. Also unknown was the device that 
was used to aerosolize the dry powders. The test formulation showed a FPF of 78% and an EF 
of 59%. As the FPF reported is higher than the actual fraction emitted it is to be assumed that 
the FPF reported is related to the emitted fraction, rather than the whole sample. Thus, the 
adjusted FPFtotal would be 46%, which is in reasonable agreement with the study conducted 
by Son and McConville (2011). In vitro dissolution studies using simulated gastric (pH 1.2) 
and phagosomal (pH 4.5) fluid showed pH dependent drug release, exhibiting more rapid 
release in the more acidic environment, which is in good agreement with literature. In vivo 
pharmacokinetic studies showed higher bioavailability and shorter onset time, if the 
formulation is administered through the pulmonary route, which also is in good agreement 
with literature. 
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In a study published by Rawal et al. in 2017, in vitro and in vivo performance of an optimized 
binary blend of micronized RF with lactose carrier particles was reported [137]. Using a DoE 
approach, the authors determined the most appropriate drug/coarse and fine lactose ratio and 
besides flow properties and blend and content uniformity, FPFs yielded were the primary 
responses. Unfortunately, the method of micronization was not reported. Aerosol testing was 
conducted using an 8-stage ACI at a flow rate of 30 L/min and dry powders were dispensed 
using the Rotahaler device. Operating the ACI at 30 L/min is somewhat unusual and 
additionally probably underestimates aerosol performance, as the pressure drop of 4kPa is 
generated at a flow rate of about 45 L/min. All formulations assessed yielded FPFs in the 
range of 23-29% and MMADs from 4.1-5.7 µm. In vivo lung pharmacokinetic studies 
administering the respirable dry powder through an unknown device or a perorally instilled 
solution of RF, showed comparable results to another study by the same group investigating 
chitosan nanoparticles, which has already been discussed in the appropriate section above. 
 
1.5.3.2.1 DPI formulations with combined therapy approaches 
The first study reporting aerosol testing of a formulation combining multiple antibiotic APIs 
was published in 2013 by Chan et al. [138]. In this study, RF, pyrazinamide, and isoniazid 
were dissolved in EtOH/water 50:50 and spray dried in order to produce respirable MPs. As a 
reference, formulations containing the individual antibiotics only were produced in the same 
manner. Formulations were characterized for solid state properties, as well as in vitro aerosol 
and dissolution testing. SEM images of formulations including all antibiotics showed 
spherical particles of different size, displaying a smooth surface. SEM images of control 
formulations showed large, thin walled, and highly collapsed (RF), agglomerated spherical 
(isoniazid), and agglomerated brick like (pyrazinamide) particles. Aerosol testing was 
conducted using a MSLI at a flow rate of 100 L/min. Powder samples were dispensed using 
the Aerolizer device. Unfortunately, only data of the test formulation is reported showing an 
FPF of 46%, and a MMAD of 3.5 µm. Interestingly, higher relative concentrations of RF 
were found in the lower stages of the impactor, which was attributed to inhomogenous 
distribution and particle fragmentation, which was confirmed using time of flight-secondary 
ion mass spectrometry (ToF-SIMS). Dissolution studies showed immediate release from the 
single antibiotic samples. Triple antibiotic samples showed a similar profile, but RF dissolved 
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at a slightly slower rate. It was concluded that dissolution rates in the triple antibiotic 
formulation were too high for effective macrophage uptake. 
 
Investigation of another combined drug formulation was published by Zhou et al. in 2014 
[139]. In this study, a similar technique was used to formulate RF and colistin, which were 
spray dried combined and individually from an EtOH/water 50:50 mixture. Analytical 
methods applied included: solid state characterization, x-ray photoelectron spectroscopy 
(XPS), ToF-SIMS, and in vitro aerosol testing, as well as an evaluation of the antimicrobial 
activity of isolated, and combined APIs. Aerosol characterization was carried out using a 
MSLI that was operated at a flow rate of 100 L/min, and powders were aerosolized using the 
Aerolizer device. SEM images of the formulations showed corrugated spherical and highly 
collapsed thin walled particles for colistin and RF samples, respectively. The morphology of 
the combination formulation was similar to that of the RF particles. Aerosolization of test 
formulations yielded high FPFs of approximately 80%, 90%, and 90% for the colistin, RF, 
and combination formulations, respectively. As already reported in a previous study, ToF-
SIMS and XPS analyses showed that RF predominantly forms the particle shell, and the 
desirable aerosol properties observed were attributed to the hygrophobicity of RF [138]. 
Additionally, the impact of relative humidity on aerosol performance was investigated; but 
only in the case of pure colistin, pronounced differences in FPFs were found. It was 
hypothesized that RF being present at the particle surface effectively protects the colistin 
within combined API particles. Administartion of a combined therapy of RF and colistin was 
found to be more effective against A. baumannii bacteria than the individual drugs, and a 
synergistic effect of both antibiotics was hypothesized. 
 
Another study focusing on the effects of different surface compositions of aforementioned 
particles was published in 2016 [140]. In order to generate particles with different surface 
properties, different ratios of RF and colistin were spray dried from EtOH/water 50:50. 
Analytical procedures reported included: characterization of solid-state properties, XPS, ToF-
SIMS, and in vitro aerosol testing. Evaluation of the antimicrobial activity of isolated, and 
combined APIs was conducted using P. aeruginosa. SEM images of particles obtained 
displayed an identical morphology to the particles obtained in the studies presented in the 
previous paragraphs [138,139]. Aerosol assessment was conducted using the NGI at a flow 
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rate of 100 L/min and aerosols were dispensed using the Osmohaler device, which is highly 
similar to the Aerolizer device used in the aforementioned previous studies. FPFs generated 
using this setup were significantly lower than ones previously reported but still showed 
excellent performance yielding 69%, 65%, 73%, and 80% for pure RF particles and combined 
particles at a colistin/RF ratio of 4:1, 1:1, and 1:4, respectively. Lower FPFs generated were 
attributed to the difference in capsule punctuation mechanism of the respective inhalers: the 
Aerolizer used in the previous study was a design using 2x4 pins, whereas the Osmohaler 
used in the present study had a 2x1 pin configuration. XPS and ToF-SIMS confirmed that RF 
was predominantly present at any colistin to RF ratio, which aligns with conclusions drawn in 
the previous study. Furthermore, all other results presented in this study were consistent with 
the previous results. 
 
A study, investigating a combination of three different antibiotic drugs in one respirable 
formulation, was published by Lee et al. in 2016 [141]. RF, colistin, meropenem, and 
tigecycline were spray dried individually and in different ternary combinations using a Büchi 
(Flawil, Switzerland) B-90 nano-spray dryer. Powders were characterized for solid state 
properties as well as in vitro aerosol performance. Additionally, antimicrobial activity was 
assessed by determination of minimal inhibitory concentrations using antibiotics sensitive and 
multi drug resistant strains of P. aeruginosa, E. coli, K. pneumonia, and A. baumanii. Aerosol 
testing was conducted using the NGI at a flow rate of 60 L/min and powder samples were 
dispensed from an Aerolizer device of unknown resistance. Aerosolized dry powders showed 
a FPF of 55, 54, and 68 for RF, colistin/meropenem/RF, and colistin/tigecycline/RF, 
respectively. 
 
Another study published in 2017 by Kadota et al. focused on the applicability of different 
carbohydrates in manufacture of combined RF and isoniazid (INH) MPs using a spray drying 
process [142]. Briefly summarized, RF and INH as well as carbohydrates (i.e. lactose, 
sucrose, maltose, β-cyclodextrin, methyl-β-cyclodextrin, and highly branched β-cyclodextrin 
(HBβCD)) were dissolved in EtOH and water, respectively. Solutions were premixed at a 
ratio of 3:10 and then spray dried using a two fluid nozzle. Particles obtained were 
characterized for their solid-state properties, as well as in vitro aerosol testing. SEM images 
show larger agglomerates of highly collapsed nanospheres and only the sample including 
HBβCD with RF showed individual collapsed spherical particles, which were larger in size. 
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Aerosol testing was conducted using an ACI at a flow rate set at either 28.3 L/min or 60 
L/min. Dry powder samples were filled into HPMC capsules and aerosolized using the 
Jethaler device. Different formulations investigated yielded FPFs in the range of 3% (INH) to 
38% (RF) for single drug formulations with HBβCD, and 25% (sucrose) to 51% (HBβCD) for 
combined formulations with different sugars. Additionally the combined HBβCD formulation 
was tested at a flow rate of 60 L/min and yielded a FPF of 53%. FPFs of the best performing 
formulation assessed did not differ strongly when investigated at different flow rates, which 
indicated that the Jethaler device provided stable performance across a wide range of flow 
rates.  
 
In 2018, Momin et al. published two publications investigating a combined dosage form that 
incorporated RF and kanamycin into one respirable formulation [143,144]. The study design 
was similar to studies published by Chan et al. [138], Zhou et al. [139], and Wang et al. [140] 
by investigating surface enrichment of RF. The approach was extended by using a DoE 
approach to optimize formulation designs: the RF to Kanamycin ratio, the EtOH to water 
ratio, and process parameters (i.e. inlet temperature), [143]. Kanamycin was chosen as 
hygroscopic model drug, which was shown to be difficult to formulate into aerosolizable dry 
powders. Spray drying with RF was utilized to improve particle properties due to its 
hydrophobicity and shell accumulation propensity; as found in several studies discussed 
earlier. Surface composition was analysed using ToF-SIMS and XPS, and aerosol testing was 
conducted using the NGI at 100 L/min after dispensing powder samples from an Aerolizer 
device. Results of the DoE study included only truncated aerosol data, since only FPFs and 
EFs were reported. However, but full characterization was provided for the optimized 
formulation, as well as reference formulations of kanamycin and RF (separately spray dried 
under optimized conditions). FPFemitteds reported were in the range of 82-85% for different 
batches prepared, which translates to FPFtotals of 69-78%. FPFemitteds were found equivalent, 
but reference formulations achieved lower EFs (84-85%) than the test formulation (91-92%). 
All other results presented in this study incl. XPS, ToF-SIMS, solid-state characterization, and 
in vitro cell toxicity were in line with previous studies. 
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1.5.3.3 Conclusion 
A variety of therapeutic strategies to, for example facilitate proactive drug targeting to 
macrophages, or manufacture high drug load formulations have been investigated. Studies 
discussed present results from all stages of preclinical to early clinical development, ranging 
from pre-formulation development to human in vivo toxicity studies. Many of the studies 
described report innovative therapeutic and technological approaches and show high data 
quality and conclusive evaluation. On the other hand, it was also found that certain studies 
display poor methodology, data quality, and evaluation. These studies have not been 
excluded, but their limitations, especially focusing on aerosol testing, have been discussed 
critically. In general, it was noted that little focus was placed on the long-term stability of the 
formulations, which actually might be highly critical with respect to the amorphous 
formulations presented; since amorphous materials have been shown to be prone to 
degradation. On the other hand, the stability of amorphous active ingredients may be 
positively influenced by incorporation into a matrix, as has been described in several of the 
studies. As of now, it is not clear which formulation strategy or therapeutic approach is the 
most suitable for a more efficient TB therapy, but many promising attempts are in the 
pipeline. Interestingly, only one study investigating PLGA or PLA formulations was 
published after 2010, and this study did not utilize the polymers as matrix excipients in order 
to prepare nano- or microparticles, but as a sustained release coating for an excipient free, 
particle engineered formulation. From this observation one might conclude that nano- or 
microparticulate formulation approaches involving PLGA/PLA have been appropriately 
investigated on a pre-clinical level, but have failed to leap into clinical testing. This stagnation 
may be due to a variety of reasons that could include: high excipient/manufacturing costs, 
non-scalability of the processes involved, or even a lack of innovation and intellectual 
property generated to attract investors. Other formulation strategies, including the use of 
different excipient classes, multiple drug combinations, or excipient free formulations are still 
under active investigation and more interesting results are to be expected in the near future.  
 
1.6 Aim and scope of the thesis 
Aim of this thesis was to develop inhalable and excipient free dry powder particles of the 
antibiotic drug rifampicin, which is used in first line tuberculosis therapy. The manufacturing 
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technique to be investigated was spray drying of suspensions and solutions of rifampicin from 
various solvents. Special focus was set on the determination of the crystallographic properties, 
aerosol properties, as well as physical and chemical stability of the particles. Additionally, 
another aim was to investigate the feasibility of using FDM 3D printing to generate a 
modified induction port to be used with the NGI, in order to provide more biorelevant aerosol 
testing for the formulations developed.  
Chapter one aimed to give a general introduction to aerosol therapy, covering physiological 
and pathophysiological conditions of the human respiratory tract as well as an introduction to 
formulation strategies for pulmonary therapeutics and aerosol testing. Special focus was set 
on experimental tuberculosis therapy using dry powder inhalation devices, which provided the 
framework of the work presented. 
Cascade impactor analysis is an important tool not only to compare different inhalable 
formulations, but it can also be utilized to predict the performance of a given 
formulation/device system in vivo. In order to provide a more biorelevant testing system for 
pulmonary formulations, the aim of the studies reported in chapter three was to show the 
feasibility of applying a rapid prototype technique (fused deposition modeling 3D printing) in 
combination with patient based 3D imaging, in order to generate a more physiologically 
relevant induction port, which was based on actual patient data obtained from a computer 
tomographic scan. The modified induction ports were tested with different, commercially 
available formulations to a) investigate, which types of formulation are susceptible to tracheal 
deposition (section 3.1) and b) estimate the quality of the IVIVC. Thus, based on the results 
obtained in section 3.1, additional commercial formulations were selected based on 
availability of in vivo lung deposition data in literature, so that the quality of the in vitro 
prediction of in vivo lung deposition could be assessed (section 3.2).  
Chapter four reports the development of respirable rifampicin particles, manufactured using 
different spray drying methods. Suspensions and solutions of rifampicin in a variety of 
organic solvents as well as water were investigated and assessed for their suitability to 
produce particles of distinct shape, aerodynamic performance, or polymorph. In a second 
study, the most promising candidates from this exploratory trial were investigated more 
detailed. Special interest in this set of studies was to get a deeper understanding of the 
mechanism of particle formation and crystallographic behavior of amorphous and crystalline 
particles obtained respectively. Formulations showing the best aerosol performance were also 
investigated, using a low performance, disposable inhalation device surrogate in order to 
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show that these formulations demand low requirements from the DPI only, as well as to use a 
more discriminating approach to evaluate the quality of suchlike formulations. Additionally, it 
was of interest to investigate the aerodynamic behavior of the test formulations using the 
modified cascade impaction experiment developed in chapter three in order to estimate, how 
the formulations developed would perform in vivo. 
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2 Materials and methods  
 
2.1 Materials 
2.1.1 Active ingredients used 
Chemical structures of the Active ingredients used are shown in Figure 17. 
2.1.1.1 Rifampicin 
 
Rifampicin for manufacture of microparticles was obtained from TCI (Tokyo, Japan). 
Rifampicin as reference material for analytical purposes was obtained from Sigma Aldrich 
(Saint Louis, MO, USA).  
2.1.1.2 Salbutamol sulfate 
Salbutamol (SAL, in USA: Albuterol) sulfate was obtained from Alfa Aesar (Thermo Fisher 
GmbH, Karlsruhe, Germany). 
2.1.1.3 Corticosteroids 
Beclometasone dipropionate was obtained from TCI (Tokyo, Japan). Fluticasone propionate 
and Ciclesonide were obtained from Swanpnroop drugs and pharmaceuticals (Maharashtra, 
India). 
60 
2. Materials and methods 
 
 
Figure 17. Chemical structures of APIs used: rifampicin (A), salbutamol sulfate (B), 
ciclesonide (C), beclometasone dipropionate (D), and fluticasone propionate (E). 
2.1.2 Commercial formulations 
Table 7 shows an overview on all commercial formulations used. All products were 
purchased from a local pharmacy. 
Table 7. Overview on commercial formulations used. 
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Substance Product name Formulation mdrug/dose [µg] Excipients used Manufacturer
Salbutamol Sultanol pMDI, suspension 100 HFA134a GSK (London, UK)
sulfate Sultanol forte solution for nebulizer 5000 Sulfuric acid
Benzalkonium chloride
Water
Cyclocaps Cyclohaler DPI 400 Lactose monohydrate PB Pharma
(Meerbusch, Germany)
Beclometasone Beclohexal pMDI, solution 100 HFA134a Hexal
dipropionate Ethanol (Holzkirchen, Germany)
Foster (+ Formoterol) pMDI, solution 100 HFA134a GSK
Ethanol (London, UK)
HCl
Fluticasone Flutide forte pMDI, suspension 250 HFA134a GSK
propionate (London, UK)
Ciclesonide Alvesco pMDI, solution 160 HFA134a AstraZeneca
Ethanol (Wedel, Germany)
2
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2.1.3 Additional materials and chemicals 
A Pari (Starnberg, Germany) Vortex valved holding chamber (VHC) was purchased from a 
local pharmacy. PLA filament 3 mm was obtained from Kiboplast (Kirchheimbolanden, 
Germany). Polyvinylalcohol (PVA, Mowiol® 4-88) and ascorbic acid was obtained from 
Sigma Aldrich (St. Louis, MO, USA). Dibasic potassiumhydrogenphosphate (Carl Roth 
GmbH, Karlsruhe, Germany), monobasic sodiumhydrogenphosphate, anhydrous magnesium 
chloride 99% (both Alfa Aesar, Haverhill, MA, USA), Apura™ Combi Titrant 2 mg/mL, and 
sodiumtartrate dihydrate (Merck kGaA, Darmstadt, Germany) was obtained from VWR. 
Water used was purified in house using a purification system (Merck-Millipore, Burlington, 
MA, USA). Isopropyl alcohol (IPA) and all other solvents used were HPLC grade. Handihaler 
dry powder inhalers were a kind gift from Boehringer Ingelheim (Ingelheim am Rhein, 
Germany). Breezhaler dry powder inhalers were a kind gift from a local hospital (Marien-
Hospital, Bochum, Germany). Actitube charcoal filters (Berlin, Germany) were obtained from 
a local source.  
 
2.2 Methods 
2.2.1 Systematic review of publications on inhalable formulations of Rifampicin 
Systematic literature review was conducted using the PubMed database [98]. Search term 
used for primary research was: “(rifampicin) AND (inhalable OR pulmonary delivery OR 
inhalation OR dry powder OR respirable)”. Primary results were pre- selected as follows: 
Exclusion of review articles, case studies, epidemiological studies, and experimental studies 
investigating other routes of applications than the pulmonary one. The data subset acquired 
was classified for publications reporting and missing aerosol testing respectively. Publications 
with aerosol testing were finally classified according to the formulation strategy used: i.e. 
application via DPI, pMDI, nebulizer, or insufflator. All articles reporting dry powder (DPI) 
aerosol testing were discussed. 
2.2.2 Manufacture of 3D printed objects 
A 3D model of a human trachea was retrieved from a CT dataset from the Gene Expression 
Omnibus database [58]. Digital Imaging and Communications in Medicine files were 
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reconstructed, cropped, cleaned up, and exported using ImageJ [145] with BoneJ [146] 
plugin. The final model was merged with adaptor fittings modeled with OpenSCAD [147] 
using Blender [148] (mIP). The model file for a 3D printed version of the USP IP (USPIP, 
USP3DIP) was generated according to USP specifications using OpenSCAD. Additionally, 
another modified USP IP (USP3DSEIP) showing an increased inner surface area, matching 
the one of the mIP but maintaining the basic geometry of the USPIP, was generated using the 
Blender software. Surface area of the model was determined using a computational approach 
by removing vertices not participating in the inner surface of the model and calculating the 
surface area of the remnants. To generate the USP3DSEIP model, a cylinder was inserted into 
the lower segment of the USP3DIP model. Gcode was generated using Slic3r [149]. Another 
modification of the mIP was introduced by replacing the distal section of the IP by its USPIP 
counterpart, thus generating a model with physiological relevant trachea and idealized MT 
section (mIPext). All models were 3D printed using a X400 3D printer (GermanRepRap, 
Feldkirchen, Germany), equipped with two 0.5 mm nozzles. The printed model was fine- 
tuned to fit, using sand paper (type kk114F, G80 G600, VSM AG; Hannover, Germany) and 
polishing paste (grade for acryl glasses and plastics, Mellerud Chemie GmbH, Brüggen 
(Niederrhein), Germany). The 3D printing parameters were set as follows: extruder 
temperature= 200 °C, bed temperature= 50 °C, layer height= 0.3 mm. To achieve optimum 
printout adhesion, the print bed was coated with 0.5 % w/v PVA solution.  
 
2.2.3 Assessment of air tightness of 3D printed objects 
Prior to use, all 3D printed models were tested for air tightness. The outlet of each test object 
was connected to a Dosage Unit Sampling Apparatus for DPIs (Copley scientific, 
Nottingham, UK), and the inlet was sealed, and the pressure drop at maximum pump capacity 
was recorded. Intrinsic resistance of all test objects and the USPIP was determined using the 
same setup. To evaluate the quality of the connecting elements, airflow consistency over the 
test objects was evaluated by following procedure: (1) the NGI was assembled (as used in a 
standard cascade impactor experiment) with the USPIP and an airflow meter (DFM 2000, 
Copley scientific, Nottingham, UK) was connected using a modified mouthpiece adapter. (2) 
The flow rate was then adjusted, sequentially, to predefined rates: 10, 20, 30, 40, 50, 60, 70, 
80, 90, and 100 L/min. with the IP being replaced with the test object at each flow rate. (3) 
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Deviation from each airflow rate at the inlet was noted (n= 1).  
2.2.4 Computational fluid dynamics (CFD) 
Airflow velocities over the USPIP and mIP that would have occurred during NGI assessment 
(below) at given conditions (i.e. pMDI setup), as well as airflow fields over the disposable 
inhaler model (ACT), were simulated using an OpenFOAM 3.01 linux distribution [150]. An 
additional simulation for the USP3DIP was omitted as it is identical to the USPIP. 3D meshes 
were generated from lithography files using SnappyHexMesh. PimpleFoam, a transient large 
time-step solver for incompressible fluids using a PISO based algorithm, was used to 
numerically solve the Navier-Stokes-Equations. Additionally, a standard k-ω turbulence 
model at a turbulence level of 5%, as proposed by [151] was implied. Results were visualized 
using ParaView. All software tools used are included in the OpenFOAM 3.01 toolbox. Figure 
18 illustrates the workflow of computational fluid dynamics studies. 
 
 
Figure 18. Work flow of CFD studies. 
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2.2.5 Manufacture of RF particles  
RF was added to predefined (see Tables 8 and 9) amounts of solvent while being exposed to 
ultrasound using an ultrasonic bath (Typ 106, Bandelin electronic, Berlin, Germany). After 
adding, samples were sonicated for 10 minutes at controlled temperature of 25 ±1 °C. 
Temperature was maintained by constant water exchange using a thermostat (DC 10, Haake 
Technik GmbH, Vreden, Germany). Solutions obtained were filtered through a suitable 0.22 
µm filter unit and stored in light protected 2.5 L glass bottles. Suspensions were stirred 
constantly and processed as obtained after recrystallization. Solutions and suspensions were 
spray dried using a Buchi B-290 (Flawil, Switzerland) spray dryer equipped with a modified 
three fluid nozzle (inner channel blocked, 0.7 mm nozzle tip, 1.5 mm screw cap), a high 
performance cyclone, an inert loop B-295, a dehumidifier B-296 (all Buchi) and an 
anemometer (model AF89-AD1AA13C0AA, Fluid components Intl. San Marcos, CA, USA). 
Process parameters were set as follows: Feed rate= 7.4 mL/min; outlet temperature= 60 ±3 
°C; nozzle flow: 0.01 NCMH, system flow: 15 NCMH. To asses the impact of the drying 
method applied, another aqueous solution of RF (RFaqexp1 was spray freeze dried using an 
in-house built spray freeze dryer [152]. In brief: the solution was sprayed into cold (−200 °C, 
cooled with liquid nitrogen) atmospheric gas, leading to rapid freezing of the droplets. Frozen 
particles were collected and subsequently freeze dried using a Lyovac GT 2 (Steris, GmbH, 
Hürth, Germany) freeze dryer. Nozzle used and atomization parameters were as applied in the 
spray drying process. After manufacture, all samples were equilibrated and stored at 32% RH 
(saturated magnesium chloride slurry). Batch size for all formulations was 10 g, except of 
RFaqexp1, RFaqexp2, and RFaqexp3 as well as RFaqAm1 and RFaqAm2, where the batch 
size was 9 g. Exact amount of RF dissolved and suspended was determined using a validated 
HPLC method, where needed. Tables 8 and 9 give an overview on sample composition in the 
exploratory and main study respectively. 
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Table 8. Overview on formulations manufactured in the exploratory study. 
 
Sample name Solvent Conc. diss Conc. susp. Sample vol. Method used
[mg/mL] [mg/mL] [mL] [ ]
RFaqexp1 water 1.6 0.0 4950 SFD
RFaqexp2 1.9 0.0 4950 SD/FD
RFaqexp3 0.8 0.0 4950 SD
RFaqexp4 1.6 0.2 3667
RFaqexp5 0.1 5.3 1833
RFIPAexp1 IPA 11.9 0.0 794
RFIPAexp2 9.6 9.4 528
RFIPAexp3 9.4 28.7 262
RFMeOHexp1 MeOH 9.5 0.0 901
RFMeOHexp2 13.5 3.4 595
RFMeOHexp3 5.5 28.2 297
RFEtOHexp1 EtOH 0.6 0.0 14092
RFEtOHexp2 0.8 1.1 9394
RFEtOHexp3 0.5 1.7 4697
RFEtOHexp4 0.5 29.9 333
RFACexp1 acetone 6.3 0.0 1332
RFACexp2 9.7 1.7 880
RFACexp3 10.6 12.1 440
RFDCMexp2 DCM 132.2 0.0 44
RFDCMexp3 56.4 284.8 29
1
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Table 9. Overview on formulations manufactured in the main study. 
 
2.2.6 Cascade impactor analysis 
2.2.6.1 Characterization of the low cost/disposable DPI surrogate  
Charcoal pipe filters (Actitubes) were modified and used as surrogate for a low performance, 
low cost, and disposable DPI (= ACT). They consist of a simple cardboard tube, which is 
filled with charcoal pellets. Ends are capped with either a ceramic, or plastic stopper, which 
are perforated with 7 and 12 holes respectively. For using it as inhaler surrogate, caps and 
charcoal filling of individual tubes were removed, the cardboard tube was cleaned by blowing 
out with compressed air, filled with the sample, and re-capped. Resistance of the empty 
inhaler was determined by adjusting to predefined flow rates (5, 10, 15, 20, 25, 30, 35, 40, 45, 
50 L/min) and recording the pressure drop using a critical flow control unit (Copley scientific, 
Nottingham, UK), n= 5. To visualize the airflow characteristics of the ACT, a CFD model 
(see Section 2.15.) was implied. Critical dimensions of the holes in the stoppers were 
determined by evaluation of SEM images of the stoppers (n= 5 each) resulting in individual 
distributions of orifice diameters for both, the plastic (n= 60) and the ceramic (n= 35) end. All 
other dimensions were determined using a caliper.  
 
2.2.6.2 Cascade impactor analysis of RF samples 
Aerodynamic properties of spray dried formulations were assessed using a Next Generation 
Sample name Solvent Conc. diss. Conc. susp. Sample vol.
[mg/mL] [mg/mL] [mL]
RFaqCryst1 water 0.2 4.0 1833
RFaqAm1 0.6 0.0 4950
RFaqAm2 1.2 0.0 4950
RFaqAm3 1.7 0.1 3667
RFIPAAm1 IPA 12.6 0.0 804
RFMeOHCryst1 MeOH 10.4 19.9 298
RFEtOHCryst1 EtOH 0.4 1.8 4698
RFEtOHCryst2 EtOH 0.6 29.4 333
1
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Pharmaceutical Impactor (MSP Co., Shoreview, MN, USA) coupled to two serial HCP5 
aspirators and a critical flow control unit (both Copley scientific, Nottingham, UK), equipped 
with either the USPIP, USP3DIP, or the mIP, as well as a preseparator unit containing 15 mL 
of MeOH. RF samples were filled into size three HPMC capsules and aerosolized using the 
Handihaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany) or Breezhaler (Novartis, 
Basel Switzerland) dry powder inhalers, or filled into and aerosolized from the ACT. All 
samples were analyzed at flow rates generating pressure drops of four kPa over the inhaler, 
being 43.3 L/min, 100.0 L/min, and 20.0 L/min for the Handihaler, Breezhaler, and the ACT 
respectively. Prior to use, all samples were equilibrated at 32% RH. Samples were recovered 
using 0.05% ascorbic acid in MeOH and evaluated using HPLC. RH was set to 50 ±2% by 
placing the DPI in a polyacrylate housing and purging with a nitrogen flow of desired RH, at 
a flow rate equivalent to the one over the NGI. RH adjustment was achieved by mixing dry 
and wet nitrogen in appropriate proportions. To investigate the stability of the aerodynamic 
performance over time, abbreviated NGI (aNGI) experiments were conducted at the 
respective time points of the stability study, as described in an earlier study [59]. An A/E type 
glass fiber filter (Pall Corporation, Ann Arbor, MI, USA) was cut to size and inserted 
upstream of stage four, generating a NGI setup comprising of three classes (i.e. inhaler (and 
capsule), induction port-S3, and filter). All experiments were carried out in triplicate. 
2.2.6.3 Cascade impactor analysis in mIP trials 
Different inhalable formulations were evaluated using a Next Generation Pharmaceutical 
Impactor (MSP Co., Shoreview, MN, USA) coupled to two serial HCP5 aspirators and a 
critical flow control unit (Copley scientific, Nottingham, UK), equipped with either the 
USPIP, USP3DIP, mIP, mIPext, or USP3DSEIP. Deviating from standard USP/Ph.Eur. 
procedure, a preseparator unit was used when analyzing pMDI and nebulizer formulations to 
increase comparability to the setup used characterizing the DPI formulation, which requires 
use of a preseparator. PMDI and nebulized formulations were analyzed at 30.0 L/min and 
15.0 L/min respectively. Sultanol forte inhalable solution was nebulized using a PARI LC 
sprint R jet nebulizer with blue insert (PARI GmbH, Starnberg, Germany). To analyze 
formulations dispensed from the Cyclohaler (the DPI) the flow rate was, as required by USP 
and Ph.Eur., set to 100.0 L/min, as the required pressure drop of four kPa over the device is 
achieved at approx. 110 L/min, which is beyond the calibrated airflow range of the NGI. 
Additionally, 15 mL of recovery solvent was added to the preseparator. Salbutamol samples 
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were recovered using MeOH/potassiumdihydrogenphosphate solution 0.0014 M, 50/50 and 
evaluated using HPLC. Beclometasone dipropionate, fluticasone propionate, and ciclesonide 
samples were recovered using MeOH. For nebulizer and DPI experiments, the relative 
humidity was set to 50 ±2% by placing the DPI in a polyacrylate housing and purging with a 
nitrogen flow of desired RH, at a flow rate equivalent to the one through the NGI. RH 
adjustment was achieved as described in the previous paragraph. For nebulizer experiments 
all inlets of the device and compressor unit were provided with nitrogen flow at desired rate 
and RH, as described above. PMDI experiments were carried out at ambient conditions. Prior 
to assessment of the nebulized formulation, independence of the method used from 
environmental influences (i.e. RH and temperature) was shown by comparison of deposition 
patterns with ones obtained with the NGI cooled to about 4 °C by submerging the device in an 
ice bath. To investigate reproducibility of the 3D printing process two additional mIP copies 
were manufactured and assessed in an aNGI [59] experiment comparing IP deposition of the 
pMDI formulation. A type A/E glass fiber filter (Pall Corporation, Ann Arbor, MI, USA) was 
cut to size and inserted upstream of S2, generating a NGI setup comprising of five classes (i.e. 
actuator, IP, preseparator, S1, and filter). The aNGI was operated at 30 L/min. Experiments 
were carried out n= 3, unless otherwise stated  
 
2.2.7 High performance liquid chromatography (HPLC) analysis 
 
2.2.7.1 HPLC analysis of salbutamol samples 
Samples were analyzed using a Waters (Milford, MA, USA) HPLC 2695 separations module 
equipped with either a 996 photodiode array detector or a 2487 dual wave-length detector 
(USP3DSE study only) using a method modified from [153]: Chromatography was carried 
out on a 250 mm RP-18 column (Lichrospher 100 RP 18-5µm EC, Merck), at a flow rate of 
1.5 mL/min and an injection volume of 100 µL. Mobile phase consisted of MeOH/phosphate 
buffer 3.0/triethylamine 50/49.9/0.1. Column temperature was set to 45 °C. Absorption was 
determined at 275 nm. The HPLC method was calibrated in the range of 0.25-20.0 µg/mL.  
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2.2.7.2 HPLC analysis of beclometasone dipropionate samples 
Chromatography was carried out using aforementioned setup. Mobile phase consisted of 
MeOH/water 95/5, flow rate was set to 1 mL/min, and injection volume was 20 µl. Column 
temperature was kept constant at 25 °C. Samples were analyzed at a wavelength of 239 nm. 
HPLC method was calibrated in the range of 0.25-20.0 µg/mL. 
2.2.7.3 HPLC analysis of fluticasone propionate samples 
Chromatography was carried out using the setup previously reported. Mobile phase consisted 
of MeOH/water 90/10, column temperature was kept at 25 °C, and injection volume was 20 
µL. Samples were analyzed at 250 nm. HPLC method was calibrated in the range of 0.25-20.0 
µg/mL. 
2.2.7.4 HPLC analysis of ciclesonide samples 
Chromatography was carried out using aforementioned setup. Mobile phase consisted of 
MeOH at a flow rate of 1 mL/min and injection volume was 20 µL. Column temperature was 
kept constant at 25 °C. Samples were analyzed at a wavelength of 245 nm. HPLC method was 
calibrated in the range of 0.25-20.0 µg/mL. 
2.2.7.5 HPLC analysis of rifampicin samples 
Samples were analyzed on an aforementioned system using a method modified from [91]: 
Chromatography was carried out on a 250 mm RP-18 column (Lichrospher 100 RP 18-5 µm 
EC, Merck), at a flow rate of 1.0 mL/min and an injection volume of 20 µL. Mobile phase 
consisted of phosphate buffer pH 5.2/MeOH/acetonitrile 50/33/17. Column temperature was 
set to 25 °C. Absorption was determined at 337 nm. The HPLC method was calibrated in the 
range of 1-200 µg/mL (NGI), and 50-150 µg/mL (purity). 
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2.2.8 Analysis of residual water by Karl Fisher titration 
Water content of spray dried samples was analyzed using a V30S volumetric titrator coupled 
to a Stromboli headspace sampler (Mettler Toledo, Columbus, OH, USA). Samples were 
dried at 150 °C and the resultant vapor was quantified by re-dissolving in MeOH and titrating 
with a 2 mg/mL combined titrant (Apura Combi Titrant). The potency of the titrant was 
determined and corrected for each experiment using a sodium tartrate dihydrate standard 
[154]. 
2.2.9 Analysis of residual solvents using headspace gas chromatography (GC) 
Analysis of residual solvents was performed on a Focus GC with TriPlus headspace 
autosampler (Thermo Scientific, Waltham, MA, USA). Chromatography was carried out on a 
FS-CS-624 (CS Chromatographie service GmbH, Langerwehe, Germany) quartz capillary 
column with an inner diameter of 0.32 mm and a length of 30 m. Inner walls were coated with 
6% poly-(cyanopropyl) phenylsiloxane and 94% poly-(dimethyl) siloxane. Gradient program 
parameters were set as follows: 1) 6 min isothermic elution at 40 °C, 2) ramp to 150 °C at 120 
°C / min, and 3) 4 min at 150 °C. Headspace incubator temperature was set to 80 °C, and 
incubation time before sampling was 10 min. Sampling volume was 1 mL and split ratio was 
1:7. 
2.2.10 Thermogravimetric analysis (TGA) 
Loss on drying (LOD) was determined using a TGA-7 thermobalance (PerkinElmer, 
Waltham, MA) in the temperature range from 30-200 °C. After 5 minutes of equilibration at 
30 °C, a temperature ramp of 10 °C/min was applied to the samples. 
2.2.11 Scanning electron microscopy  
Samples were mounted onto SEM stubs using double adhesive tape and sputter coated with 
gold for two cycles of two minutes each. Images were taken using a Hitachi S-2460N 
scanning electron microscope (Hitachi Ltd., Tokyo, Japan) in high vacuum. Acceleration 
voltage was 10 kV, working distance was set as needed and is reported on the individual 
pictures.  
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2.2.12 X-ray powder diffractometry (XRPD) 
Powders were analyzed in a 5-40° 2θ range with a PANalytical X´pert X-ray diffractometer 
(PANalytical, Almelo, the Netherlands) using nickel filtered CuKα radiation at a wavelength 
of 1.5406 Å, which was generated at an acceleration voltage and current of 45 kV and 40 mA 
respectively. Samples were placed in circular stainless steel sample holder and kept in 
spinning motion during measurement.  
For humidity and temperature trials, the aforementioned system was equipped with a THC 
(Anton Paar, Graz, Austria) temperature/humidity chamber. N2 was used as purge gas, and 
sample temperature was kept constant at 25 °C. Samples were subjected to two cycles of 0-
20-40-60-80-97-80-60-40-20-0% RH with each stage held for 150 minutes, after the RH in 
the chamber had stabilized. X-ray diffractograms were recorded every hour so that a 
minimum of two data points per step was recorded. After completing the second cycle, 
samples were sequentially heated up to predefined temperatures of 40, 60, 80, 100, and 120 
°C, and equilibrated for 15 min before recording the diffractogram. 
 
2.2.13 Differential scanning calorimetry (DSC) 
Samples were placed into non-hermetic sealed, punctured 40 µL aluminum pans, and 
analyzed at a temperature range from 30-200 °C, using a DSC2 differential scanning 
calorimeter (Mettler Toledo, Greifensee, Switzerland). Samples were analyzed under N2 
purge in standard mode, applying a heat rate of 10 °C/min.  
2.2.14 Acoustic levitation (AL) experiments 
To get a deeper understanding of the mechanism behind the formation of the spray dried 
particles, single droplets of solvents (IPA, MeOH, water) and solutions of RF therein were 
dried in an experimental acoustic levitator, which is described in detail here [155]. In brief: A 
standing sound wave was being formed between an emitting piezo transducer and a concave 
reflector. A liquid droplet of 1 ±0.01 µL of volume was placed below one of the pressure 
nodes, which generates a stable levitation of the droplet. Drying of the back illuminated 
droplet was observed with a CCD camera (Basler scA1390, Germany) coupled to a long-
distance microscope (Navitar Zoom 6000, USA). Magnification of the microscope was 
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calibrated using a high precision microscale. In the acoustic field the droplet was exposed to a 
dry nitrogen flow of 0.5 L/min (n= 10). 
2.2.14.1 Contact angle measurements 
Contact angle measurements were conducted by drop shape analysis (DSA) using a FM 40 
(Krüss, Hamburg, Germany) drop shape analyzer (n= 5). 
2.2.14.2 Viscosity 
Viscosity of solutions used in the acoustic levitation experiments was determined using an 
Ubbelohde type viscometer 501 03/ 0c (SI analytics GmbH, Mainz, Germany), which was 
placed into a water bath providing exact temperature control. Temperature was adjusted to 
25.0 °C. Hagenbach correction was applied to the results (n= 5). 
2.2.14.3 Surface tension 
Surface tension of plain solvents and solutions of RF therein was determined using a model 
13356 (Krüss, Hamburg, Germany) ring tensiometer. Temperature was adjusted to 25.0 °C 
(n= 5). 
2.2.14.4  Solutions density 
Density of RF solutions in EtOH, IPA, and H2O as well as control pure solvents was 
determined using a Gay-Lussac type pycnometer (ISO 3507 compliant model, Brand, 
Wertheim, Germany). Equilibration temperature was 25 °C (n= 5). 
2.2.14.5 Dynamic vapor sorption (DVS) 
DVS experiments were carried out on a DVS 1 (Surface Measurement Systems, Middlesex, 
UK) placed in a temperature controlled cabinet (t= 25 °C) using in-house made quartz pans. 
Prior to experiments, samples were dried at 0% RH until a dm/dt stability of 0.002 %/min was 
reached. Then samples were exposed to increasing humidity at a ramp of 10% RH/h before 
being equilibrated at 97% RH using aforementioned endpoint (= half cycle). Two consecutive 
full cycles were performed during each experiment. 
2.2.15 Stability testing 
Stability testing of the formulations was performed on RFaqCryst1, RFEtOHCryst1, 
RFMeOHCryst1, RFaqAm1, and RFIPAAm1 in accordance to the International Conference 
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on Harmonization (ICH) guideline Q1A(R2) “Stability Testing of New Drug Substances and 
Products” [156]. As refrigerated storage was proposed for RF bulk powder, samples were 
stored in a climate cabinet (Type 9120-0040, Binder GmbH, Tuttlingen, Germany) at 
accelerated conditions for refrigerated products, i.e. 25 ±2 °C and 60 ±5% RH. Samples were 
analyzed at predefined time points of one, three, and six months using HPLC, XRPD, DSC, 
and aNGI analyses. Additionally, another set of samples was stored in the refrigerator (4 °C) 
and analyzed after six months.  
2.2.16 Data processing and statistical analysis 
 
NGI overview plots show relative stage deposition. Error bars indicate one SD. Cumulative 
undersize plots including S1-MOC were generated and linearized by log-transforming stage 
cutoffs and probit-transforming relative frequencies. A linear regression model was used to 
calculate the MMAD, FPFs related to the emitted (FPFemitted) or total (FPFtotal) dose, and 
geometric standard deviation (GSD), as described in USP <601>. Emitted fraction (EF) is the 
mass fraction of particles emitted from the DPI, pMDI, or nebulizer. Groups in mIP studies 
were compared using one-way ANOVA followed by Bonferroni adjusted two sample t-test at 
a family error rate of 0.05, if group means were found significantly different (p <0.05). 
Statistical analyses were performed using R 3.3.1 [157] with chemCal and ggplot2 packages. 
Acoustic levitator data was standardized by relating to the first time point acquired. Axis ratio 
and diameter of the backlight area equivalent sphere (deq(area)) were calculated from images 
acquired and plotted over time, error bars indicate one SD. Plotting was conducted using R 
3.3.1 with ggplot2 package. 
TGA data was analyzed using Pyris (PerkinElmer) software. 
 
Data from contact angle measurements was processed using Drop Shape Analysis 1.92.1.1 
software (Krüss, Hamburg, Germany). 
XRPD overview plots were generated from unmodified data using R. Datasets from studies 
using the humidity control chamber were corrected for baseline offset and Kα reflections 
using X´pert Highscore (PANalytical, Almelo, the Netherlands) software and plotted using R 
3.3.1 with ggplot2 package. 
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DSC data was analyzed using STAR (Mettler Toledo) software. Overview plots were 
generated using R 3.3.1 with ggplot2 package. 
Chemical stability of feed solution used for manufacture of RFaqexp3 was evaluated testing 
for normality using Shapiro-Wilk test using R 3.3.1. 
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3 Investigating Next Generation Pharmaceutical Impactor performance 
using modified 3D printed induction ports 
 
3.1 Results and discussion of induction port design, manufacture, and formulation 
screening 
3.1.1 Results 
3.1.1.1 Cascade impactor analysis using model salbutamol formulations  
A trachea model for use with the NGI, a USP IP replica, and a model based on USP IP 
geometry but with an inner surface equivalent to the trachea model were manufactured and 
assessed. The test objects are shown in Figure 19. Table 10 provides an overview on the test 
objects and formulations assessed. The maximum operating pressure drop of sealed test 
objects was determined as 95.0 kPa, 94.5 kPa, 94.6 kPa, and 94.1 kPa for the USPIP, 
USP3DIP, mIP, and the USP3DSEIP respectively. If measurable, intrinsic resistance of test 
objects was found to be lower than 0.005 (√!"# ∗!"#)/!. Deviations from airflow adjusted 
using the USPIP were determined as 1.2 ±1.1%, 0.2 ±0.5 %, and 1.3 ±1.0 % for the 
USP3DIP, mIP, and the USP3DSEIP respectively. Two additional copies of the mIP were 
manufactured and assessed using an aNGI setup. Test objects were found to show statistically 
equivalent (p= 0.27871) SAL deposition of 62.6 ±3.0%, 62.9 ±2.8%, and 64.4 ±2.1% 
respectively.  
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Figure 19. Photographs of the USP3DIP (a), USP3DSEIP (b), mIP (c), and USPIP (d). 
Table 10. Overview on test objects and formulations tested. 
 
NGI experiments of SAL formulated as pMDI using the USPIP show high IP deposition, little 
preseparator deposition, and a fairly narrow particle size distribution (see Figure 20, Table 
Formulation tested
IP Description pMDI pMDI + VHC DPI Nebulizer
USPIP Standard USP IP + + + +
mIP Trachea model IP + + + +
USP3DIP 3D printed copy of USPIP + - + +
USP3DSEIP 3D printed copy of USPIP + - - -
with surface area of mIP
1
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11). USPIP and USP3DIP were found to perform statistically equivalent. Statistically 
different results were obtained comparing the USPIP to the mIP, as experiments showed an 
increase in IP deposition. GSD increase was statistically significant (p= 0.04148), whereas the 
MMAD remained equivalent. Increased mIP deposition was found to have a strong impact on 
FPFtotal, which decreased significantly (p= 0.00218), when compared to the USPIP.  
 
Figure 20. Results of NGI experiments analyzing the Sultanol pMDI, comparing USPIP, 
USP3DIP, and mIP (n= 9). 
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Table 11. Overview on aerosol characteristics of formulations and IPs tested. 
 
Aerodynamic characterization of SAL formulated as binary dry powder blend for inhalation 
showed only moderate USPIP deposition, but high deposition in the preseparator unit (see 
Figure 21). USP3DIP was found to perform equivalently to the USPIP. The mIP showed a 
significantly increased deposition, when compared to the USPIP, and preseparator deposition 
decreased slightly, but not significantly. Comparison of these IPs, did not result in statistically 
significant differences in MMAD, GSD, or FPF (see Table 11).  
IP tested
Formulation USPIP USP3DIP mIP USP3DSEIP
pMDI MMAD [µm] 2.47 ±0.12 2.58 ±0.11 2.32 ±0.08 2.48 ±0.09
GSD [] 1.76 ±0.03 1.81 ±0.02 2.11 ±0.10 1.77 ±0.05
FPFtotal [%] 28.82 ±1.99 28.21 ±1.49 14.15 ±1.19 29.84 ±2.45
FPFemitted [%] 33.99 ±3.63 33.83 ±1.68 16.72 ±1.60 34.92 ±2.45
Femitted [%] 85.00 ±3.08 83.38 ±0.52 84.69 ±1.23 85.50 ±0.91
DPI MMAD [µm] 3.03 ±0.12 3.03 ±0.12 2.72 ±0.32
GSD [] 3.20 ±0.19 3.06 ±0.08 3.08 ±0.12
FPFtotal [%] 21.62 ±1.48 23.17 ±1.95 20.44 ±2.22
FPFemitted [%] 27.18 ±0.87 28.50 ±1.87 25.36 ±2.72
Femitted [%] 79.50 ±3.33 81.25 ±1.74 80.67 ±2.18
nebulizer MMAD [µm] 3.46 ±0.07 3.23 ±0.76 3.00 ±0.13
GSD [] 2.31 ±0.12 2.61 ±0.41 2.32 ±0.03
FPFtotal [%] 26.46 ±3.04 26.63 ±2.24 27.06 ±1.82
FPFemitted [%] 60.72 ±3.26 60.37 ±6.31 61.09 ±1.34
Femitted [%] 43.50 ±2.91 44.19 ±1.37 44.30 ±2.77
pMDI + VHC MMAD [µm] 2.28 ±0.08 2.23 ±0.05
GSD [] 1.76 ±0.08 1.73 ±0.09
FPFtotal [%] 23.25 ±5.20 24.37 ±3.03
FPFemitted [%] 82.41 ±2.83 75.47 ±4.83
Femitted [%] 28.14 ±5.80 32.22 ±2.30
1
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Figure 21. Results of NGI experiments analyzing the Cyclocaps Cyclohaler DPI, comparing 
the USPIP, USP3DIP (n= 6), and mIP (n= 9). 
NGI experiments assessing the deposition of SAL formulated as solution for nebulization 
showed a broad distribution over all NGI stages (see Figure 22). Little mass was retained in 
the IP and preseparator. The major deposition was found within the nebulizer itself. 
Characteristics determined using the USPIP were statistically equivalent to that using the 
USP3DIP and the mIP (see Table 11). A statistical difference in deposition was found in the 
USPIP, when compared to the USP3DIP.  
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Figure 22. Results of NGI experiments analyzing the Sultanol nebulizer solution, comparing 
the USPIP, USP3DIP, and mIP. 
To get a better understanding of the underlying mechanism we designed another IP with a 
surface area equivalent to the one of the trachea, still maintaining the basic geometry of the 
USPIP. Surface area of the USP3DIP and the mIP was calculated as 128.4 cm2 and 201.3 cm2 
respectively. To generate the new model (USP3DSE), a cylinder with an inner surface of 72.9 
cm2 and an inner diameter equivalent to the USP IP was inserted into the lower segment of 
the USP3D model. Cascade impaction analysis of SAL formulated as pMDI showed 
statistical equivalence of deposition rates (Figure 23) and consequently of MMAD, GSD, and 
FPF (Table 11), when compared to the USPIP.  
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Figure 23. Results of NGI experiments using the Sultanol pMDI, comparing the USP3DSEIP, 
USPIP, and mIP. 
3.1.1.2 CFD studies  
To visualize the effect of different geometries of the USPIP and the trachea model on airflow 
velocities within the IPs, as occurring during assessment with the NGI, a CFD model was 
generated and evaluated. Figure 24 shows characteristic slices depicting the flow fields over 
the USPIP and the mIP. Intensity distributions of the flow velocity over planes normal to the 
flow vector were found to differ strongly.  
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Figure 24. Results of CFD studies over the USPIP (a) and mIP (b). Heat maps show airflow 
velocities over charateristic slices. 
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3.1.1.3 Cascade impactor analysis using salbutamol pMDI formulation with VHC  
The effect of a VHC device on particle deposition in the trachea model and its effect on PSD 
and lung deposition was investigated (see Figure 25). NGI experiments showed that adding a 
VHC to the assembly decreases IP deposition drastically as a large fraction was retained 
within the VHC. Femitted decreased significantly (p= 0.00007), whereas FPFemitted increased (p= 
0.00087). MMAD, GSD, and FPFtotal were found to be statistically equivalent (see Table 11). 
Replacing the USPIP with the mIP was shown to increase IP deposition significantly. 
MMAD, GSD, FPFtotal, FPFemitted, and Femitted were found to be statistically equivalent, though 
a decrease in FPFemitted was observed.  
 
Figure 25. Results of NGI experiments using the Sultanol pMDI, analyzing the effect of 
adding a VHC to the USPIP and mIP. 
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3.1.2 Discussion 
Since pressure drops generated using sealed 3D printed models were found comparable to the 
pressure drop achieved using the USPIP, air tightness of the printed models was found to be 
sufficient. Additionally, the quality of the joints connecting the test objects to the NGI and 
mouth piece adapters was assessed by determining deviations from the various flow rates 
adjusted using the USPIP. Since all test objects show no relevant intrinsic resistance, similar 
airflow rates can be expected when using set conditions (i.e. replacing the IP only). All 
deviations observed were found to be well below 5%, and therefore compliant with USP and 
Ph.Eur. requirements. Based on these observations it was concluded that the test objects are 
suitable for use in cascade impaction experiments using the NGI. Statistical equivalence of 
mIP deposition in an aNGI assessment of the pMDI formulation using three different copies 
of the mIP proves robustness of the manufacturing method. A 3D printed replica of the USPIP 
was generated and assessed, to evaluate the impact of using a different material (i.e. PLA 
instead of stainless steel) as well as the increase of surface roughness, which is a consequence 
of using FDM technique. In FDM, printouts are generated by stacking layers of extruded 
polymer filament generating a rougher surface, when compared to e.g. stainless steel. It was 
found that material and increased surface roughness have no significant effect on NGI 
experimental outcomes, when analyzing SAL formulated as pMDI or DPI. Thus, results of 
experiments using the USPIP and the mIP are comparable. The increase in IP deposition, as 
observed analyzing the pMDI, hypothetically can be explained by two different concepts. As 
aerosol particles dispensed from a suspension based pMDI are expected to interact (e.g. 
electrostatic interaction or capillary forces [8]) with surfaces to some extent, an increase of 
surface area exposed to the aerosol might lead to an increased deposition rate. Additionally, 
increased particle retention might be caused by alteration of the IP’s geometry. This could 
lead to increased impaction or settling of the particles. So conclusively one must assume that 
both hypothetical interactions combined would explain the actual increase observed. Cascade 
impaction analysis showed statistically equivalent deposition, and consequently MMAD, 
GSD, and FPF, when determined using the USP3DSEIP (see Figure 23). Based on this 
observation one must conclude that the increase in deposition is solely caused by geometric 
factors. This conclusion is in good agreement with the statistical equivalence observed, when 
comparing the USP with USP3DIP, as increased surface roughness consequently demands an 
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increase in surface area, with constant object geometry. Apparently only a certain sub-
population of aerosol particles are prone to surface interactions at given experimental 
parameters, and the surface area provided in the USP IP is sufficient for their deposition. This 
conclusion underlines that including physiological conditions in the design of an alternate IP, 
with the goal of better IVIVC is relevant, and is in good agreement with literature. 
Observation of the lack of a surface area related component, might be dose dependent though. 
Since the dose applied in this experimental setup already was the maximum dose 
monographed in USP and Ph.Eur. (i.e. 10 puffs), this can be evaluated as irrelevant, when 
USP/Ph.Eur. standards are applied. CFD simulations show that the trachea model generates 
sections with increased, as well as such with decreased airflow velocity, when compared to 
the USPIP. An increase in flow velocity leads to a higher acceleration of particles entrained 
by the air stream. Due to the increased momentum, this might cause separation from the 
stream, if particles undergo radial acceleration (i.e. a change in motion vector), and 
consequently impaction leading to an increase in overall particle deposition. Contrary, areas 
with lower velocities might facilitate settling of particles. Simulations show a consecutive 
cascade of high and low velocity sections in the trachea model, which might be causal for the 
increased particle deposition, as observed during NGI experiments. The increase in IP 
deposition causes a drop in FPF when determined with mIP. Interestingly, this correlates 
better to lung deposition, as reported in the product’s prescribing information [158], compared 
to the one obtained using the USPIP. To date, no study available reports in vivo lung 
deposition of a SAL pMDI formulation, conducted after the transition from 
chlorofluorocarbon (CFC) to hydrofluoroalkane (HFA) propellants. Nevertheless, as in vitro 
assessment indicates equivalence of CFC and HFA formulations [159–163], a lung deposition 
of about 10-15%, as determined in scintigraphic studies [164,165] using aerodynamically 
equivalent 99mTc-labelled teflon beads, appears reasonable. So, in this instance the 3D trachea 
model provides superior information to the formulation scientist, when compared to the 
USPIP. Much effort has already been made to investigate different approaches to improve 
IVIVC by replacing the USPIP with model IPs closer to physiological conditions. The MT 
model most intensely characterized and investigated was developed at the University of 
Alberta and became commercially available through Copley Scientific (Alberta idealized 
throat, AIT). Here, the investigators intended to generate a MT model representing the 
majority of individuals, showing no irregularities of the respiratory tract. Based on averaged 
observations made using CT and MRT imaging, as well as direct observations on hospitalized 
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patients, basic geometrical shapes were compiled into an idealized extrathoracic airways 
model [75]. A study published by Copley, Mitchell, and Solomon, investigating the effect of 
replacing the USPIP by the AIT when analyzing a commercial pMDI formulation of SAL 
reports a FPFemitted of 38.0 ±1.4 % and 33.4 ±1.3 % for the USP IP and the AIT respectively 
[73]. MMAD and GSD are reported as 2.5 ±0.1 µm and 1.9 ±0.2 µm respectively. 
Recalculating MMAD, GSD, and FPF from data provided there, but applying the data 
processing method used in this study, generates results comparable to those reported. Though 
the manufacturer of the pMDI used in this study is unclear and experimental setups differ 
slightly (i.e. no preseparator unit was used and stages were coated with silicone oil) a suitable 
level of comparability of both studies is observed. So it is reasonable to conclude that the 3D 
printed trachea model used in this study retains more particles dispensed from a SAL pMDI, 
thus generating a greater decrease in FPFs, when compared to the AIT. Additionally, results 
obtained here correlate better to in vivo data, so the trachea model provides not only a better 
IVIVC when compared to the USP IP, but also to the AIT. However, when evaluating the 
models one must be aware that our focus was on the prediction of lung deposition, whereas 
the AIT was designed and tested for MT IVIVC. Results of the present study are consistent 
with Copley, Mitchell, and Solomon, reporting differences in geometry to be more critical for 
particle deposition than surface related effects [73], which had been concluded from a 
previous study [166]. The main difference, between both MT models is that the developer of 
the AIT had put emphasis on modeling and idealizing the mouth cavity as well as the trachea, 
whereas the focus of this study was on the trachea only. Connection to the mouth piece 
adaptor here, was established through an element of the dimensions of the USP IP inlet, 
which is attached to the trachea at an angle of about 110°. Another important difference is the 
degree of idealization in the AIT that eventually might have caused a loss in geometry 
information, which has been shown to be causal for increased deposition rates in this study. 
Here, one might distinguish between geometries derived from physiological conditions, i.e. 
from CT scans, and artificial geometries, introduced to establish feasibility for the use with 
the NGI (e.g. with the addition of connectors). Experiments conducted using the DPI, as well 
as ones using the pMDI with the VHC indicate that when compared to the USP IP or AIT, the 
shortened distance from the valve to the 110° bend is not responsible for the increased 
deposition observed, since particle velocities (and consequently momentum) are dependent on 
the airflow velocity over the CI only. When compared to the USP IP, airflow velocities at the 
bend are lower, which in combination with the larger angle generates less radial acceleration. 
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Thus, less particle deposition is to be expected. Anyways, with this experimental setup it 
cannot be excluded that this mechanism might participate in the overall effect to a certain 
extent. The impact of the shortened distance from the pMDI nozzle orifice to the bend on 
aerosol characteristics could be assessed by adding further modifications e.g. an elongated IP 
inlet or an oral cavity to the model. These modifications were not yet included in this study as 
our primary aim is to demonstrate that FDM rapid prototyping using PLA filament is a 
suitable method to manufacture modified induction ports for NGI experiments and that results 
are responsive to alterations of the IP’s geometry.  
As the trachea shows the most complex geometry upstream from the bronchi it was chosen as 
critical physiological element to be investigated in this study. Though IVIVC already was 
found superior compared to the AIT it might be improved by assessing and taking into 
account the impact of e.g. the angle at which the aerosol plume enters the IP or, as mentioned, 
the absence of an oral cavity model, if found relevant. Besides in IVIVC to patient 
populations showing no irregularities of the respiratory tract the individual based approach of 
our model might be utilized to generate a platform technology to investigate particle 
deposition in special patient populations, or eventually be applied in a completely 
personalized approach. Here it could be e.g. utilized to generate a patient specific airways 
model to assess, which inhalable formulation would be most effective for the individual 
present. Another benefit of this method is that it can be rapidly adapted in case 
recommendations on how the pMDI is to be used are updated. E.g. Fadl et al. [167] showed 
that the angle at which the pMDI is applied has an impact on its performance. Anyways, as of 
now this observation has not been implemented into clinical practice but might eventually be 
incorporated into the respective guidelines. Another possible application might be to establish 
a better transferability of data generated in animal models. Further investigation is needed to 
evaluate if this finding can be confirmed with other pMDI formulations currently marketed 
and if different formulation strategies (e.g. formulating as solution or suspension) are critical 
to cascade impaction experiments when using the mIP. The VHC used in this study 
demonstrated a similar particle retention to that of the USPIP, but must be regarded to as part 
of the inhaler when processing the data. From a therapist’s point of view this means reduced 
particle impaction in the upper airways, which is, besides omitting the need to perform pMDI 
actuation and inhalation maneuver simultaneously, the desired benefit of using a VHC/spacer. 
The impact of the reduction of particle velocities in the IP when adding a VHC has already 
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been discussed in the previous section. Due to the similarity of particle retention performance 
of both IPs to the VHC, the impact of replacing the USP IP with the mIP is marginal for 
overall formulation performance, though an increase in IP deposition was observed. Based on 
this dataset one must conclude that using the mIP instead of the USPIP does not provide 
additional information for pMDI assessment, when using a spacer device. Increased mIP 
deposition when analyzing a dry powder formulation of SAL was shown to be pronounced, 
but corresponded to a decrease in preseparator deposition. Cumulative IP and preseparator 
deposition was equivalent, showing 48.0 ±2.5% and 52.8 ±3.5% deposition for the USPIP and 
the mIP respectively. Thus, it can be concluded that the performance of the preseparator unit 
has a greater impact on PSD and FPF than the IP. Since all components upstream from S1 are 
excluded from the dataset when calculating the PSD, differentiation between deposition in the 
IP or preseparator does not offer additional information, especially because no size cut-offs 
can be attributed to any of the classes. So, in this specific case, replacing the USPIP by the 
mIP does not provide additional information for the researcher. This observation is contrary to 
the one made when analyzing the pMDI, where the impact of the preseparator was found 
negligible and unaffected from the IP performance. Higher preseparator deposition analyzing 
the DPI might be caused by incomplete de-agglomeration of the binary blend used in this 
formulation. Experimental behavior of a certain fraction of API particles (which have been 
traced in this study) might be strongly correlated to the behavior of the carrier lactose 
particles. Besides primary API particle size, density, shape, and de-agglomeration of the 
particles are critical parameters for their aerodynamic performance. When compared to 
suspension based pMDI formulations, DPI formulations must not only overcome 
interparticulate cohesive forces, but also adhesive forces to the carrier particle to de-
agglomerate. So in this respect the suspension based pMDI can be understood as a border case 
of a hypothetical DPI using identical API particles, if alterations of the primary particles 
caused by e.g. the instability of suspension and effects caused by the increased exit velocity 
caused by evaporating propellant are ignored. So further investigation is needed to evaluate if 
conclusions drawn from experiments with this formulation are applicable to more modern 
formulation/inhaler systems as well, or if more sophisticated formulations behave more 
similar to pMDIs. The increase in IP deposition when comparing USPIP to USP3DIP 
analyzing a nebulized formulation indicates that data generated using the mIP might be 
compromised by material related effects. This might cause an underprediction of deposition in 
the lungs. Since deposition in the IP was found to be low (less than 2%) the impact of this 
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result is negligible. Due to their intrinsic aerosol characteristics, i.e. absence of agglomerates 
leading to a broad, monodisperse distribution, assessment of nebulized formulations does not 
benefit from modifications of the IP.  
 
3.2 Results and discussion investigating cascade impactor performance of additional 
commercial pMDI formulations using modified induction ports  
3.2.1 Results 
3.2.1.1 Induction ports assessed in this study  
Figure 26 shows a photograph of induction ports assessed in this study. In addition to the 
USPIP, USP3DIP, and the mIP, another model (mIPext) was manufactured and assessed. This 
new model shows the trachea geometry investigated in the previous section (proximal section 
of the mIPext) merged with the MT region of the USPIP (distal section of the mIPext). This 
new model allows more differentiated investigation of the mechanisms, leading to increased 
mIP deposition, as reported in the previous section. 
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Figure 26. Photographs of the USP3DIP (a), mIP (b), mIPext (c), and USPIP (d). 
  
a b c
d
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3.2.1.2 Determination of valve diameter of pMDIs used  
SEM images in Figure 27 show nozzles of actuators used in this study as well as nozzle 
diameters derived from the images.  
 
 
Figure 27. SEM images showing nozzles of actuators used in this study. 
Product Valve diameter [µm] 
Alvesco 285 ±1 
Beclohexal 347 ±7 
Flutide 570 ±1 
Foster 329 ±3 
Sultanol 526 ±2 
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3.2.1.3 Cascade impactor analysis of Sultanol pMDI using the mIPext 
Cascade impactor analysis of the Sultanol salbutamol pMDI formulation using the mIPext 
showed an increase in IP deposition, when compared to the USPIP, and a decreased IP 
deposition when compared to the mIP (see Figure 28). MMAD, FPFtotal, and FPFemitted were 
found not significantly different (see Table 12), when compared to the USPIP. 
 
Figure 28. Results of NGI experiments using the sultanol pMDI formulation, analyzing the 
impact of the mIPext. 
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Table 12. Overview of aerosol characteristics for pMDI formulations and IPs tested. 
 
  
IP tested
Formulation USPIP USP3DIP mIPext mIP
Sultanol MMAD [µm] 2.47 ±0.12 2.58 ±0.11 2.37 ±0.16 2.32 ±0.08
GSD [] 1.76 ±0.03 1.81 ±0.02 1.71 ±0.05 2.11 ±0.10
FPFtotal [%] 28.82 ±1.99 28.21 ±1.49 26.41 ±3.23 14.15 ±1.19
FPFemitted [%] 33.99 ±3.63 33.83 ±1.68 30.65 ±4.27 16.72 ±1.60
Femitted [%] 85.00 ±3.08 83.38 ±0.52 86.30 ±1.74 84.69 ±1.23
Flutide MMAD [µm] 3.17 ±0.16 2.98 ±0.06 2.79 ±0.11 2.66 ±0.06
GSD [] 1.80 ±0.04 1.77 ±0.01 1.77 ±0.01 1.75 ±0.03
FPFtotal [%] 38.29 ±3.18 35.99 ±1.50 30.21 ±2.88 25.84 ±1.45
FPFemitted [%] 42.08 ±3.16 39.44 ±0.83 32.74 ±2.47 27.96 ±1.58
Femitted [%] 91.44 ±1.67 91.23 ±2.10 92.21 ±2.49 92.41 ±0.15
Beclohexal MMAD [µm] 1.18 ±0.06 1.12 ±0.02 1.08 ±0.00 0.98 ±0.01
GSD [] 2.05 ±0.15 2.14 ±0.06 1.90 ±0.04 2.01 ±0.03
FPFtotal [%] 65.15 ±1.25 56.52 ±2.69 56.34 ±3.49 51.14 ±0.70
FPFemitted [%] 70.47 ±1.74 63.89 ±0.67 64.80 ±4.03 56.67 ±0.80
Femitted [%] 92.51 ±3.53 88.47 ±4.30 86.94 ±0.46 90.26 ±1.52
Alvesco MMAD [µm] 1.38 ±0.06 1.26 ±0.01 1.22 ±0.01 1.21 ±0.02
GSD [] 1.84 ±0.03 1.83 ±0.06 1.74 ±0.05 1.78 ±0.07
FPFtotal [%] 55.60 ±1.29 54.98 ±0.50 58.35 ±1.70 50.71 ±2.08
FPFemitted [%] 68.57 ±1.15 67.03 ±0.71 71.55 ±1.70 62.17 ±1.20
Femitted [%] 81.07 ±0.94 82.02 ±0.22 81.55 ±0.47 81.54 ±1.79
Foster MMAD [µm] 1.21 ±0.02 1.15 ±0.02 1.14 ±0.06 1.02 ±0.03
GSD [] 1.96 ±0.07 2.04 ±0.00 2.04 ±0.04 2.18 ±0.03
FPFtotal [%] 37.47 ±1.89 35.06 ±0.31 32.15 ±1.35 24.01 ±0.41
FPFemitted [%] 40.47 ±2.06 37.44 ±0.34 34.50 ±1.49 25.80 ±0.60
Femitted [%] 92.58 ±1.31 93.65 ±0.24 93.20 ±1.76 93.20 ±1.76
1
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3.2.1.4 Cascade impactor analysis of the Flutide forte pMDI formulation 
NGI analysis of the Flutide forte formulation using the USPIP showed a fairly high IP 
deposition (see Figure 29). S1, S2, S6, and S7 showed low particle deposition whereas S3-S5 
contained the main fraction of the particles downstream from the IP. MOC and filter stages 
were found to show no particle deposition. USP3DIP was found to perform statistically 
equivalent to the USPIP. Contrary, mIPext, and mIP showed a statistically significant increase 
in IP deposition, when compared to the USPIP with the increase being more pronounced in 
the case of the mIP. MMAD, FPFtotal, and FPFemitted were found to differ significantly (p= 
0.03861, p= 0.03442, and p= 0.01811, respectively) when comparing the mIP to the USPIP. 
In the case of the mIPext, the increase in IP deposition did not result in significant differences 
in MMAD, FPFtotal, FPFemitted, or GSD, though a decrease in all parameters was observed (see 
Table12). 
 
Figure 29. Results of NGI experiments using the Flutide forte formulation. 
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3.2.1.5 Cascade impactor analysis of the Beclohexal pMDI formulation 
Analysis of the Beclohexal formulation using the NGI with the USPIP showed moderate IP 
deposition and a low particle deposition in S1-S4 as well as the filter stage. The main fraction 
of the sample recovered downstream from the IP was collected from S5-MOC (see Figure 
30). When comparing the USPIP, USP3DIP, and mIPext, a slight but insignificant increase in 
IP deposition, which resulted in a statistically significant decrease in FPFemitted (p= 0.03985) 
in the case of USP3DIP, was seen. In contrast, the mIP showed a more pronounced and 
statistically significant increase in IP deposition, when compared to the USPIP. FPFtotal and 
FPFemitted were found to decrease significantly, when using the mIP. An overview of the 
aerosol characteristics that were determined can be found in Table 12. 
 
Figure 30. Results of NGI experiments using the Beclohexal formulation. 
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3.2.1.6 Cascade impactor analysis of the Alvesco pMDI formulation 
Compared to the other formulations assessed, Alvesco ciclesonide showed an increased 
actuator deposition resulting in a Femitted of about 80% only (see Figure 31). NGI analysis 
using the USPIP showed fairly low IP deposition and little deposition in S1-S3. Apart from 
the actuator and IP stages, main particle deposition occurred in S4-filter stages. Aerosol 
characteristics that were determined are shown in Table 12. IP deposition, FPFtotal, FPFemitted, 
and GSD were found to be statistically equivalent when comparing USPIP and USP3DIP, 
though a slight increase in IP deposition was observed. S4 and S7 deposition was found to 
differ significantly. MIPext deposition was found to be lower, when compared to the USPIP 
and USP3DIP. When compared to the USPIP, mIP deposition was found to be significantly 
higher. FPFtotal was found to be insignificantly lower, whereas FPFemitted decreased to a 
statistically significant extent.  
 
Figure 31. Results of NGI experiments using the Alvesco formulation. 
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3.2.1.7 Cascade impactor analysis of the Foster pMDI formulation 
NGI assessment of the foster formulation using the USPIP showed little actuator deposition, 
high IP deposition, little deposition in S1-S3 and the filter stage and moderate deposition in 
S4-MOC (see Figure 32). Aerosol characteristics are summarized in Table 12. USPIP and 
USP3DIP were found to perform equivalently. Though not being statistically significant (p= 
0.05734), mIPext showed an increase in deposition, when compared to the USPIP, resulting 
in an insignificant decrease in FPFtotal (p= 0.06067) and FPFemitted (p= 0.05477). In contrast, 
mIP showed a significant increase in IP deposition leading to a significant decrease in FPFtotal 
(p= 0.02221) and FPFemitted (p= 0.02931). 
 
Figure 32. Results of NGI experiments using the Foster formulation. 
3.2.1.8 IVIVC 
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availability of such data in literature. Table 13 gives an overview on sources included and 
lung depositions reported. 
 
Table 13. Studies included for comparison of in vitro aerosol data with in vivo lung deposition 
from literature. 
 
[168][169][170][171][172][169][170][173][174][175] 
 Figure 33 correlates FPFemitteds determined using the USPIP, mIP, and mIPext and deposition 
data reported in literature. Diagonal lines indicate ideal correlation i.e. direct transferability of 
in vitro to in vivo data. It should be mentioned that the prescribing information of Sultanol 
reports a lung deposition of 10-20 %, which has been averaged, and so represents 15 ±5%. 
Additionally, data presented for the Foster formulation [173], was normalized to the emitted 
fraction. Figure 34 presents relative deviations of FPFemitted to lung deposition determined in 
vivo. Smaller deviations indicate better IVIVC and dashed lines depict the SD from data 
reported in the study. IVIVC using the mIP yielded good results for all except the Advair 
formulation and was found superior compared to the mIPext and USPIP in all cases except for 
the Foster formulation. IVIVC using the mIPext was found better to IVIVC using the USPIP 
in all cases but the ciclesonide formulation.  
Formulation tested Lung deposition [%] Study
Salbutamol Sultanol (GSK, London, UK) 10-20 [168]
Fluticasone propionate Advair HFA (GSK, London, UK) 16 (mild asthma) [169]
Flovent HFA (GSK, London, UK) 24 (mild asthma) [170]
Beclometasone dipropionate Qvar (3M, St.Paul, MN, USA) 53 ±7 [171]
Qvar (TEVA, Petach Tikwa, Israel) 60 ±14 [172]
Qvar 58 (mild asthma) [169]
Qvar 55 (mild asthma) [170]
Foster (Chiesi, Parma, Italy) 37 ±10 [173]
Ciclesonide n/r 52 ±9 (mild asthma) [174]
n/r 52 ±11 [175]
1
99 
3. Investigating NGI performance using modified 3D printed induction ports 
 
 
Figure 33. Comparison of in vitro prediction with in vivo lung deposition data from literature. 
Errorbars indicate one SD. The dashed line depicts ideal correlation. 
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Figure 34. Deviations of predicted from in vivo depositions. Dashed lines indicate SD 
reported in studies, if applicable. 
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3.2.2 Discussion 
In context of the previous chapter, the aim of this study was three-fold: a) to provide 
additional data supporting the observations made, b) to get a clearer idea which characteristics 
of pMDI formulations and actuator design trigger increased IP deposition, and c) to get a 
deeper understanding of which mechanisms are causal for any increased IP deposition 
observed. To address these issues, another set of four commercially available pMDI 
formulations was assessed using the USPIP, USP3DIP, and the mIP. Additionally, another 
modified IP (mIPext) was designed in a way that it would show the trachea geometry 
investigated in the previous chapter, but using the MT geometry of the USPIP, allowing 
plume expansion and deceleration of the aerosol particles before their transition into the 
proximal part of the IP.  
Commercial formulations assessed show a broad range of aerosol characteristics and USPIP 
deposition ranging from about 25% in the Alvesco formulation up to more than 55% in the 
Foster formulation. Based on their IP deposition characteristics, products assessed can be 
classified into two groups. One group comprising of the Beclohexal and Alvesco formulations 
showing moderate IP deposition and another group, comprising of the Sultanol, Flutide, and 
Foster formulations, showing extensive IP deposition. Both pMDI formulations in the low 
deposition group are solution based, which presumably offers advantages for fine aerosol 
production, as no particles must be de-agglomerated. An interesting characteristic of the 
Alvesco formulation is the increased actuator deposition (in comparison to all formulations 
assessed) which is not easily understood as both formulations are qualitatively equivalent; i.e. 
API with HFA 134a and ethanol as solubility enhancer. This might be explained comparing 
the actuator nozzle diameters of both devices (see Figure 27). The slightly decreased nozzle 
orifice of the Alvesco pMDI might produce a wider spray cone (and hence increased actuator 
deposition [32]) which also reflects in the actuator design having a spherical mouthpiece 
whereas the mouthpiece of the Beclohexal pMDI is rather ellipsoid. Additionally, the ethanol 
content of the formulations might differ. A higher ethanol content would prolong the drying 
kinetics of the primary droplets produced, which also might trigger increased actuator 
deposition. However, since the quantitative composition is not reported, it would be 
speculative to draw any solid conclusions about this. 
In contrast, preparations in the high deposition group are suspension based (Sultanol and 
Flutide), which also reflects in the actuator nozzle orifice diameters, which are significantly 
wider than their solution-based counterparts. An exception to this is the Foster pMDI, which 
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is solution based and shows an orifice diameter comparable to those found in the low 
deposition group, but shows increased IP deposition. An explanation for this can be found 
evaluating the formulation of the pMDI; besides ethanol and HFA 134a it also contains 
hydrochloric acid. Adding an acidic agent might have been necessary to solubilize the 
formoterol hemifumarate, which, along with beclometasone dipropionate, is also incorporated 
into the formulation. Though HCl is claimed on the label it is to be assumed that a solution of 
HCl in water was added. Due to its relatively low vapor pressure this would undoubtedly 
prolong the drying kinetics of the primary droplets produced, which, as discussed before, 
would act to reduce overall aerosol performance. 
Though increased mIP deposition was observed for all formulations tested, high USPIP 
deposition was found to be indicative of increased mIPext deposition. Using the data 
discussed in the previous chapter, it was found that no valid quantitative assessment of the 
processes participating in the mechanism to cause an increase in observed IP deposition could 
be made. It should be noted that any increase in IP deposition may be a result of inertial 
impaction of particles in the IP bend as well as impaction/settling of particles caused by the 
trachea geometry, and pMDI with VHC and DPI experiments indicated relevance of the latter 
impaction/settling process. Cascade impactor analysis of the Sultanol pMDI formulation used 
in the previous chapter using the mIPext showed an increase in IP deposition when compared 
to the USP and USP3D IPs, but lower deposition when compared to the mIP. This is in good 
agreement with conclusions drawn from the previous study, as it could be interpreted that the 
increased deposition now found was caused by geometrical factors of the proximal part of the 
IP only, whereas the fraction differing from the mIP deposition was also related to increased 
inertial impaction in the bend of the IP, caused by the shortened distance from the pMDI 
device to the bend of the mIP. Similar results were obtained when analyzing the Flutide forte 
formulation. Here, a significant increase in IP deposition was observed for both mIPs, when 
compared to the USPIP. Additionally, the difference in deposition between the mIP and the 
mIPext was found to be less pronounced when compared to the Sultanol pMDI, indicating 
that inertial impaction in the bend of the IP here contributes to a lesser extent. The Foster 
pMDI behaved similar to the Sultanol formulation, so that conclusions drawn there are 
applicable.  
Contrary, analysis of the Beclohexal and Alvesco formulations showed statistically increased 
mIP depositions, whereas the mIPext depositions were found statistically equivalent, when 
compared to the USPIP. So, it is to be concluded that for these formulations the increase in 
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mIP deposition observed, is solely caused by inertial impaction at the bend of the mIP; in 
contrast, increased impaction or settling in the proximal part of the mIP does not occur. 
Interestingly, mIPext deposition was found to be lower than USPIP deposition in the case of 
the Alvesco formulation. This might be correlated to the high actuator deposition, which can 
already retain the particles that would otherwise impact in the bend of the trachea. As 
discussed in the previous chapter the change in motion vector when transitioning from the 
distal to the proximal section of the mIP is less pronounced, when compared to the USPIP. 
This consideration also applies to the mIPext, as the angle connecting the two elements is 
identical to that of the mIP. So, this observation could be interpreted as evidence for the 
relevance of the head position of the patient when using a pMDI device, which is not reflected 
in the USPIP. As discussed in the previous chapter, this observation is in good agreement 
with literature. Nevertheless, this specific case might provide a suitable test system for future 
studies utilizing the 3D printed mIP model to investigate this effect more closely.  
All pMDI formulations showing tracheal deposition are found in the high USPIP deposition 
group, whereas all low deposition group formulations investigated were not susceptible to 
that. As FPFs of low USPIP deposition pMDIs were found to be higher than ones of high IP 
deposition pMDIs, this finding might be attributed to the overall aerosol properties of these 
formulations, as apparently these pMDIs lack the fraction of aerosol particles that would be 
separated in the trachea. So, the ratio of both mechanisms participating in the overall effect is 
directly correlated to the overall aerosol performance, i.e. only formulations containing larger 
aerosol particles (or agglomerates) are susceptible to tracheal deposition. This finding is in 
good agreement with a study by Leach et al. conducted in 2012 [169]. Here, the authors 
compared in vitro and in vivo deposition of a HFA solution based pMDI formulation of 
beclometasone (QVAR, TEVA, Petach Tikwa, Israel) and a suspension based HFA 
formulation of Fluticasone (Advair, GSK, London, UK). The authors used radiolabelled 
aerosol particles to identify areas of deposition in the patients and quantify relative deposition. 
Radiolabelling was validated by cascade impaction assessment, allowing an estimate on how 
comparable findings of this study are to the present one. Unfortunately, some inconsistencies 
in the analytical method reported compromise detailed evaluation of the study. It is reported 
that aerosol characteristics were generated using the NGI, whereas deposition plots show a 
stage setup matching the ACI without terminal filter. Assuming that S0 and S7 reported in the 
plots correspond to S1 and MOC stages, which would be in that position in a regular NGI 
setup, data shows good agreement with results from this study. However, it must be noted that 
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the QVAR formulation shows higher actuator and consequently lower overall CI deposition, 
when compared to the Beclohexal formulation. It is unclear, how many actuations of the 
pMDI have been applied in each run but since the maximum number monographed in the 
USP and Ph.Eur. (i.e. n= 10) was applied in the present study, it is to be assumed that the 
number of actuations was equal, or less. As deposition in the actuator is likely to be a surface 
related effect this mechanism might be saturable, which would cause a decrease of relative 
actuator deposition at increased numbers of actuations. Anyways, as Leach et al. reported in 
vivo deposition data calculated as fractions ex valve, it is a valid assumption that data 
provided there is applicable to the formulations investigated here. Figure 35 shows γ-
scintigraphic images of beclometasone and fluticasone deposition, as reported by Leach et al. 
The beclometasone formulation shows high deposition in the MT region and the lungs, 
whereas the fluticasone formulation shows deposition in the MT, trachea, and lungs. This 
finding supports the conclusion that tracheal deposition is relevant, though depending on the 
overall performance of the formulation, and that the proximal section of the mIP is related to 
physiological reality.  
 
 
Figure 35. In vivo particle deposition of beclometasone (left) and fluticasone (right) pMDI 
formulations. Reproduced from [169] with kind permission from Elsevier.  
. 
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Another aim of this study was to provide additional data on the correlation of particle 
deposition predicted to in vivo deposition, so formulations assessed were selected based on 
availability of appropriate data in the literature. Due to their limited availability, studies 
investigating lung deposition in mild asthmatic patients have also been included. In the case 
of pMDIs, comparative studies indicate that the impact of mild asthmatic symptoms on lung 
deposition is rather low [172,173], so in this context these groups might be treated 
equivalently. 
In the case of salbutamol, FPFemitted determined using the mIP correlates well with in vivo 
deposition data reported in the product´s prescribing information. Comparability of this data 
set has already been discussed in the previous chapter. In contrast, the mIPext and USPIP 
rather overestimate lung deposition (see Figures 33 and 34). Similar results were observed in 
the case of the Flutide formulation, but IVIVC using the mIPext was found closer to that 
achieved with the mIP. And, predictions of lung deposition showed a greater deviation from 
in vivo deposition in the case of the Advair formulation. Advair is a combination preparation 
that includes fluticasone propionate and salmeterol xinafoate as a single dose formulation and 
as such, differs from the fluticasone propionate only formulation, assessed in this study. 
Nevertheless, as both formulations are formulated using the same approach it may be assumed 
that they perform similarly. The study presents cascade impactor data in order to validate the 
radio labeling technique applied, but fails to provide aerosol characterization of the test 
formulations. Comparability of data presented in that study to the in vitro performance 
reported in this study has already been discussed, in the previous paragraph. It was found that 
all IPs tested tended to overestimate the lung deposition that could be obtained. IVIVC of 
formulations containing beclometasone only, was found to be accurate within the precision 
range of the in vivo studies, whereas the USPIP rather over estimated its performance. In 
contrast, mIPext and USPIP provided good prediction in case of the Foster formulation, 
whereas the mIP underestimated in vivo performance, but not significantly. Comparing in vivo 
and in vitro data of the ciclesonide formulation shows that USPIP and mIPext overestimated 
lung deposition, whereas good IVIVC was achieved using the mIP.  
Drawing conclusions from all the studies evaluated, NGI studies conducted using the mIPext 
tended to over predict lung deposition, whereas analysis with the mIP provided good IVIVC 
in most cases. Consequently, one must conclude that the distal section of the USPIP and the 
mIPext, which is supposed to mimic the MT region (see previous chapter), lacks 
physiological relevance. On the other hand, keeping in mind that the increase in mIP 
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deposition for many formulations was found to be caused by inertial impaction in the 
shortened MT region of the IP, these findings highlight the necessity to further investigate the 
exact mechanism that retains the particles in the MT region, and to incorporate these findings 
into the mIP. Thus, the next iteration of the mIP should include a biorelevant MT section. 
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4 Development of respirable, excipient free formulations of rifampicin 
 
4.1 Results and discussion of the exploratory study 
4.1.1 Results 
4.1.1.1 Manufacturing process 
Solutions or suspensions of rifampicin, spray dried (SDr) from various solvents, was found to 
be a suitable method to produce dry powders that were appropriate for inhalation testing. 
Process yields were found to differ strongly among different formulations (Table 14). Lower 
process yields at higher solid content of formulations SDr from acetone was related to 
increased deposition in the column, rather than the product collection vessel of the spray drier. 
And only product collected from the collection vessel was included in this study. 
 
In reference to Table 14 it should be noted that the formulation designated “RFDCMexp1” 
could not be manufactured, as the suspension was too viscous for atomization with the 
modified three fluid nozzle for the spray drier. Furthermore, spray freeze drying of the 
RFaqexp1 did not result in individual particles suitable for inhalation testing. And although 
spray freezing of the solution was found as suitable method to produce individual ice spheres, 
subsequent freeze-drying induced collapse and agglomeration of the particles. Recovery of 
the mass was possible only by scraping it off from the collection vessel, which eventually 
caused the formation of soft pellets. Due to this result, this formulation was omitted and no 
additional experiments were conducted. Similar results were obtained by consecutive spray 
and freeze drying of formulation RFaqexp2. Here, the collapse of the powder bed was not as 
pronounced as in the case of RFaqexp1, so soft pellets obtained were tested for their aerosol 
properties. 
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Table 14. Overview of manufacturing process during the exploratory study. 
 
4.1.1.2 Stability of aqueous solutions for the duration of the SDr process 
 
Figure 36 shows process characteristics acquired during the manufacture of RFaqexp3, as 
well as concentrations of the feed solution and relative absorption at 334 nm and 475 nm for 
the duration of the acquisition. Concentration means are normally distributed, as indicated by 
the Shapiro-Wilk test (p= 9.0 x 10-10). Similarly, relative absorptions were also found to be 
normally distributed (p= 3.5 x 10-10). 
Sample name Solvent Yield Approx. process time
[%] [h]
RFaqexp2 23.0 12.5
RFaqexp3 29.9 12.5
RFaqexp4 13.9 8.3
RFaqexp5 26.2 4.1
RFIPAexp1 IPA 39.7 1.8
RFIPAexp2 57.2 1.2
RFIPAexp3 55.1 0.6
RFMeOHexp1 MeOH 36.1 2.0
RFMeOHexp2 36.5 1.3
RFMeOHexp3 67.5 0.7
RFEtOHexp1 EtOH 14.5 31.7
RFEtOHexp2 17.4 21.0
RFEtOHexp3 32.2 10.5
RFEtOHexp4 36.8 0.6
RFACexp1 acetone 43.0 3.0
RFACexp2 29.9 2.0
RFACexp3 19.4 1.0
RFDCMexp2 DCM 12.0 0.1
RFDCMexp3 6.9 0.1
1
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Figure 36. Process characteristics of RFaqexp3 showing in- and outlet temperature, aspirator 
set, and chemical stability of the RF feed solution. 
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4.1.1.3 XRPD analysis of samples from the exploratory study 
XRP diffractograms of samples manufactured are shown in Figure 37. XRP diffractograms of 
the individual samples were shifted on the y-axis for better comparability. 
 
Figure 37. Results of XRPD analysis of samples from the exploratory study. 
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4.1.1.4 Aerodynamic assessment of RF formulations using the Handihaler device 
Aerosol characteristics of samples dispensed from the Handihaler device are shown in Table 
15. 
Table 15. Overview of aerosol characteristics of samples from the exploratory study. 
 
  
Sample name FPF EF MMAD GSD
[%] [%] [µm] [ ]
RFaqexp2 47.92 ±4.12 97.89 ±1.67 1.70 ±0.19 3.21 ±0.07
RFaqexp3 90.06 ±3.74 98.80 ±0.08 1.38 ±0.30 3.54 ±0.37
RFaqexp4 78.02 ±0.32 97.92 ±0.16 1.82 ±0.13 3.21 ±0.08
RFaqexp5 47.17 ±1.74 91.15 ±2.05 3.03 ±0.06 2.02 ±0.02
RFIPAexp1 40.12 ±2.46 75.82 ±7.34 2.84 ±0.10 1.92 ±0.04
RFIPAexp2 32.20 ±2.26 82.16 ±1.63 3.09 ±0.15 2.04 ±0.04
RFIPAexp3 24.90 ±3.37 83.13 ±0.74 3.44 ±0.20 2.14 ±0.02
RFMeOHexp1 23.27 ±2.06 72.47 ±3.20 2.96 ±0.14 2.09 ±0.06
RFMeOHexp2 33.18 ±4.07 60.59 ±5.12 2.56 ±0.05 1.96 ±0.05
RFMeOHexp3 31.04 ±1.13 81.51 ±2.53 3.91 ±0.01 2.08 ±0.03
RFEtOHexp1 6.24 ±0.42 84.74 ±1.71 6.36 ±0.19 2.07 ±0.33
RFEtOHexp2 13.28 ±1.17 74.46 ±2.29 3.00 ±0.07 2.07 ±0.12
RFEtOHexp3 44.05 ±3.09 89.13 ±1.16 3.87 ±0.18 1.67 ±0.06
RFEtOHexp4 43.70 ±3.52 88.48 ±1.57 3.83 ±0.16 1.91 ±0.02
RFACexp1 7.07 ±1.92 83.99 ±2.32 2.96 ±0.21 1.89 ±0.02
RFACexp2 28.30 ±2.74 61.22 ±1.78 2.52 ±0.05 2.02 ±0.02
RFACexp3 32.20 ±2.26 82.16 ±1.63 3.09 ±0.15 2.04 ±0.04
RFDCMexp2 37.00 ±1.00 79.31 ±2.56 3.41 ±0.25 2.23 ±0.05
RFDCMexp3 35.29 ±3.53 69.31 ±4.37 3.00 ±0.09 2.09 ±0.04
1
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4.1.1.4.1 Samples SDr from water 
 
Aerodynamic assessment of samples spray dried from watery solutions (RFaqexp2, 
RFaqexp3, and RFaqexp4) showed low to moderate inhaler and capsule deposition, moderate 
deposition over NGI stages S1-S7 and moderate to high deposition in the terminal filter (see 
Figure 38), which resulted in exceptionally high FPFs. As mentioned in the previous section, 
product recovery of RFaqexp2 from the vessel used for freeze drying facilitated the formation 
of soft pellets. NGI analysis of this formulation showed that a large fraction of the sample 
deposited in the preseparator stage. In contrast, RFaqexp3 and RFaqexp4 showed little 
preseparator deposition. Analysis of RFaqexp5 showed moderate inhaler, IP, and preseparator 
deposition, moderate deposition over S1-S6, and little or no deposition on S7, the MOC, or 
filter stages. Aerosol characteristics can be found in Table 15. 
 
 
Figure 38. Results of cascade impactor experiments of samples SDr from water (exploratory 
study). 
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4.1.1.4.2 Samples SDr from IPA 
 
Cascade impactor analysis of samples SDr from IPA showed moderate to high inhaler, IP, and 
preseparator deposition (see Figure 39). S1-S6 deposition was found to be moderate. S7-filter 
stages showed little to no deposition. The highest FPF was observed for RFIPAexp1 (see 
Table 15). 
 
Figure 39. Results of cascade impactor experiments of samples SDr from IPA (exploratory 
study). 
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4.1.1.4.3 Samples SDr from MeOH 
 
Cascade impactor analysis of solutions and suspensions SDr from MeOH showed moderate to 
high inhaler, IP, and preseparator deposition (see Figure 40). Deposition at S1-S6 was found 
to be moderate. All samples showed little deposition at S7-filter stages. The average FPF 
value obtained was found to be in an intermediate range (see Table 15). 
 
 
 
Figure 40. Results of cascade impactor experiments of samples SDr from MeOH (exploratory 
study). 
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4.1.1.4.4 Samples SDr from EtOH 
 
Samples SDr from ethanolic solutions (RFEtOHexp1) showed moderate to high inhaler and 
capsule deposition, high deposition at the IP and preseparator and little deposition at S1-S6 
(see Figure 41). Downstream from S6, practically no deposition was observed. RFEtOHexp2 
showed high inhaler and capsule, moderate IP, and high preseparator deposition. Similarly to 
RFEtOHexp1, deposition at S1-S6 was found to be very little; but the average MMAD (see 
Table 15) was shifted to a smaller diameter. RFEtOH3 and RFEtOH4 showed moderate 
deposition for the inhaler, capsule, and IP, and little deposition at the preseparator. Both 
formulations displayed moderate to high deposition at S2-S4, low to moderate deposition at 
S1, S5, and S6, and practically no deposition at S7-filter stages. 
 
Figure 41. Results of cascade impactor experiments of samples SDr from EtOH (exploratory 
study). 
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4.1.1.4.5 Samples SDr from acetone 
Samples SDr from acetone showed moderate to high inhaler, IP, and preseparator deposition 
(see Figure 42). Moderate deposition at S2-S6 was found in the case of RFACexp2 and 
RFACexp3. In contrast, RFACexp1 showed moderate deposition at S1-S3. All samples 
showed little S7, MOC, and filter deposition. Aerosol characteristics can be found in Table 
15. 
 
Figure 42. Results of cascade impactor experiments of samples SDr from acetone (exploratory 
study). 
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4.1.1.4.6 Samples SDr from DCM 
 
Samples SDr from DCM showed moderate to high inhaler and IP deposition and moderate 
deposition in S2-S5. Preseparator as well as S6-filter deposition was found to be low (see 
Figure 43). Aerosol characteristics are shown in Table 15. 
 
 
 
Figure 43. Results of cascade impator experiments of samples SDr from DCM (exploratory 
study). 
  
0.0
0.2
0.4
0.6
inh
ale
r +
 ca
psu
le IP
pre
sep
ara
tor
sta
ge 
1
sta
ge 
2
sta
ge 
3
sta
ge 
4
sta
ge 
5
sta
ge 
6
sta
ge 
7
MO
C
filte
r
stage [ ]
re
lat
ive
 m
as
se
s [
 ]
formulation
RFDCMexp2
RFDCMexp3
118 
4. Development of respirable, excipient free formulations of rifampicin 
 
4.1.2 Discussion 
In the exploratory study trials, processability of solutions and suspensions of RF in various 
solvents, including standard organic solvents and water, was investigated and evaluated. As a 
secondary outcome parameter, suitability of formulations obtained for inhaler testing was 
assessed using the Next Generation Pharmaceutical Impactor. Additionally, XRPD analysis 
was utilized to discriminate between different (pseudo-) polymorphs of RF.  
 
Stability of the manufacturing process was assessed analyzing both, stability of the process 
parameters as well as chemical stability of the feed solution. As RF is reported to show 
limited stability in aqueous solutions and process time of this batch was the longest in this 
study, RFaqexp3 was evaluated as most critical batch and was monitored in detail. The feed 
solution supplied was sampled and quantified at intervals of 30 minutes, over the period of the 
entire manufacturing process and concentration means were found to be normally distributed 
(Shapiro-Wilk test), indicating good stability. Additionally, a full UV-vis spectrum was 
recorded at each time point. According to the Ph.Eur. relative absorption of RF at 334 nm and 
475 nm approximates as 1.75, so this method was used to verify chemical stability, in case the 
HPLC method used fails to separate degradation products (especially RF-quinone and 
desacetyl-RF) and RF. However, relative absorptions were found to comply with 
requirements and deviations were distributed evenly over the entire process.  
It was concluded that RF remains stable in aqueous solution, for the duration of the process. 
Inlet and outlet temperatures were found to be stable over the entire process as well. During 
the process, the terminal filter unit became congested with product. As a result the aspirator 
set point was adjusted over time in order to maintain the pre-specified flow rate through the 
system of 15 NCMH. The terminal cloth filter had to be replaced with a clean one after 
approx. 360 minutes; reflecting in the interruption in the liquid feed, the drop in aspirator set 
point, and a temporary increase in outlet temperature (related to interrupted solvent 
atomization prior to switching off the aspirator). Decrease and subsequent overshooting of 
inlet temperature after exchanging the filter, was due to the heating interruption when 
replacing the filter, and consequent readjustment. The process presented is a representative 
example for all batches manufactured, but it should be noted, that inlet temperature, process 
duration, and number of filter bags used is dependent on the individual batch composition. 
Process parameters were recorded for all batches manufactured, but will not be discussed 
individually as it is very similar to what has already been presented earlier. 
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In the following section, all formulations that were manufactured in this study will be 
evaluated and discussed. 
 
4.1.2.1 RFaqexp1  
It was found that spray freeze drying of aqueous solutions of RF did not result in a product 
suitable for inhalation testing. Manufacture of individual frozen spheres was found to be 
feasible, but subsequent freeze drying induced collapse of the particles, which was to be 
expected as the solid content of solutions sprayed was well below 0.2%w/w, whereas a solid 
content of 1% is reported [176] as lower limit to generate structural intact lyophilisates. As 
equilibrium solubility was found to be 0.2 mg/mL (= 0.02%w/v), a high degree of 
supersaturation would be necessary to provide concentrations high enough for the individual 
particles to remain structurally intact. Alternatively, incorporation of a matrix forming 
excipient (e.g. carbohydrate) might be suitable to produce intact spherical particles. But since 
the focus of this study was on the development of an excipient-free formulation, this was 
beyond the scope of these studies.  
4.1.2.2 RFaqexp2 
Consecutive spray then freeze drying of aqueous, supersaturated solutions was found to be a 
feasible way to produce soft pellets, which generally demonstrated better flow properties than 
non-agglomerated dry powders. As this was not considered to be in the scope of the study, 
powder flow properties of the samples were not quantified. However, this advantage in 
formulation processability was achieved at the cost of a drastic reduction in aerosol 
performance, as soft pellets were not found to de-agglomerate easily following air 
entrainment, and thus impacted largely in the preseparator stage when analyzed using the 
NGI. A FPF of approximately 50% indicates superior performance to most commercially 
available DPI formulations. Nevertheless, this formulation shows a 50% lower FPF, when 
compared to equivalent formulations, which had not been subjected to the terminal freeze 
drying step (i.e. RFaqexp3 and RFaqexp4). Therefore, this manufacturing strategy was 
excluded from further investigation but might be continued at a later stage of development, if 
flow properties of non-agglomerated particles prove to be insufficient for processability 
during, for example scale up or production when automated filling is involved. 
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4.1.2.3 RFaqexp3 and RFaqexp4  
Spray drying of supersaturated aqueous solutions of RF resulted in easily aerosolized 
powders. This reflects in extraordinarily high FPFs, when analyzed using the NGI, which are 
at minimum comparable to high performance investigational DPI formulations and surpass 
commercial formulations available (also including pMDI and nebulized formulations), except 
of the Staccato (Alexza Pharmaceuticals, Mountain View, CA, USA), which performs 
equivalently well [8]. Thus, these formulations (as well as another RF concentration) were 
incorporated into the main study and will be discussed there in detail. 
4.1.2.4 RFIPAexp1  
As expected, spray drying of solutions of RF in IPA yielded amorphous particles showing the 
characteristic collapsed spheres (‘donut shape’, data not shown), which is widely reported in 
literature. Aerosol performance of this formulation was found to be the best of all amorphous 
batches except RFaqexp3 and RFaqexp4. Hence, this formulation was included in the main 
study as reference formulation. 
4.1.2.5 RFIPAexp2 and RFIPAexp3  
Spray drying of suspensions of RF in IPA yielded crystalline particles of the F-I polymorph. 
Aerosol assessment showed intermediate performance. As these formulations showed no 
special crystalline state, nor high aerosol performance, these formulations were not included 
into the main trials. 
4.1.2.6 RFMeOHexp1  
Spray drying of solutions of RF in MeOH produced particles similar to RFIPAexp1. 
However, aerosol performance was found to be lower than RFIPAexp1. It may be assumed 
that reduced FPF is related to a lower geometrical diameter of the particles, which is probably 
due to a) the slightly lower solubility of RF in MeOH when compared to IPA and b) that RF 
has a higher tendency to supersaturate in MeOH, which facilitates protracted crust formation 
upon drying of the particles. Hypothesis b) is deduced from the observation that RF forms an 
unknown (pseudo-) polymorph when recrystallized from MeOH, which is hypothesized to 
require a certain degree of supersaturation in the solvent. As RFMeOHexp1 is equivalent to 
RFIPAexp1 but shows lower aerosol performance, this formulation was not further 
investigated. 
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4.1.2.7 RFMeOHexp2  
Despite the fact that this formulation is produced using a suspension, the spray dried product 
shows no distinct crystalline structure, which is probably related to the access amount of RF 
dissolved, dominating the overall solid state properties of the sample. Aerosol performance 
was found to be lower than RFIPAexp1, so this formulation was deemed to offer no benefit 
and was not further investigated. 
4.1.2.8 RFMeOHexp3  
This formulation is similar to RFMeOHexp2 but with a higher solid fraction in the 
suspension, and yielded crystalline particles of an unknown (pseudo-) polymorph. Though the 
aerosol performance is intermediate only, this formulation demanded further investigation in 
the main study to clarify the solid state. 
4.1.2.9 RFEtOHexp1 
Spray drying of ethanolic solutions of RF produced ultrafine amorphous particles, which is 
due to the low equilibrium solubility of RF in EtOH. Aerosol performance was low, as this 
formulation was extremely cohesive, due to its small geometric diameter (also see acoustic 
levitator experiments in 4.3.1.9). Though not being suitable for inhalation therapy, it is 
hypothesized that this formulation might provide a good testing system for DPI devices, as 
low aerosol performance is expected not to be related to inadequate geometry of the 
individual particles but rather incomplete de-agglomeration. De-agglomeration efficiency of 
the DPI would directly correlate to the aerosol performance. However, as of now this 
conclusion is speculative and should require further investigation in additional studies. 
Production costs of this formulation may be extremely high, as a large amount of EtOH 
(about 15 L) was needed to produce powder in a quantity sufficient for the tests in the main 
study. As the spray rate of the SDr was kept constant over all batches at 7.4 mL/min, this 
resulted in a spray process duration of more than 30 hours, which demanded the manufacture 
of three sub-batches. For these reasons it was excluded from the main study. 
 
4.1.2.10 RFEtOHexp2 
XRPD analysis of this formulation showed that it has a significant degree of amorphous 
domains, though traces of an unknown (pseudo-) polymorph could be identified. As aerosol 
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performance was found to be low, this formulation was omitted in favor of RFEtOH3 and 
RFEtOH4. 
 
4.1.2.11 RFEtOHexp3 and RFEtOHexp4  
Both formulations show the same (pseudo-) polymorph found in RFEtOHexp2 but at a higher 
degree of crystallinity. De-agglomeration of both formulations was easily achieved and 
overall aerosol performance was deemed good. Thus, and in order to clarify the solid state of 
the samples, RFEtOHexp 3 was included into the main study. Having a solid content of the 
spray solution identical to a formulation previously reported by Son and McConville [91], 
RFEtOHexp4 was included as a reference to assure comparability. 
 
4.1.2.12 RFACexp1  
Unexpectedly, spray drying of solutions of RF in acetone yielded predominantly amorphous 
particles showing distinct traces of crystalline F-I domains. Two different mechanisms 
leading to this observation are imaginable. Either, particles crystallized from amorphous 
material after spray drying or crystalline nanoparticles passing the 0.22 µm filter were 
included in the feed solution prior to spray drying. Secondary recrystallization appears 
somewhat unlikely, as no other amorphous sample has shown such behavior so formation of 
nanocrystals is considered to be more likely. However, similarly to RFEtOHexp1, powders 
were very cohesive, demonstrating poor aerosol properties. Thus, this sample was excluded 
from further investigation.  
 
4.1.2.13 RFACexp2 and RFACexp3  
Spray drying of suspensions of RF in acetone was found to yield amorphous particles 
showing aerodynamic properties comparable to RFIPAexp1, but at lower performance. 
During the spray drying process both batches showed high deposition in the spray cylinder. 
Product was collected from the collection vessel only. It was unexpected to find amorphous 
material, as spray drying of suspensions was expected to yield crystalline particles. This 
might be related to the high deposition of product in the spray cylinder. Only larger particles 
exceeding a certain aerodynamic diameter would impact in this site so particles suspended 
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might have been removed from the product collected. Even so, as these formulations offer no 
benefit over RFIPAexp1, they were excluded from further investigation. 
 
4.1.2.14 RFDCMexp2 and RFDCMexp3  
Spray drying of solutions and suspensions of RF in DCM produced amorphous particles 
showing intermediate aerosol performance. It was unexpected that spray drying of 
suspensions would produce amorphous material. This observation may be explained by 
particle separation during the spray drying process. High spray column deposition was 
observed, so it may be assumed that, due to the high solubility (approx. 200 mg/mL), two 
distinct particle populations were formed. Recrystallization of RF in DCM presumably yields 
a suspension with larger primary particles, which is due to excessive particle growth that is 
related to high solubility. The larger, crystalline particles impacted in the spray column 
whereas the aerodynamically smaller amorphous particles, which formed from the material 
dissolved, were separated in the cyclone; where they were collected and analyzed. As these 
formulations offer no benefit over RFIPAexp1 they were excluded from additional 
investigation. 
 
Table 16 gives an overview on key findings of the exploratory study and which batches were 
additionally investigated in the main study trials. 
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Table 16. Overview of key conclusions of the exploratory study. 
 
  
Sample name Solvent FPF Crystallinity Polymorph Incl. in
[%] [ ] [ ] main study?
RFaqexp2 water 47.92 ±4.12 amorphous
RFaqexp3 90.06 ±3.74 amorphous x
RFaqexp4 78.02 ±0.32 amorphous x
RFaqexp5 47.17 ±1.74 crystalline unknown I x
RFIPAexp1 IPA 40.12 ±2.46 amorphous x
RFIPAexp2 32.20 ±2.26 crystalline F-I
RFIPAexp3 24.90 ±3.37 crystalline F-I
RFMeOHexp1 MeOH 23.27 ±2.06 amorphous
RFMeOHexp2 33.18 ±4.07 amorphous
RFMeOHexp3 31.04 ±1.13 crystalline unknown II x
RFEtOHexp1 EtOH 6.24 ±0.42 amorphous
RFEtOHexp2 13.28 ±1.17 semi-crystalline unknown III
RFEtOHexp3 44.05 ±3.09 crystalline unknown III x
RFEtOHexp4 43.70 ±3.52 crystalline unknown III x
RFACexp1 acetone 7.07 ±1.92 crystalline F-I
RFACexp2 28.30 ±2.74 amorphous
RFACexp3 32.20 ±2.26 amorphous
RFDCMexp2 DCM 37.00 ±1.00 amorphous
RFDCMexp3 35.29 ±3.53 amorphous
1
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4.2 Results and discussion of the main study investigating manufacture of respirable 
rifampicin particles using organic solvents 
4.2.1 Results 
4.2.1.1 Manufacture 
Manufacture of formulations of RF recrystallized from organic solvents i.e. EtOH and MeOH 
investigated during the exploratory study was repeated successfully. RFIPAAm1 was 
manufactured as reference sample. Table 17 shows product yields and processing times from 
the manufacturing process. 
Table 17. Product yields of SDr samples. 
 
4.2.1.2 Physicochemical characterization  
4.2.1.2.1 SEM images of particles obtained 
SEM pictures (see Figure 44) of RFEtOHCryst1 and RFEtOHCryst2 showed particles of flake 
like shape in the size range around two to three µm. RFMeOHCryst1 showed two different 
particle populations of distinct morphology and size. One population showed larger particles 
of brick like shape, whereas the other displayed smaller particles of collapsed spherical shape 
similar to RFIPAAm1. RFIPAAm1 showed collapsed spheres as well and displayed the 
characteristic ‘donut shape’, typically known from spray dried solutions.  
Sample name Solvent Yield Approx. process time
[%] [h]
RFEtOHCryst1 EtOH 44.6 0.6
RFEtOHCryst2 58.8 8.4
RFMeOHCryst1 MeOH 78.0 0.5
RFIPAAm1 IPA 42.0 1.8
1
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Figure 44. SEM images of RFEtOHCryst1 (top left), RFEtOHCryst2 (top right), 
RFMeOHCryst1 (bottom right), and RFIPAAm1 (bottom left). 
4.2.1.2.2 XRPD analysis of RF samples SDr from organic solutions or suspensions 
XRPD analysis (see Figure 45) showed that spray drying of suspensions of RF in EtOH and 
MeOH produced crystalline particles. The x-ray diffractograms obtained are similar to F-II 
but present characteristic differences. Both samples recrystallized from EtOH are identical. 
RFIPAAm1 was found to be amorphous, which is consistent with results of the exploratory 
study. X-ray diffractograms of RFEtOHCryst1 exposed to different relative humidities 
(Figure 46) showed that particles decreased in crystallinity on drying by exposure to dry N2 
gas. Consecutive exposure to water vapor was found to induce irreversible peak shifts, 
indicating changes in the crystal composition of the particles, which was found terminated at 
60% RH. Further increases in vapor saturation of the gas phase led to an increase in 
crystallinity, as indicated by an increase of absolute peak intensities. When exposed to lower 
vapor pressure, intensities were found to decrease and this process was found fully reversible. 
RFEtOHCryst1	
RFIPAAm1	
RFEtOHCryst2	
RFMeOHCryst1	
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RFMeOHCryst1 displayed similar behavior as RFEtOHCryst1 (Figure 47), but transition 
already occurred during the initial drying step. RFIPAAm1 was found to remain amorphous 
regardless at which RH it was being equilibrated (Figure 48). X-ray diffractograms of 
RFEtOHCryst1 and RFMeOHCryst1 exposed to increasing temperature showed that both 
samples decrease in crystallinity. RFMeOHCryst1 was found to be less thermo stable, 
showing mainly amorphous diffractograms at a temperature of 80 °C (Figure 50), whereas 
RFEtOHCryst1 (Figure 49) was found predominantly amorphous at a higher temperature of 
100 °C. RFIPAAm1 remained amorphous at any temperature (Figure 51). 
 
 
Figure 45. X-ray diffractograms of samples SDr from organic solvents. 
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Figure 46. X-ray diffractograms of RFEtOHCryst1, equilibrated at different RF after initial 
drying. 
 
Figure 47. X-ray diffractograms of RFMeOHCryst1, equilibrated at different RH after initial 
drying. 
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Figure 48. X-ray diffractograms of RFIPAAm1, equilibrated at different RH after initial 
drying. 
 
Figure 49. X-ray diffractograms of RFEtOHCryst1, equilibrated at different temperatures 
after initial drying. 
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Figure 50. X-ray diffractograms of RFMeOHCryst1, equilibrated at different temperatures 
after initial drying. 
 
Figure 51. X-ray diffractograms of RFIPAAm1, equilibrated at different temperatures after 
initial drying. 
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4.2.1.2.3 Analysis of residual solvents using the GC and Karl Fisher analysis 
Analysis of residual solvents showed that RFEtOHCryst1 and RFEtOHCryst2 contain 
residual EtOH (Table 18). RFMeOHCryst1 was found to contain residual MeOH. Analysis of 
residual solvents showed that RFIPAAm1 contained residual isopropyl alcohol. All samples 
contained residual water. 
 
Table 18. Overview of physical and chemical charaterization of RF samples. 
 
Sample name Purity HPLC Water content Organic solvents TGA
[%] [%] [%] [%]
RFEtOHCryst1 91.0 ±0.2 0.6 ±0.3 8.4 ±0.1 (EtOH) 90.6 ±0.2
RFEtOHCryst2 90.3 ±1.9 1.3 ±0.2 7.9 ±0.7 (EtOH) 90.3 ±0.2
RFMeOHCryst1 95.3 ±0.6 1.8 ±0.1 5.8 ±0.6 (MeOH) 94.5 ±0.2
RFIPAAm1 97.6 ±1.5 1.1 ±0.2 2.9 ±0.2 (IPA) 96.2 ±0.3
1
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4.2.1.2.4 DSC analysis of RF samples SDr from organic solutions or suspensions 
Differential scanning calorimetry experiments of RFEtOHCryst1 and RFEtOHCryst2 showed 
broad desolvation peaks showing maxima at about 155 °C and 135 °C respectively (Figure 
52), followed by a glass transition at 163 °C and an exothermic event starting from 180 °C. 
Results obtained from samples of RFMeOHCryst1 yielded similar results. The desolvation 
peak, that showed a maximum at about 130 °C, was less pronounced here. Also, peaks 
associated with decomposition are less pronounced. RFIPAAm1 showed an earlier 
desolvation peak (max= 68 °C). The glass transition, which was found at 163 °C, was 
followed by another exothermic peak.  
 
 
Figure 52. Results of DSC analyses of samples SDr from organic solvents. 
4.2.1.2.5 DVS analysis of RF samples SDr from organic solutions or suspensions 
DVS analysis of RFEtOHCryst1 and RFEtOHCryst2 showed a loss in mass after exposure of 
one 0-97-0% RH cycle (see Figures 53 and 54). Desolvation isotherms of the first and second 
cycle were found to be congruent. Sorption/desorption isotherms of the second cycle showed 
characteristics identical to the isotherms obtained when analyzing RFMeOHCryst1. The 
isotherms differ in the extent of water uptake during the terminal equilibration step at 97% 
RH, which also is reflected in the extent of the hysteresis observed. RFMeOHCryst2 showed 
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three distinct sorption kinetics (Figure 55). The first and second displayed a sigmoidal 
transition with an inflection point at about 25% RH, and the second and third transitioned 
gradually one into the other. Extrapolated linear fits were found to intersect at 87.6% RH. 
Maximum water uptake at the equilibrated stage (Cycle 2) was found to be 9.9% w/w, 12.8% 
w/w, and 10.8% w/w for RFEtOHCryst1, RFEtOHCryst2, and RFMeOHCryst1 respectively. 
RFIPAAm (Figure 56) displayed a different sorption behavior, showing two distinct linear 
sorption kinetics and extrapolated linear fits intersected at 78.0% RH. Maximum water uptake 
was found to be 17.2% w/w.  
 
Figure 53. Results of DVS analysis of RFEtOHCryst1. 
−5
0
5
10
15
20
0 25 50 75 100
RH [%]
dm
 [%
]
direction
sorp
desorp
cycle
cycle 1 
cycle 2
134 
4. Development of respirable, excipient free formulations of rifampicin 
 
 
Figure 54. Results of DVS analysis of RFEtOHCryst2. 
 
Figure 55. Results of DVS analysis of RFMeOHCryst1. 
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Figure 56. Results of DVS analysis of RFIPAAm1. 
4.2.1.3 Aerodynamic assessment of formulations using the Handihaler device  
All formulations assessed showed good aerosol properties. Table 19 shows an overview on 
FPF, EF, MMAD, and GSD of the formulations tested. RFEtOHCryst2, was found to empty 
well from the capsule and showed moderate preseparator and low IP deposition respectively 
(Figure 57). In contrast, RFEtOHCryst1, RFMeOHCryst1, and RFIPAAm1 displayed 
extensive retention in device and capsule, which was found to reduce after storage in the case 
of RFEtOHCryst1 (as indicated in Section 4.2.1.6). IP deposition was found to be moderate, 
with RFIPAAm1 showing significantly lower deposition, when compared to the other 
formulations assessed. Preseparator deposition was found to be low for all formulations 
except RFIPAAm1, which showed moderate deposition. Particle size distributions of 
RFEtOHCryst1 and RFMeOHCryst1 were found to be similar, which was reflected in 
comparable MMAD and GSD values. In comparison, RFEtOHCryst2 showed a slight 
increase in MMAD, but GSD was found comparable. Conversely, MMAD of RFIPAAm1 
was found to be lower and the GSD higher, when compared to the other formulations 
assessed. All samples showed little to no MOC and filter stage deposition. 
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Table 19. Aerodynamic characteristics of RF samples dispensed from the Handihaler device. 
 
 
 
Figure 57. Results of cascade impactor experiments analyzing samples SDr from organic 
solvents, using the Handihaler device. 
Sample name FPF EF MMAD GSD
[% ] [% ] [µm ] [ ]
RFEtOHCryst1 36.6 ±2.1 72.8 ±2.1 3.2 ±0.0 1.9 ±0.0
RFEtOHCryst2 38.2 ±0.8 86.6 ±1.5 3.9 ±0.2 1.9 ±0.4
RFMeOHCryst1 36.5 ±0.7 71.8 ±1.7 3.2 ±0.2 1.9 ±0.1
RFIPAAm1 37.1 ±4.3 69.1 ±2.3 2.0 ±0.6 2.9 ±0.1
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4.2.1.4 Aerodynamic assessment of formulations using the Breezhaler device 
 
Assessment of aerosol properties using the Breezhaler device (Figure 58) yielded better 
results when compared to the Handihaler. Inhaler and capsule depositions were found to be 
lower in all cases, but RFMeOHCryst1 showed an increased deposition. Cumulative IP and 
preseparator depositions were found to be reduced in all cases except RFIPAAm1, this 
translated into higher FPFs (Table 20). Overall performance of RFIPAAm1 was found to be 
similar with both devices, though an increase in MMAD was noted. 
 
Table 20. Aerodynamic characteristics of RF samples dispensed from the Breezhaler device. 
 
  
Sample name FPF EF MMAD GSD
[%] [%] [µm] [ ]
RFEtOHCryst1 54.5 ±6.8 80.3 ±1.6 2.7 ±0.4 2.4 ±0.1
RFEtOHCryst2 50.1 ±2.6 87.1 ±1.1 3.3 ±0.2 2.5 ±0.0
RFMeOHCryst1 52.2 ±1.3 61.4 ±2.7 1.6 ±0.1 2.2 ±0.1
RFIPAAm1 35.91 ±1.5 73.7 ±4.6 3.0 ±0.2 2.8 ±0.2
1
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Figure 58. Results of cascade impactor experiments analyzing samples SDr from organic 
solvents, using the Breezhaler device. 
 
4.2.1.5 Aerodynamic assessment of formulations using the mIP  
Samples were also investigated using a modified 3D printed induction port. The effect of 
material and surface properties on aerosol characteristics was assessed using a 3D printed 
copy of the USP IP. RFEtOHCryst1 was found to show statistically equivalent deposition on 
all stages (Figure 59), when comparing USPIP and USP3DIP. Using the mIP, a statistically 
significant increase in IP deposition was observed. Compared to the USPIP, S3 showed a 
statistically significant decrease in deposition. MMAD, GSD, and EF were found to be 
statistically equivalent for all IPs (Table 21). Though not being significant, FPFtotal showed a 
slight decrease. Analysis of RFMeOHCryst1 showed statistical equivalence when using the 
USPIP and USP3DIP (Figure 60). Significantly increased IP deposition was found using the 
mIP. GSD, FPFtotal, and FPFemitted were found to be statistically equivalent in all cases. 
MMAD was found to be significantly different when comparing the USP3DIP to the mIP. 
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Aerosol analysis of RFIPAAm1 using the USPIP and USP3DIP showed statistical 
equivalence of deposition in all stages with the exception of S1, where deposition was found 
slightly increased in the case of the USP3DIP (Figure 61). MMAD, GSD, and FPFs were 
found statistically equivalent. In contrast, increased IP deposition was found using the mIP 
that corresponded to a significant decrease in preseparator deposition, when compared to the 
USP3DIP. MMAD, GSD, and FPFs were found statistically equivalent for all three IPs tested. 
Table 21. Overview of aerosol characteristics of RF samples SDr from organic solvents, using 
the USPIP, USP3DIP, and mIP. 
 
IP tested
Sample name USPIP USP3DIP mIP
RFEtOHCryst1 MMAD [µm] 3.21 ±0.07 3.17 ±0.10 3.25 ±0.21
GSD [] 1.90 ±0.02 1.90 ±0.02 1.96 ±0.03
FPFtotal [%] 40.89 ±2.07 41.62 ±0.68 38.62 ±3.06
FPFemitted [%] 52.57 ±1.05 54.06 ±1.28 47.52 ±3.31
Femitted [%] 77.76 ±2.41 77.03 ±3.01 81.27 ±2.40
RFMeOHCryst1 MMAD [µm] 3.14 ±0.14 3.36 ±0.07 3.02 ±0.05
GSD [] 1.91 ±0.07 2.04 ±0.02 2.04 ±0.02
FPFtotal [%] 36.46 ±0.66 37.03 ±2.15 34.05 ±3.09
FPFemitted [%] 50.81 ±0.46 50.82 ±0.73 49.83 ±1.18
Femitted [%] 71.77 ±1.68 72.88 ±4.34 68.29 ±5.41
RFIPAAm1 MMAD [µm] 2.65 ±0.06 2.69 ±0.07 2.52 ±0.18
GSD [] 1.98 ±0.04 1.99 ±0.02 2.03 ±0.05
FPFtotal [%] 31.53 ±2.17 35.63 ±2.45 35.53 ±1.64
FPFemitted [%] 43.33 ±3.52 46.14 ±2.77 47.35 ±2.64
Femitted [%] 72.87 ±3.93 77.26 ±1.37 75.10 ±3.17
1
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Figure 59. Results of cascade impactor analysis of RFEtOHCryst1, using the USPIP, 
USP3DIP, and mIP. 
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Figure 60. Results of cascade impactor analysis of RFMeOHCryst1, using the USPIP, 
USP3DIP, and mIP. 
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Figure 61. Results of cascade impactor analysis of RFIPAAm1, using the USPIP, USP3DIP, 
and mIP. 
 
4.2.1.6 Stability study  
Table 22 shows sample content of RFEtOHCryst1, RFMeOHCryst1, and RFIPAAm1 as 
determined by HPLC after storage at ICH accelerated conditions as well as samples stored for 
six months at four °C. XRPD and DSC analyses results were consistent over the test period 
for all samples analyzed, indicating that no re-crystalization or polymorphic transformation 
occurred. RFEtOHCryst1 showed statistically significant changes in Femitted over time (p= 
0.01972), which did not result in significantly increasing S4-filter stage deposition. Figure 62 
shows the results of aNGI experiments. 
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Table 22. Content of samples SDr from organic solvents after storage. 
 
 
 
Figure 62. Results of aNGI experiments after one, three, and six months of storage at ICH 
accelerated conditions. 
HPLC [%]
Sample name t= 0 t= 1 t= 3 t= 6 t= 6
months months months months months (fridge)
RFEtOHCryst1 90.8 ±0.5 91.0 ±0.2 89.3 ±1.6 89.9 ±1.3 89.5 ±1.7
RFMeOHCryst1 95.0 ±0.9 95.3 ±0.6 69.0 ±1.8 81.5 ±2.6 94.4 ±0.9
RFIPAAm1 97.6 ±1.5 91.6 ±0.4 67.8 ±4.5 60.2 ±2.8 96.2 ±0.3
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4.2.2 Discussion 
 
Selected organic formulations investigated in the previous chapter were successfully repeated 
and process parameters as well as product properties were found in line with the exploratory 
study. Operational parameters were found comparable in terms of process time, process 
stability (data not shown) as indicated by outlet temperature, energy consumption, and 
product yield. Consistency of energy consumption was deduced from the rate of aspirator set 
[%] over time, necessary to maintain the specified system flow rate of 15 NCMH. As the 
terminal cloth filter became congested during the process, pressure drops over the filter unit 
increased as a function of process time. Aspirator levels were to be adjusted at certain 
intervals in order not to exceed the predefined operational specifications of the process. This 
also included timely exchange of the filter bag, when pressure drops exceeded a certain 
threshold value. Plots of aspirator set over time are expected to be characteristic for each 
formulation, which was found to be the case in these studies.  
Also, solid state properties of the batches produced were consistent with ones of samples in 
the exploratory study. XRP diffractograms of RFEtOHCryst1 and RFEtOHCryst2 as well as 
RFMeOHCryst1 were found identical to RFEtOHexp3, RFEtOHexp4, and RFMeOHexp3 
respectively. RFIPAAm1 showed a significant amount of residual isopropyl alcohol, which 
probably is easily reduced by adding an additional drying step. As samples were not intended 
for in vivo testing and as residual IPA at that quantity is not expected to diminish aerosol 
performance of the sample, no additional drying steps have yet been incorporated.  
X-ray diffractograms of RFEtOHCryst1 and RFMeOHCryst1 were found to differ, indicating 
the formation of two distinct polymorphs or solvates. Analysis of residual solvents using gas 
chromatography and Karl Fisher analyses showed that large amounts of solvents, from which 
samples were recrystallized (being ethanol and methanol respectively), were retained within 
the powder. Additionally, both samples showed residual water at a lower quantity. TGA 
results were found in line with Karl Fisher and GC analyses so suitability of all methods 
applied can be assumed.  
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Figure 63. DVS isotherms of ethanol and water vapor, investigating a formulation 
manufactured by SDr a suspension of RF recrystallized from EtOH (redrawn from [177]). 
DVS analysis of RFEtOHCryst1 showed a negative mass balance when equilibrated at 0% 
RH after subjecting the sample to one 0-97-0% RH cycle, which was shown to be related to 
the ethanol guest molecule exchange, earlier by this group (Figure 63) [177]. In that study, 
spray dried powder, similar to RFEtOHCryst1, was exposed to water and ethanol vapor 
respectively. The exposure to water vapor induced a loss in mass; conversely, exposure to 
ethanol vapor showed typical sorption behavior for a crystalline sample. It was concluded that 
ethanol was incorporated into the crystal lattice but might be replaced upon exposure to water 
vapor, which was thought indicative of a channel solvate mechanism. The results presented in 
those exposure studies demonstrate good agreement with x-ray trials that investigate changes 
in crystal structure of samples exposed to different RHs. In both cases, rearrangement of guest 
molecules was found to terminate at a RH of 60%. This hypothesis is also strongly supported 
by a study published by Li in 2011 [92] that investigated a different isostructural series of RF 
solvates. It was shown that guest solvent molecules found in samples recrystallized from 
different solvent mixtures were located in a solvent channel of indefinite extension along the 
α plane of the crystal lattice, and may be exchanged, depending on ambient conditions. A 
recent study published by Wicher et al. [95] reported similar results, but in samples 
recrystallized from different solvent mixtures. As previously mentioned, initial drying 
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followed by an exposure to high RH induced an irreversible change in the x-ray 
diffractograms obtained from RFEtOHCryst1. In contrast, RFMeOHCryst1 showed changes 
in the x-ray diffractograms when exposed to high RH that were found fully reversible 
(Figures 46 and 47). Additionally, x-ray data indicated that RFEtOHCryst1 converted into 
RFMeOHCryst1 after ethanol was ejected from the crystal lattice, since both formulations 
yielded identical x-ray diffractograms after being subjected to one cycle of 0-97-0% RH 
(Figure 64). Based on this observation one must conclude that RFEtOHCryst1 and 
RFMeOHCryst1 belong to an isostructural group of RF solvates. 
 
 
Figure 64. Comparison of x-ray diffractograms of RFEtOHCryst1 and RFMeOHCryst1 after 
exposure to one 0-97-0% RH cycle. 
 
Interestingly, DVS analyses of both samples show a sigmoidal transition from one sorption 
kinetic to another, taking place at about 20% RH, which was also reflected in the x-ray pattern 
obtained. This might be interpreted in a way that exposure to this relative humidity induces 
slight changes in the lattice that might be associated with early rehydration. Thus, water 
uptake observed prior to this threshold would be surface bound only. It is to be mentioned 
though, that this effect is more pronounced in the case of RFMeOHCryst1. SEM and XRPD 
0
10000
20000
30000
40000
10 20 30 40
position [°2..]
cts
 [ 
]
formulation
RFEtOHCryst1
RFEtOHCryst1 97% RH, after one full cycle
RFMeOHCryst1
RFMeOHCryst1 97% RH, after one full cycle
0e+00
5e+04
1e+05
10 20 30 40
iti  [ Θ]
cts
 [ 
]
cycle
1
2
stage
pre experiment
0 % sorb
20 % sorb
40 % sorb
60 % sorb
80 % sorb
97 % sorb
80 % desorb
60 % desorb
40 % desorb
20 % desorb
0 % desorb
0
10000
20000
30000
40000
10 20 30 40
position [°2..]
cts
 [ 
]
formulation
RFEtOHCryst1
RFEtOHCryst1 97% RH, after one full cycl
RFMeOHCryst1
RFMeOHCryst1 97% RH, after one full cycle
147 
4. Development of respirable, excipient free formulations of rifampicin 
 
data showed that RFMeOHCryst1 contains a second population of amorphous particles, so 
this effect might also be related to a rearrangement of easily accessible water, adsorbed to the 
amorphous particles into the desolvated channel solvate. It was shown that both samples 
increase in crystallinity, when exposed to higher RH, which might be explained by more 
complete rehydration of the channels. Slight and reversible shifts in the x-ray diffractograms 
observed when (de-) hydrating the samples are attributed to differences in the channel 
geometry, when comparing the desolvated and hydrated state, as different guest molecules 
occupy different volumes. RFEtOHCryst1 and RFMeOHCryst1 were found to decrease in 
crystallinity, when exposed to higher temperatures (Figures 49 and 50). Interestingly, 
RFMeOHCryst1 turned amorphous at a lower temperature than RFEtOHCryst1, which is in 
good agreement with the channel solvate concept, as methanol has a higher vapor pressure 
than ethanol at a given temperature, and is thus expected to be more easily replaced in the 
channel. This observation is also in line with DSC experiments conducted, showing an earlier 
onset and maximum of the desolvation peak in the case of RFMeOHCryst1. It was observed 
that temperatures in DSC and x-ray experiments do not match, as applying a heating rate is 
not feasible in XRPD due to the time required to record the x-ray diffractograms. As Samples 
were equilibrated at the respective temperatures during the x-ray trials, lower desolvation 
temperatures were observed in both cases. As already mentioned, this is a heating rate related 
phenomena and DSC and x-ray experiments are expected to match at infinitely low heating 
rates in the DSC. Observation of a glass transition during the DSC experiments was also in 
good agreement with the XRPD trials. DSC thermograms recorded are in good agreement 
with ones reported in literature, and show desolvation peaks of differing extent, followed by 
the aforementioned glass transition. Interestingly RFEtOHCryst1 shows a pronounced 
exothermic event at about 180 °C that is less pronounced in RFEtOHCryst2, RFMeOHCryst1, 
and RFIPAAm1 samples. Commonly, this event is interpreted as “melting” of the desolvated 
crystals [91,96], which was based on hot stage microscopic observations. This sharp 
exothermic peak could be interpreted differently, and is more likely associated to oxygen 
dependent degradation, which was reported earlier by this group [177]. In that study, the 
degradation process was assessed by heating up samples to the respective temperature using 
the DSC under N2 and O2 purges respectively, followed by HPLC assessment of the 
recovered sample and it was shown that an O2 purge induced complete degradation of the 
sample while degradation was found less complete under a N2 purge. Thus, this exothermic 
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event should be evaluated as artifact introduced during sample preparation and in fact it was 
no longer observed during the stability studies. 
Several polymorphs, hydrates, and solvates of RF have already been reported in literature 
[90,92–96,178]. X-ray diffractograms obtained have been compared to relevant data provided 
in the respective publications and Figure 65 provides an overview on diffraction patterns 
reported. It should be noted that Li identified the RF pentahydrates reported by Pelizza et al. 
as members of one isostructural series, which was based on single crystal x-ray data. 
Comparing XRPD data provided in both studies shows that RF  0.54 EtOH  3.92 H2O bears 
characteristics of both pentahydrates proposed.  
 
 
Figure 65. X-ray diffractograms of several RF hydrates reported in literature (redrawn from 
[90–92]). 
Comparison of x-ray diffraction patterns shows that RFEtOHCryst1 (and RFEtOHCryst2) are 
identical to a RF dihydrate, proposed by Son and McConville, which was to be expected as 
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manufacturing procedure reported there was also applied in this study, though minor 
alterations (e.g. different temperature for recrystallization, different outlet temperature) have 
been introduced. Interestingly, Henwood et al. reported [90] XRPD data obtained from a 
series of RF solvates characterized as dihydrate that show a higher degree of similarity to the 
one obtained from the RFMeOHCryst1 sample. It was also found to bear strong similarity to 
x-ray diffractograms of vacuum dried RF dihydrate, reported by Son and McConville [91], 
strengthening the hypothesis that these RF dihydrates as well as RFEtOHCryst1 and 
RFMeOHCryst1 belong to one isostructural group. Taking into account that samples reported 
by Henwood et al. were recrystallized from a variety of solvents including benzene, 
tetrahydrofuran, dimethylformamide, and ethyl acetate, this is quite remarkable as these 
solvents provide fundamentally different hydrogen bond acceptor and donor properties when 
compared to ethanol or methanol, which Li described as essential for intermolecular 
interaction and crystal formation. Additionally, Li and Wicher et al. [92,95] reported that RF 
crystallizes in a zwitterionic state, when crystallized from protic solvents whereas 
recrystallization from aprotic solvents promotes the non-ionic state. Thus, one might 
hypothesize that the initial polymorph obtained after recrystallization was lost during the 
(vacuum) drying step applied and that polymorphic transition occurred upon rehydration. 
Anyways, it is to be mentioned that the sample reported (only one diffractogram stated as 
representative for the entire series was provided) also shows additional peaks, but as 
calculated and measured diffractograms from the pentahydrate isostructural family published 
by Li show, multiple similar x-ray diffractograms can be characteristic for one isostructural 
series. 
Stoichiometries reported are not instantly brought in line with results of the present study. As 
both solvates were reported to have incorporated water only, one must assume that at the 
stage of determination all guest molecules (which are expected to be initially present) already 
had been exchanged. LOD determined in the respective studies were expected to agree with 
maximum differences in mass observed in the DVS experiments, especially in the case of 
RFEtOHCryst2, which had the same solvent/RF ratio as the RF dihydrate reported by Son and 
McConville, thus assuming amorphous content might be comparable. Comparing DVS and 
TGA data of the amorphous reference formulation provided there, indicates that samples had 
been stored under moisture protective conditions, as the LOD of 0.94% would be expected for 
sample equilibration at a RH lower than 30%, which might have been a result of storage in a 
closed container, creating a rather dry microenvironment. Anyways, this hypothesis is only 
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valid assuming that additional drying had occurred, which has not been reported. As 
significant differences were observed here and water content of the samples was shown to 
alter as a function of RH, one might hypothesize that the dihydrate reported might have been 
analyzed at an incomplete state of hydration. It was also noted that content of RF slightly 
decreased during stability testing, whereas it was found statistically equivalent in this study, 
so decrease observed might be associated with a higher degree of rehydration occurring over 
time, rather than chemical degradation. Similar considerations apply comparing data 
presented here to the study published by Henwood et al. In this case, samples were vacuum 
dried so complete removal of guest molecules prior to hydration can be assumed. As samples 
have not been equilibrated to a specific RH, nor DVS data was presented, incomplete 
rehydration appears plausible. DVS results from this study showed maximum water uptake 
determined during the second cycle of 9.9% 12.1%, and 10.8% for RFEtOHCryst1, 
RFEtOHCryst2, and RFMeOHCryst1 respectively, which would be equivalent to a molar 
RF/water ratio of 1:4.8, 1:5.8, and 1:5. Even so, completeness of solvent exchange was not 
verified after DVS experiments so a non removable fraction of solvent might still be present 
(under the given experimental conditions). Also, it is to be assumed that a certain fraction of 
the water adsorbed is surface bound and might have a measurable, though probably not 
pronounced, effect, especially considering that primary particle sizes of the samples were 
small, which consequently demands a high surface area. Additionally, one needs to keep in 
mind that RFMeOHCryst1 displays a certain fraction of amorphous particles that tend to 
incorporate bulk water at higher RH. For this particle collective, behavior similar to 
RFIPAAm1 showing extensive water uptake and swelling, is to be expected. It is to be 
mentioned that non-congruence of sorption isotherms of RFIPAAm1 is to be attributed to 
mechanical rearrangement of the sample and sorption kinetics were found slower during the 
first cycle, which might be explained by the higher vapor pressure required to provide energy 
needed for the rearrangement. Though RF/water ratios derived from DVS data might be 
interpreted in a way that they indicate formation of another pentahydrate, several observations 
contradict this hypothesis. It is to be mentioned that XRP diffractograms of RFEtOHCryst1 
and RFEtOHCryst2 as well as RFMeOHCryst1 differed from all powder x-ray data provided 
on the pentahydrate series. Also RFaqCryst1, which will be presented in the next chapter, was 
identified as member of the pentahydrate family and shows fundamentally different water 
sorption behavior, requiring an extensive amount of time to equilibrate at 0% RH so 
apparently guest molecules are bound more tightly, or solvate channels are more narrow in 
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this family (see [95]). In contrast, samples investigated in this chapter require more time to 
equilibrate at higher RH, but were found to de-solvate readily. And though this study provides 
valuable information on macroscopic behavior and stability of this isostructural family, 
crystallographic assessment would be needed to clarify if samples presented in this chapter 
are another permutation of one of the isostructural families already reported, or if they belong 
to an individual class. 
 
Assessment of aerosol properties using the Handihaler device showed good performance for 
all formulations. All formulations except RFEtOHCryst2 showed extensive retention within 
inhaler and capsule, which is to be attributed to the conservative storage conditions applied; 
so as not to alter the initial solid state obtained after spray drying. Especially in the case of 
spray dried samples, it is advisable to equilibrate samples intended for dry powder 
aerosolization at higher RH, in order to reduce electrostatic charges introduced during the 
manufacturing process. In this study, samples were collected in the container intended for 
storage being a screw cap glass vial that was attached to the high-performance cyclone of the 
spray drier, and sample manipulation afterwards was reduced to a minimum. Prior to 
separation from the air stream, powders were found to propagate in a vortical motion along 
the walls of the vessel, which leads to triboelectric charging. Before further use, all samples 
were equilibrated at 32% RH, which in an earlier study was found to maintain the solid state 
of RFEtOHCryst samples, but might not be sufficiently high to efficiently remove 
electrostatics at the given timeframe (data not shown). Samples analyzed in the exploratory 
study (see previous chapter) were treated less solid-state conservatively and showed better 
emptying (i.e. they were exposed to ambient conditions before equilibration to 32% RH). One 
exception was RFEtOHexp2, but this formulation consisted of extremely fine particles and 
was not easily de-agglomerated, so low ejection rate was attributed to that. Better ejection of 
RFEtOHCryst2 might be explained by the higher water content (Section 4.3.1.2.3) of the 
sample, indicating that it might have been exposed to higher RH during manufacture or 
sample handling. RFIPAAm1 showed lower IP and correspondingly higher preseparator 
deposition, which is to be attributed to incomplete powder de-agglomeration. RFEtOHCryst2 
was found to have a larger MMAD when compared to RFEtOHCryst1, which is expected to 
reflect larger geometric diameters of the primary particles. Due to the higher solid content of 
the suspension that was spray dried, a larger diameter of the primary particles was in line with 
expectations. Existence of a second particle population observed (SEM) in the case of 
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RFMeOHCryst1 was not reflected in cascade impactor data, as overall content of that 
population may have been too low to be detected at the level of precision of the impactor, or 
incomplete de-agglomeration of this fraction from the other particles may have been a factor. 
In light of the aforementioned considerations, it is to be concluded that samples assessed were 
not tested under conditions optimized for aerosol performance, hence the potential 
performance of the formulations might actually be higher than reflected in these studies. 
Comparing results obtained here to those reported with similar formulations by Son and 
McConville [91], overall performance reported in this study was found to be lower. Apart 
from reasons already mentioned, this might be attributed to application of non-standard 
conditions during inhalation testing in that study, as the NGI was operated at a flow rate of 60 
L/min, which generates a higher pressure drop than 4 kPa over the Handihaler, and might 
result in better, though less biorelevant powder de-agglomeration.  
Aerosol properties of samples have also been investigated using the Breezhaler device. Here, 
aerosol performance of all crystalline samples was found to be better, as indicated by higher 
FPFs, smaller MMADs, and larger GSDs. Though not being immediately obvious, larger 
GSD in this case might be indicative of better particle de-agglomeration, since agglomerates, 
which had impacted in earlier stages using the Handihaler, partially de-agglomerated and 
impacted in later stages using the Breezhaler; becoming accessible for determination of the 
aPSD. This is an interesting case, highlighting the necessity to evaluate aPSDs in context of 
the entire experimental setup and one needs to keep in mind that aPSDs reported might not 
reflect the entire particle population of the bulk powder, unless a suitable method (e.g. 
pressure titration) is being performed. Better performance of the crystalline samples assessed 
may likely be attributed to a higher degree of de-agglomeration achieved by the Breezhaler 
device. This could be related to the lower intrinsic resistance (Section 1.4.1.2.1) of the device, 
demanding a higher system flow rate to achieve the required ∆p of 4 kPa. In this specific case 
this demanded operation of the NGI at 100.0 L/min, as the flow rate actually required is 
beyond the calibrated range of the NGI. Thus, more energy per unit time is introduced into the 
system, which is expected to aid better de-agglomeration. Interestingly, RFIPAAm1 showed 
comparable performance for both inhalers. At first glance, this observation is in good 
agreement with data published by Son and McConville [91], where performance of the 
amorphous reference formulation was even found lower when investigated using an Aerolizer 
(compared to the Handihaler) type device. As already mentioned (Section 1.4.3.3), one needs 
to keep in mind that CI analysis was performed at 60 L/min, so the Aerolizer might not have 
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de-agglomerated the powder properly, which also is reflected by the extensive retention 
within the capsule reported there, and it is to be assumed that this mechanism is not 
responsible for the performance observed here. Comparing IP depositions of all formulations 
on both devices shows that all crystalline formulations demonstrate lower IP deposition when 
using the Breezhaler. This is understandable, as larger agglomerates are expected to be broken 
up more efficiently, and thus not impacting in the bend of the IP. In the case of RFIPAAm1 
an apparently higher degree of de-agglomeration came at the cost of higher triboelectric 
charging, leading to higher adherence to the IP walls, especially at the inlet section. This 
hypothesis is also supported by the increase in MMAD observed. Smaller particles, 
especially, are expected to show increased adherence due to triboelectric charging, so it 
should be assumed that a certain fraction of fine particles was removed by this mechanism, 
consequently leading to an increase in MMAD. Based on these observations, one can 
conclude that the different inhalers investigated have device specific, balanced, and geometry 
derived properties. In this case the ability to more efficiently de-agglomerate at the cost of 
triboelectric induction of the powders, and depending on the properties of powders to be 
aerosolized, different inhalers are expected to be more suitable for the given formulation than 
others. As a consequence, triboelectric charging of the powder could prove to be an intrinsic 
limit to performance of de-agglomeration units, if traditional approaches in DPI design, 
involving kinetic de-agglomeration, are applied. On the other hand, triboelectric charges are 
expected to rapidly dissipate upon exposure to high RH as occurring in biological systems, so 
this consideration might be limited to the device itself, lowering its overall impact. 
 
Aerodynamic properties of RFEtOHCryst1, RFMeOHCryst1, and RFIPAAm1 have also been 
investigated using the modified IP, presented in Chapter 3. To show independence from the 
manufacturing method, a copy of the USPIP was 3D printed and assessed. As all formulations 
except RFIPAAm1 showed statistically equivalent deposition in the USPIP and USP3DIP, it 
should be assumed that manufacturing technique and materials used have no influence on 
outcome of these experiments. RFEtOHCryst1 showed a significant increase in IP deposition 
that corresponded to a decrease in preseparator and S3 deposition. MMAD and GSD were 
found to be unaffected. The FPF showed a decrease by approximately 5%, which was not 
statistically significant. Due to the low extent of this effect its therapeutic impact would be 
expected to be low, and such differences in lung deposition are certainly hard to assess in an 
in vivo setting. Similar results were obtained analyzing the RFMeOHCryst1 formulation. 
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MMADs of RFMeOHCryst1 determined using the USP3DIP and the mIP respectively, 
demonstrated a significant difference of about 0.3 µm, but the impact of this observation must 
be evaluated as little. It is to be concluded that all formulations assessed are not suspected to 
perform significantly different, when tested in an in vivo setting. RFaqAm1 showed 
statistically insignificant increase in the mIP only but also slight increase in preseparator 
deposition was observed. Cumulative IP and preseparator deposition differed significantly (p= 
0.01653) comparing USP and USP3D IP as well as USPIP and mIP (p= 0.00294). It is to be 
assumed that in this case we see a slight influence of the material used, causing increased 
adherence/retention. As a consequence a statistically decreased deposition in S5 was observed 
that also translated in statistically significant decrease in FPFs, in the case of the mIP. 
Anyways, though mIP and USP3D perform statistically equivalent, it is to be assumed that the 
USPIP overestimates lung deposition in this case. It is to be mentioned that the effect is as 
low as about 6% in predicted deposition so in an IVIVC this effect is hardly expected to be 
traceable. 
 
 Stability testing of formulations assessed showed good chemical stability of samples 
recrystallized from ethanol. The amorphous sample spray dried from IPA was found to be 
chemically unstable, which is in line with literature [91]. Surprisingly, RFMeOHCryst1 
showed certain degradation, which was not expected as crystalline samples were deemed to 
be stable. Interestingly, content determined after three months of storage was found lower 
than the one determined after six months. Repetition of the experiments at both time points 
(t= 3 months was already repeated as content determined differed from expectation) verified 
correctness of the analytical method used. A possible explanation for this might be separation 
of the two particle populations found in this formulation. For stability testing, powder aliquots 
were prepared reflecting each time point and stored in a separate vial, so that manipulation of 
the samples during analysis at the respective time points would not affect the results obtained. 
As one population was found fully amorphous, they are expected to show different 
degradation kinetics so differences found here might actually reflect the extent of amorphous 
content in the respective samples. Anyways, all samples assessed were found to be chemically 
stable at refrigerated conditions. During the entire test period, no recrystallization or 
amorphization occurred, as indicated by XRPD and DSC measurements. Aerosol performance 
was found to be stable for all samples over the entire test period. Only RFEtOHCryst1 
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showed a slight increase in Femitted, which did not translate into higher deposition lower than 
S3. 
  
4.3 Results and discussion of the main study investigating manufacture of respirable 
rifampicin particles using water  
4.3.1 Results 
4.3.1.1 Manufacture 
Manufacture of aqueous formulations described in chapter 4.1. was repeated successfully. 
One formulation spray dried from an isopropyl alcoholic solution of RF was successfully 
manufactured as reference formulation. Table 23 shows product yields from the 
manufacturing process. 
Table 23. Product yields of samples SDr from water. 
 
4.3.1.2 Physicochemical characterization  
4.3.1.2.1 SEM images of particles obtained 
SEM pictures (see Figure 66) of RFaqCryst1 showed micro particles of brick like shape, 
displaying different axis ratios and sizes. Contrary, images of RFaqAm1, RFaqAm2, and 
RFaqAm3 showed highly collapsed, thin walled microspheres. RFIPAAm1 was already 
discussed in the previous chapter. 
 
Sample name Solvent Yield Approx. process time
[%] [h]
RFaqCryst1 water 27.6 4.1
RFaqAm1 27.8 12.5
RFaqAm2 25.4 12.5
RFaqAm3 30.3 8.3
RFIPAm1 IPA 42.0 1.8
1
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Figure 66. SEM images of RFaqCryst1, RFaqAm1, RFaqAm2, RFaqAm3, RFIPAAm1, and 
the starting material obtained from TCI. 
4.3.1.2.2 XRPD analysis of RF samples SDr from aqueous solutions or suspensions 
XRPD analysis (see Figure 67) showed that spray drying of an aqueous suspension 
(RFaqCryst1) generates crystalline particles, whereas all other samples were found to be 
amorphous. No sample showed polymorphic transition or recrystallization upon exposure to 
RFaqCryst1	 RFaqAm1	
RFaqAm2	
RFaqAm3	RFIPAAm1	
RFTCI	
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different RH (see Figures 68 and 69). Exposure to higher temperatures induced a decrease in 
crystallinity in the case of RFaqCryst1 and RFaqAm1 remained amorphous (see Figures 70 
and 71). 
 
Figure 67. X-ray diffractograms of samples SDr from water. 
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Figure 68. X-ray diffractograms of RFaqCryst1, equilibrated at different RH. 
 
Figure 69. X-ray diffractograms of RFaqAm1, equilibrated at different RH. 
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Figure 70. X-ray diffractograms of RFaqCryst1, equilibrated at different temperatures. 
 
 
Figure 71. X-ray diffractograms of RFaqAm1, equilibrated at different temperatures. 
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4.3.1.2.3 Analysis of residual solvents using the GC 
Analysis of residual solvents showed that RFIPAAm1 contained residual isopropyl alcohol 
(see Tab 2) (also see previous chapter). 
Table 24. Overview of physical and chemical characterization of RF samples. 
 
4.3.1.2.4 DSC analysis of RF samples SDr from aqueous solutions or suspensions  
DSC thermograms (see Figure 72) of RFaqAm1, RFaqAm2, and RFaqAm3 showed broad 
desolvation peaks of residual solvent from about 40-100 °C, followed by a glass transition at 
164 °C. RFIPAAm1 showed a less pronounced desolvation peak, followed by a glass 
transition at the same temperature. RFaqCryst1 showed two overlaying desolvation 
endotherms, peaking at 100 °C and 113 °C respectively. Similar to the amorphous samples 
investigated, RFaqCryst1 showed a glass transition at 164 °C. 
 
Figure 72. Results of DSC analysis of samples SDr from water. 
Sample name Purity HPLC Water content Organic solvents TGA
[%] [%] [%] [%]
RFaqCryst1 91.7 ±1.3 7.0 ±0.3 0.0 92.5 ±0.0
RFaqAm1 94.1 ±0.1 5.7 ±0.2 0.0 95.1 ±0.7
RFaqAm2 93.5 ±0.9 4.3 ±0.9 0.0 94.9 ±0.3
RFaqAm3 93.3 ±0.7 6.0 ±0.1 0.0 93.0 ±0.0
RFIPAAm1 97.6 ±1.5 1.1 ±0.2 2.9 ±0.2 (IPA) 96.2 ±0.3
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4.3.1.2.5 DVS analysis of RF samples SDr from aqueous solutions or suspensions 
DVS analysis of samples spray dried from water showed two distinguishable sorption 
patterns. RFaqAm1, RFaqAm2, and RFaqAm3 showed biphasic sorption kinetics with 
terminal linearity and intersections (2nd cycle) at 80.2% RH, 79.0% RH, and 77.2% RH 
respectively. Samples showed accelerated uptake at higher RH. Maximum water uptake 
observed for amorphous samples was found at approximately 15%w/w (Figures 73-75). At 
lower RH the physisorbed water was found to be easily liberated, and samples were found to 
equilibrate before terminal drying. It should be noted that sorption isotherms of cycles one 
and two are not in agreement, as samples swell at higher RH. RFaqCryst1 was less 
distinguishable for the individual sorption kinetics, and the intersection point was found at 
30.1% RH (Figure 76). Equilibration at 97% RH led to a lower increase in mass, when 
compared to RFaqAm1, RFaqAm2, and RFaqAm3. RFaqCryst1 showed pronounced 
desorption upon drying at 0% RH. All samples showed pronounced hysteresis. (Note: DVS 
data of RFIPAAm1 was already presented and discussed in 4.2.1.2.5). 
 
Figure 73. Results of DVS analysis of RFaqAm1. 
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Figure 74. Results of DVS analysis of RFaqAm2. 
 
Figure 75. Results of DVS analysis of RFAqAm3. 
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Figure 76. Results of DVS analysis of RFAqCryst1. 
 
4.3.1.3 Aerodynamic assessment of formulations using the Handihaler device  
All formulations assessed showed good to excellent aerosol properties. Table 25 provides an 
overview on FPF, EF, MMAD, and GSD of the formulations tested. RFaqCryst1 was found to 
empty well from the capsule and showed low and moderate IP and preseparator deposition, 
respectively (Figure 77). In contrast, RFIPAAm1 displayed extensive retention in the device 
and capsule, which was observed to reduce slightly after storage (Section 4.2.1.7). Both IP 
and preseparator depositions were found to be similar, leading to an overall performance 
comparable to that of RFaqCryst1 (Table 25). All three formulations that were spray dried 
from aqueous solutions (RFaqAm1, RFaqAm2, and RFaqAm3) demonstrated excellent 
aerosol properties, with powder retention within the device and capsule combined, well below 
5%. Both IP and preseparator deposition values were found to be low. And these formulations 
showed high deposition in the MOC and the terminal glass fiber filter.  
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Table 25. Aerodynamic characteristics of RF samples SDr from water, dispensed from the 
Handihaler device. 
 
 
Figure 77. Results of cascade impactor experiments analyzing samples SDr from water, using 
the Handihaler. 
4.3.1.4 Characterization of the ACT  
In order to assess if formulations investigated would be suitable for application by a single 
use, disposable DPI, they were also analyzed for their aerosol properties using a low cost, 
Sample name FPF EF MMAD GSD
[%] [%] [µm] [ ]
RFaqCryst1 41.0 ±3.6 88.7 ±1.1 2.9 ±0.1 2.1 ±0.0
RFaqAm1 88.7 ±2.0 98.0 ±0.2 1.4 ±0.2 3.2 ±0.1
RFaqAm2 81.8 ±0.9 98.4 ±0.2 1.6 ±0.1 3.0 ±0.1
RFaqAm3 80.0 ±0.4 98.1 ±0.2 1.6 ±0.1 3.4 ±0.1
RFIPAAm1 37.1 ±4.3 69.1 ±2.3 2.0 ±0.6 2.9 ±0.8
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disposable DPI surrogate (ACT). The model was chosen to provide little de-agglomeration 
efficiency only and based on a charcoal filter unit that originally consisted of a cardboard tube 
of uniform diameter, which was filled with charcoal pellets and capped with one perforated 
ceramic and plastic stopper, respectively. In this study, the charcoal pellets were removed and 
replaced with the test formulation. Modified (charcoal pellets were removed) Actitubes 
showed high airflow resistance of 1.1 × 10!!(√!"# ∗!"#)/! (Figure 78) creating a pressure 
drop of 4 kPa over the inhaler at a flow rate of 19.2 ±0.3 L/min. The average orifice diameter 
in the caps was determined to be 0.92 ±0.2 mm. Figure 76 shows results of the CFD study, as 
well as SEM images of the end caps and a photograph of the entire Actitube and components. 
The CFD study showed that high airflow velocities were generated inside the inlet and outlet 
channels, while low velocities are maintained inside the cardboard tube that holds the bulk 
powder prior to aerosolization (Figure 79). The inside of the plastic cap shows slightly 
increased velocities, when compared to the tube body.  
 
Figure 78. Pressure drop of modified Actitube charcoal filters over flow rate. 
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Figure 79. Top: results of CFD study. Characteristic slices depict flow velocity fields over the 
Actitubes. Bottom: SEM images of the ceramic end cap (a), plastic end cap (b), and a 
photograph of the Actitube (c). 
  
a	 b	 c	
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4.3.1.5 Aerodynamic assessment of formulations of RF SDr from watery solutions or 
suspensions, using the ACT  
RFaqCryst1 and RFIPAAm1 were found to perform poorly when dispensed from the ACT, 
showing FPFs well below 10% (Table 26). In contrast, RFAqAm1, RFAqAm2, and 
RFAqAm3 showed FPFs higher than 10%, with RFAqAm1 exhibiting the highest FPF. 
Figure 80 provides an overview for cascade impactor experiments using the ACT.  
Table 26. Aerodynamic characteristics of RF samples dispensed from the ACT. 
 
  
Sample name FPF EF MMAD GSD
[%] [%] [µm] [ ]
RFaqCryst1 5.8 ±2.3 51.0 ±16.7 4.6 ±0.4 2.1 ±0.1
RFaqAm1 33.6 ±3.0 90.3 ±0.2 3.9 ±1.4 3.9 ±0.6
RFaqAm2 17.3 ±2.8 99.6 ±0.0 4.7 ±0.5 3.1 ±0.4
RFaqAm3 11.8 ±3.4 99.2 ±0.0 5.3 ±1.2 2.5 ±0.1
RFIPAAm1 7.2 ±4.3 66.7 ±9.9 3.7 ±0.2 2.0 ±0.0
1
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Figure 80. Results from cascade impactor experiments analyzing samples SDr from water, 
using the ACT. 
 
4.3.1.6 Aerodynamic assessment of formulations of RF SDr from watery solutions or 
suspensions using a modified induction port  
 
Aerosol characteristics of RFaqCryst1, RFaqAm1, and RFIPAAm1 investigated using a 
modified induction port are shown in Table 27. RFaqCryst1 showed increased deposition in 
the mIP when compared to the USPIP (Figure 81), corresponding to a lower deposition in the 
preseparator unit, with no significant difference in aerosol characteristics. Additionally, 
USPIP and USP3DIP yielded statistically equivalent results. 
In the case of RFaqAm1, a slight but significant increase in preseparator deposition was found 
when the USP3D was used (Figure 82). Deposition in the mIP was found to be increased, but 
not significantly. Additionally, USP3DIP and the mIP showed statistically lower deposition 
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on S5. Increased mIP deposition resulted in a statistical decrease in FPFtotal (p= 0.02819) and 
FPFemitted (p= 0.01763). 
Table 27. Aerodynamic characteristics of RF samples SDr from water, using the USPIP, 
USP3DIP, and mIP. 
 
 
IP tested
Sample name USPIP USP3DIP mIP
RFaqCryst1 MMAD [µm] 2.85 ±0.07 2.70 ±0.15 2.92 ±0.17
GSD [] 2.08 ±0.02 2.09 ±0.01 2.09 ±0.00
FPFtotal [%] 42.55 ±1.75 45.57 ±5.23 41.39 ±4.11
FPFemitted [%] 48.22 ±2.02 51.34 ±6.22 45.77 ±5.35
Femitted [%] 88.26 ±1.42 88.80 ±1.44 90.55 ±1.66
RFaqAm1 MMAD [µm] 1.44 ±0.18 1.59 ±0.01 1.51 ±0.08
GSD [] 3.14 ±0.08 3.32 ±0.01 3.34 ±0.13
FPFtotal [%] 88.71 ±2.04 85.31 ±2.16 81.99 ±1.89
FPFemitted [%] 90.52 ±1.89 86.86 ±2.37 83.29 ±2.47
Femitted [%] 98.00 ±0.22 98.21 ±0.26 98.44 ±0.19
1
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Figure 81. Results of cascade impactor analysis of RFaqCryst1, using the USPIP, USP3DIP, 
and mIP. 
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Figure 82. Results of cascade impactor analysis of RFaqAm1, using the USPIP, USP3DIP, 
and mIP. 
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4.3.1.7 Investigation of particle formation using the acoustic levitator  
4.3.1.7.1 Rheological properties of liquids and solutions used 
Physicochemical characteristics of liquids used are shown in Table 28.  
Table 28. Physicochemical characteristics of liquids used in the levitator experiments. 
  
4.3.1.7.2 Determination of contact angle of plain solvents by DSA 
Figure 83 shows images of the DSA. Uneven surfaces seen in the images of EtOH and IPA 
are due to the material, which had been dissolved and then re-solidified. Droplets of EtOH 
and IPA were found to spread entirely. The contact angle for water was determined to be 95.9 
±3.1°. 
 
 
Figure 83. Images of droplets of water, EtOH, and IPA on compacted RFIPAAm1. 
4.3.1.7.3 Acoustic levitator experiments  
Droplets of pure IPA or EtOH were found to show reduced drying times to that of water. It 
Solvent CRF ⇢   ⌫
[mg/mL] [g/cm3] [ g/s2] [mm2/s]
H2O 1.5 ±0.06 1.00 ±0.00 46.8 ±0.5 0.95 ±0.01
EtOH 1.4 ±0.01 0.79 ±0.00 23.1 ±0.5 1.37 ±0.00
IPA 1.5 ±0.00 0.78 ±0.00 21.5 ±0.6 2.65 ±0.02
H2O 0 1.00 ±0.00 70.2 ±0.2 0.92 ±0.01
EtOH 0 0.79 ±0.00 22.1 ±0.7 1.37 ±0.00
IPA 0 0.78 ±0.00 22.8 ±0.5 2.65 ±0.01
1
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was noted that pure IPA, EtOH, and aqueous solutions of RF show a greater droplet 
deformation at a set energy input, which consequently demanded adjustment of the driving 
voltage of the piezo and droplet repositioning relative to the nodes, so as to stay within the 
pre-specified range for the axis ratio. Drying of droplets of pure solvents (IPA, EtOH, or 
H2O) in the acoustic field showed a steady reduction of relative deq(area). It was observed that 
∆deq(area)/∆t developed in a nonlinear manner (Figure 84), increasing slightly over time. Axis 
ratios of pure solvent droplets were found to decrease slightly over time. After reaching a 
critical mass threshold, all solvents showed an increase of variability in the length of the 
major axis, which is correlated to ghosting of the image, caused by an increase in x-position 
instability of the droplet in the acoustic field. Evolution of the axis ratio over time, when 
adding RF to the solvent, was found to be equivalent to the plain solvent in the case of EtOH 
and IPA (Figure 84). Rel. deq(area) evolution of pure EtOH and a ethanolic RF solution were 
found to be identical. Rel. deq(area) evolution of solutions of RF in IPA were initially aligned 
to the ones of pure solvent, but eventually a plateau was reached with no further change over 
time (Figure 84, top right panel). Axis ratio evolution of aqueous solutions of RF were found 
to differ strongly, steadily increasing over time until a plateau was reached, before abruptly 
changing. Rel. deq(area) evolution over time of aqueous RF solutions initially showed 
congruence with the pure solvent droplets, but after reaching a critical point, relative deq(area) 
abruptly dropped to a plateau; eventually changing its level, as observed with the axis ratio. 
Figure 85 shows characteristic pictures of different stages of the drying process for solutions 
of RF, as well as SEM images of the resulting particles, recovered from the levitator. In the 
case of EtOH, no particles could be recovered.  
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Figure 84. Results of levitation experiments: evolution of rel. axis ratio and deq(area) over 
time (left and right panel series respectively). 
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Figure 85. Characteristic backlight pictures, depicting the evolution of RF solutions from 
droplet to particle (first three columns). SEM images (last column) of particles obtained from 
drying IPA (top) and H2O (bottom). 
4.3.1.8 Stability study  
Table 29 shows drug content of RFaqCryst1, RFaqAm1, and RFIPAAm1 as determined by 
HPLC, after storage at ICH accelerated conditions as well as samples stored for six months at 
four °C. XRPD and DSC analysis results were consistent over the test period for all samples 
analyzed, indicating that no re-crystalization or polymorphic transformation occurred. Figure 
86 shows the results of aNGI experiments. 
Table 29. Content of RF samples SDr from water after storage. 
 
HPLC [%]
Sample name t= 0 t= 1 t= 3 t= 6 t= 6
months months months months months (fridge)
RFaqCryst1 91.7 ±1.3 91.0 ±1.7 80.1 ±0.4 80.4 ±1.6 92.5 ±0.0
RFaqAm1 94.1 ±0.1 87.7 ±5.5 65.1 ±0.7 59.8 ±1.4 95.1 ±0.7
RFIPAAm1 97.6 ±1.5 91.6 ±0.4 67.8 ±4.5 60.2 ±2.8 96.2 ±0.3
1
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Figure 86. Results of aNGI experiments after one, three, and six months of storage at ICH 
accelerated conditions. 
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4.3.2 Discussion 
Manufacture and testing of formulations investigated in the exploratory study was 
successfully repeated, demonstrating consistent product and process properties. Solid state 
properties of the batches produced, were consistent with the results of the exploratory study. 
Compositions of formulations spray dried from aqueous solutions were slightly modified to 
include an additional concentration, in order to estimate how robust these formulations are, 
when aerosol performance is evaluated (in the context of solid content of the feed solutions). 
XRP diffractograms of RFaqCryst1 were found to be identical to RFaqexp5, and all other 
samples were consistently amorphous. RFIPAAm1 showed a significant amount of residual 
isopropyl alcohol (as discussed in the previous section, 4.2.1.2.3). Samples spray dried from 
water had significant amounts of residual water, but preliminary studies investigating a 
similar formulation showed that FPFs drop, when the powders are kept over a drying agent 
such as silica (data not shown). Furthermore, as already mentioned, formulation batches 
produced in this study were not intended for in vivo testing, and, as residual solvents at that 
quantity were not expected to fundamentally influence aerosol properties, samples were 
processed in accordance with the other formulation test batches.  
 
Aerodynamic testing showed that all amorphous formulations spray dried from water have 
excellent aerosol properties. FPFs were found to be extremely high so effective lung targeting 
is to be expected. High deposition in the terminal filter unit indicated that a major fraction of 
these formulations was in the aerodynamic nm range; providing a suitable tool to test the 
hypothesis that particles showing an aerodynamic diameter lower than one µm are not 
expected to persist within the lungs, but rather are exhaled, which was based on investigations 
using inert standard particles [12]. Due to the high surface area associated with the low 
aerodynamic diameter (also see next paragraph for the mechanism of particle formation) and 
the high capacity of incorporating water as shown in DVS experiments, one might 
hypothesize that this type of particle would alter its aerodynamic properties (i.e. settling 
velocity) as a function of time, when in a biorelevant environment. However, this hypothesis 
is not easily tested in vitro, since the residence time of the particles expected in vivo is not 
reflected in the cascade impactor experiment.  
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Spray drying of suspensions of RF recrystallized from water yielded a formulation with good 
aerosol properties, which was indicated by fine particle fractions comparable to ‘state of the 
art’ commercially available formulations. This type of formulation performed slightly better 
than particles spray dried from suspensions of RF in EtOH or MeOH, which had been 
discussed in the previous section (4.2.1.3). But it should be anticipated, that this formulation 
has potential for improvement in its performance by optimization of composition, and/or 
process parameters, as well as storage conditions. In this set of studies, manufacturing 
parameters were chosen so as to be suitable for processing with a greater variety of solvents, 
but each solvent of course, demands for specific optimization. Also, storage conditions were 
selected in a conservative way, and the focus was on chemical and thermodynamic stability, 
rather than optimization of aerosol performance. RFaqCryst1 was also found to be superior to 
RFIPAAm1, an amorphous reference formulation spray dried from IPA, by displaying higher 
FPFs and improved long-term stability. 
Since it was found that powders spray dried from aqueous solutions of RF were easily de-
agglomerated with high FPFs, these formulations should be considered as interesting 
candidates for application with a low cost, disposable DPI device. It was concluded that these 
formulations demand little performance from the DPI’s de-agglomeration unit to perform 
properly, so no complex geometries or intricate flow paths need to be incorporated into their 
design. To verify this hypothesis, aerosol characterization was also performed using a low 
performance, low cost DPI surrogate (ACT). Consisting of a simple cardboard tube that is 
sealed with two perforated stoppers that create a high intrinsic resistance, the low-cost 
disposable inhaler model was designed to reflect a worst case scenario inhalation device. CFD 
simulations showed that little impartment of energy into the powder bed is expected, since 
flow velocities of a non-turbulent current within the device are limited by a high pressure 
drop, generated at the inlet of the device. The low aerosol performance of RFaqCryst1 and 
RFIPAAm1 is in good agreement with the CFD study conducted. As a consequence, 
RFaqCryst1 and RFIPAAm1 showed pronounced retention of the powder within the DPI 
model, with the emitted fraction having a high degree of agglomeration; as indicated by high 
IP and preseparator deposition values. Conversly, RFaqAm1, RFaqAm2, and RFaqAm3 were 
found to empty well from the device. Nevertheless, these formulations also showed high 
preseparator deposition indicating that samples were not fully de-agglomerated. The FPFs 
recorded were found to be in the range of 10-30%, indicating acceptable aerosol properties in 
the case of RFaqAm1. These powders were found to empty easily from the device, with little 
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IP deposition. The major fraction of the particles was deposited in the preseparator stage, so 
incomplete de-agglomeration is to be assumed. Even so, it was confirmed that powders 
designed using this formulation strategy could be manufactured in a way that they do not 
demand high performance devices to aerosolize properly, which leaves more room to focus on 
patient and product safety as well as cost and material efficiency, when developing such a 
delivery system. As an additional benefit, using the ACT offered a more discriminative test 
system for high performance formulations. Using the Handihaler device, RFaqAm1, 
RFaqAm2, and RFaqAm3 yielded similar FPFs of 88.7 ±2.0%, 81.8 ±0.9%, and 80.0 ±0.4% 
respectively, whereas analysis using the ACT yielded FPFs of 33.6 ±2.3%, 17.3 ±2.8%, and 
11.8 ±3.4% respectively. Interestingly, FPFs determined using the ACT were found to be 
negatively correlated to the concentrations of the spray dried solutions, which is good 
agreement with our expectations (also see Equation 1) but the Handihaler device failed to 
resolve these intricate differences. So the concept of aerosol testing using a low performance 
device might offer additional information for the formulation scientist.  
Aerodynamic properties of RFaqCryst1 and RFaqAm1 were investigated using a more bio-
relevant, 3D printed induction port, which was developed earlier by this group. Also, the 
effect of material properties on IP deposition was investigated using a 3D-printed copy of the 
USPIP. RFaqCryst1 showed statistically equivalent IP deposition and overall performance 
when investigated with the USPIP and USP3DIP respectively, so it can be concluded that 
material and surface properties were irrelevant here, which is in good agreement with 
literature and in line with results presented in Chapter three. MIP deposition was found to be 
increased when compared to the USPIP and USP3DIP but corresponded to a drop in 
preseparator deposition, so consequently cumulative IP and preseparator deposition of 33.6 
±2.3% and 36.5 ±5.7 for the USPIP and the mIP, respectively were found to be statistically 
equivalent (p= 0.47997). Also, MMAD, GSD, and additionally FPFs were found to be 
statistically equivalent. This is in good agreement with literature and confirms observations 
made during the initial assessment of the mIP using a DPI formulation (Cyclocaps 
Cyclohaler). RFaqAm1 showed insignificantly increased IP deposition in the case of the 
USP3DIP and mIP, when compared to the USPIP. Also, deposition in the preseparator stage 
was found to be slightly increased, which was significant in the case of the USP3DIP. 
Correspondingly, a significant decrease in deposition was found in S5, which resulted in 
significantly lower FPFs, when comparing the USPIP and mIP. This finding could be 
indicative that actual in vivo performance might be over predicted, using the USPIP, but it is 
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unclear, if the predicted relative reduction of 8% would be traceable in vivo. Though not being 
significant, a slight reduction in FPFs was observed comparing the USPIP and the USP3DIP, 
which could be indicative of a material related effect observed. So, in this case the model 
would erroneously under predict the actual lung deposition. Due to the low difference in 
predicted lung deposition and the uncertainty associated with the possible influence of the 
material, it is to be assumed that in this case using the mIP offers no additional information. 
Results from cascade impactor analysis of RFIPAAm1 using the mIP were discussed in the 
previous section. 
 
Aerosol properties of formulations spray dried from aqueous solutions were found to be 
consistently high. To understand the mechanism leading to the extraordinary aerosol 
characteristics observed for this type of formulation, the process of particle formation was 
investigated using an acoustic levitator. Due to the low solid content of the solutions, these 
formulations were expected to show spherical, amorphous particles of fairly low geometric 
diameter, which would result in rather low aerosol performance, as these powders would not 
be easily de-agglomerated. The acoustic levitator provides a suitable tool to investigate the 
mechanism of particle formation during the spray drying process. A droplet of one µL of the 
test solution is kept in constant levitation in an acoustic field, while being exposed to a steady 
nitrogen flow at a pre-specified flow rate and temperature. Mass transfer from the droplet is 
measured indirectly by determining geometries from backlight images of the droplet. The 
evolution of droplet diameter over time is indicative for the mass transfer rate, if constant 
droplet geometry is being assumed. The droplet’s shape deviates from the ideal sphere as, in 
order to overcome gravity, the acoustic force is applied. In reality, interactions of the droplet 
with the acoustic field are more complex, as also frequency of the signal as well as the 
position of the droplet relative to the acoustic output nodes influences the overall extent and 
geometry of the force applied to the droplet. If transducer frequency and transducer/reflector 
geometries are kept constant, comparable deformation is expected, if the liquids used show 
similar rheological properties [179,180]. In the case of the aqueous solutions of RF it was 
found that particle deformation (i.e. ratio of the major and minor axis of the ellipsoid at set 
conditions) was more pronounced than the one observed for pure water, so viscosity, density, 
and surface tension values were estimated to investigate those differences in rheology. 
Density was found to be identical when comparing plain solvents to solutions of RF in the 
respective solvent, which was to be expected at solid content as low as 0.15%w/v. Viscosity 
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was found to be equivalent in the case of EtOH and IPA, whereas a decrease in viscosity was 
observed for aqueous solutions of RF. But, given the precision of the experimental setup and 
control of environmental conditions, this result was considered to be insignificant. In contrast, 
aqueous solutions of RF showed a significant and pronounced decrease in surface tension, 
when compared to water. Based on this finding one must conclude that RF shows interfacial 
activity and so must be regarded as a surfactant. Solutions of RF in organic solvents showed 
no difference in surface tension, indicating a higher degree of solubilization of the drug 
molecules. As reduced surface tension (being the amount of energy required to magnify a 
surface by one unit) at given energy input must result in a larger surface, deviation from the 
ideal sphere must occur, as this geometrical shape minimizes the surface area to volume ratio.  
In order to increase the comparability of samples with different deformation behavior, droplet 
diameters were reported as the diameter of a backlight image area equivalent sphere (= 
deq(area)). Plots of deq(area) over time can be used to visualize at what relative droplet volume 
crust formation of the material dissolved occurs. It is expected that the concentration of the 
material dissolved, increases over the period of the drying process, as solvent is being 
constantly removed from the system. When reaching a specific threshold value, the 
solvent/solute system transforms from a liquid into a semi-solid state, and the overall 
geometry of the particle becomes dominated by the solidified material. This hypothetically 
occurs in two different ways: (i) either the solidified material is evenly distributed throughout 
the droplet, or (ii) phase separation occurs, facilitating formation of a shell of solid material 
and incorporating a liquid core. If additional solvent is removed, this is expected to lead to the 
formation of solid or hollow particles respectively. Depending on the wall thickness and 
viscoelastic behavior at given temperature of the shell, it either collapses upon removal of the 
core liquid and forms characteristic ‘donut shaped’ particles, or forms microspheres, if the 
walls withstand the forces occurring. One needs to keep in mind that during the drying 
process additional processes such as diffusion of solvent from the core into the shell occur, 
which might have a different kinetic rather than mass transfer from the particle surface, which 
also changes over time as it is surface area dependent. As experiments in the acoustic levitator 
were conducted at a lower temperature, and at different mass flow rates of the drying gas than 
occurring during the spray drying process, no quantitative predictions on, for example, 
kinetics during spray drying can be made. This method provides fundamental information, 
helping to distinguish between different mechanisms of particle formation and is therefore 
suitable for use when investigating the mechanism responsible for the different particle 
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properties observed, comparing particles from spray dried solutions from water to ones from 
IPA or EtOH. Droplet diameter evolution upon drying of solutions of RF in IPA occurred as 
expected, based on aforementioned considerations. When compared to the plain solvent, 
initially, both droplets show congruent diameter evolution. At a characteristic time point (i.e. 
at a specific concentration of the solute) the diameter remained constant in the case of the 
solution, whereas there was a steady decreases in the case of the pure solvent until complete 
evaporation of the droplet occurred, or the droplet was ejected from the system. At the end of 
the drying phase standard deviations were found to increase, which is related to increasing 
instability of the droplet in the acoustic field, which often times was found to increase to the 
extent whereby the droplet was ejected from the acoustic field. Aqueous based solutions 
initially showed congruent drying curves when compared to the plain solvent. In contrast to 
the solutions with IPA, evolution of the diameter did not transit smoothly into a plateau phase 
indicating crust formation, but exhibited an abrupt change in particle diameter, which 
remained constant upon additional drying. This can be interpreted as rapid re-arrangement of 
the particle’s basic geometry (i.e. particle collapse). It was observed that in some cases 
another re-arrangement event occurred, which became obvious by a shift in plateau level. 
Also, evolution of the droplet/particle axis ratio over time was found to differ significantly 
when comparing watery solutions of RF to solutions in IPA, or pure solvents. Solutions of RF 
in IPA or EtOH, as well as the pure solvents, show little changes in droplet geometry over 
time. It was noted that droplets became more spherical at lower volumes, which is in good 
agreement with our expectations, as forces applied to the droplet are expected to be lower at 
lower volumes, which is due to the lower mass experiencing gravitational pull, as well as 
smaller a volume available for interactions with the acoustic field. So cohesive forces at the 
droplet’s surface (i.e. surface tension) become dominant, leading to an increase in sphericity. 
In contrast, droplets of aqueous solutions of RF showed a constant change in axis ratio, which 
is of increasing deviance from the ideal sphere. This behavior is not readily understood, but 
becomes comprehensible upon evaluation of backlight pictures of the droplet at characteristic 
time points. The first picture (Figure 85, bottom panel series), which was taken at the 
beginning of the drying process, shows droplet morphology comparable to the ones found for 
pure solvent droplets. The second picture, taken at about half of the time of the process 
duration, could be interpreted to show that after early crust formation the core droplet partly 
detached from the shell, which is subsequently deformed by the acoustic field, as the droplet 
in the core decreases in diameter. It should be assumed that initially the shell might be 
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stabilized by vapor pressure, created by the evaporating core droplet. Thus, at this stage the 
particle would form a ternary system consisting of the liquid core, a gas phase consisting of 
water vapor, and the semi-solid shell. It was noted that some particles show early collapse, 
whereas others maintain the ellipsoid shape longer. This might be related to early rupture of 
the shell, due to the vapor pressure inside. In this scenario the shell would no longer be 
stabilized, collapsing around the liquid core, as observed in the figure. However, it is to be 
highlighted that this was not occurring in all cases and that this picture was chosen, as it 
clearly shows detachment of the liquid core from the shell, which is not easily visible if early 
collapse does not occur. The third picture, taken at the end of the process, shows a particle 
that has lost its liquid core and comprises of the shell only. Interestingly, standard deviations 
of the particle´s axis ratio increased earlier in the case of the aqueous solution of RF, when 
compared to the plain solvent. The images taken during the study were compiled into a video 
sequence that indicated that the droplet was moving individually within the shell. It was also 
found that in some cases, multiple droplets occur in one shell. Interaction with the shell 
apparently shifts the center point of rotation of the particle outside the latter, as mass 
distribution within the system shifts upon drying of the core, and core-shell interactions 
become more dominant. Additionally, the images indicate that the core-forming droplet was 
ejected from the system, when a critical mass was reached, while the shell (or fragments of it) 
often times remain within the acoustic field. To exit from the shell, the droplet must penetrate 
the crust; this destroys it and induces collapse of the now evacuated shell. This eventually 
leads to the highly collapsed particles observed in the acoustic levitator, as well as in the spray 
drying trials. It was also observed that in some cases (Figure 85) the shell is ripped apart and 
only fragments of it remain in the field. This process was interpreted as a cause for the drastic 
and sudden change in axis ratio observed, analyzing the axis ratio evolution of droplets of 
aqueous solutions of RF. Multiple re-arrangements observed would thus be associated with 
the consecutive ejection of multiple droplets from the shell. To support the hypothesis that the 
core droplet detaches early from the shell, contact angle measurements of IPA, EtOH, and 
aqueous droplets on RFIPAAm1 compressed to a disk were conducted. It was assumed that 
the angle between the inner surface of the shell and the liquid core must exceed a certain 
threshold, for detachment to occur, so fundamental differences in the contact angle were 
expected, when comparing the organic solvents to water. Experiments conducted were found 
to support this hypothesis as water showed a contact angle greater than 90°, whereas ethanol 
and IPA were found to spread entirely on the surface. Figure 87 depicts different mechanisms 
184 
4. Development of respirable, excipient free formulations of rifampicin 
 
of particle formation from solutions of RF in IPA (top series) and water (bottom series), as 
proposed based on results of this study. It should be mentioned that formation of only one 
core droplet is depicted here. 
 
Figure 87. Schematic overview on particle formation mechanisms proposed. 
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As already mentioned, drying kinetics observed in the acoustic levitator are not comparable to 
ones occurring upon spray drying. Reducing the temperature and therefore the velocity of the 
process is necessary to more closely investigate its distinct phases. It is to be assumed, that 
during the spray drying process crust formation might occur in a similar way as found in the 
acoustic levitator, but the shell would be subjected to increased vapor pressure, causing the 
shell to burst. Induced by the drop in pressure associated with that, the solvent core might 
flash evaporate, causing the shell to collapse. Assuming this, onset time of crust formation, 
properties of the solvent-shell interface, and shell thickness when collapsing would mainly 
influence the morphological properties of the resultant particle. Also, during spray drying 
obviously no force from the acoustic field is imparted, this leads to less asymmetric particles. 
Comparing both processes investigated and applying aforementioned considerations for 
applicability of this model to spray drying, it was concluded that aqueous samples of RF 
show: a) an earlier onset in solid crust formation, b) that the shape of the shell early decouples 
from the shape of the liquid core, which c) results in a more voluminous shell with lower wall 
thickness, that d) produces highly collapsed, low apparent density particles after solvent 
evaporation.  
Conclusions drawn from these experiments are in good agreement with literature. In 2013, 
Chan et al. published a study incorporating a reference formulation of RF spray dried from 
EtOH/water 50/50 [138], yielding particles showing shape and performance similar to 
RFaqAm1, RFaqAm2, and RFaqAm3 . This as well as several follow up publications focused 
on the manufacture of combined antibiotic formulations incorporating RF ([139], [140], 
[141], [143]). It was found that presence of RF was the key factor for aerosol performance for 
these formulations and from this observation the hypothesis was derived that RF must be the 
factor responsible for basic particle geometry and that accumulation of RF in the particles’ 
surface was to be expected. In order to test this hypothesis, particle surface composition was 
analyzed using XPS and ToF-SIMS (Section 1.5) and the predominance of RF in the shell 
was confirmed. Accumulation of RF in the shell was attributed to the hydrophobicity of RF. 
Interestingly, Chan et al. also report increased relative deposition of RF to other drugs 
incorporated in the lower stages of the cascade impactor, which was attributed to 
inhomogenous drug distribution and fragmentation of the particle. Both observations made 
are in good agreement with the model of particle formation presented in this study as 
predominance of RF in combined antibiotic particles at the particle surface is to be expected, 
assuming interfacial accumulation of RF leading to shell formation as proposed here. 
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Separation of more hydrophilic drugs incorporated appears reasonable, as they are expected to 
dissolve in the liquid core, which was shown to separate from the shell. Also flash 
evaporation of the core material would presumably lead to separation of drugs incorporated.  
 
Being produced by spray drying aqueous suspensions of RF, RFaqCryst1 shows a distinct x-
ray diffraction pattern that differs from both solvent free polymorphic forms of RF. XRP 
diffractograms recorded after exposure to different RH show that it became more amorphous 
upon drying but increased in crystallinity when being exposed to higher RH, which was not 
only associated with an increase of intensity of the diffractogram but also with slight and 
reversible alterations in the x-ray reflection pattern (Figure 68). RFaqCryst1 further decreased 
in crystallinity upon solvent removal by thermal drying, as indicated by XRPD and DSC. 
Showing two overlapping desolvation peaks, DSC experiments indicate two distinct types of 
water. First desolvation peak (max.≈ 100 °C) is likely to be associated with physisorbed or 
bulk water, whereas the second desolvation peak (max.≈ 115 °C) is attributed to the removal 
of crystal water that is more tightly bound thus exiting at temperatures higher than its boiling 
point. A Tg at approximately 165 °C is indicative of amorphous material in the sample. This 
hypothesis is also supported by DVS results that indicated a minimum of two different 
sorption kinetics. Being relatively slow, desolvation kinetic observed upon terminal drying at 
0% RH (end of cycle) is indicative for the removal of more tightly bound crystal water. This 
is in good agreement with the more rapid water uptake at higher RH, as indicated by the short 
time needed to fully equilibrate at 97% RH (about 90 minutes). As this process was found to 
be fully reversible, one might hypothesize that solvent molecules are located inside a channel 
within the crystal lattice. Conversly, RFIPAAm1 requires a longer period of time (about 330 
min) to fully equilibrate at 97% RH, which probably is related to the necessity to displace RF 
molecules, as macroscopically observed by swelling of the sample. And in contrast, 
RFaqCryst1 shows no extensive swelling, which becomes accessible by the higher 
congruence of sorption isotherms of Cycle 1 and 2. So one must conclude that mechanisms of 
water incorporation differ.  
Comparison of x-ray diffractograms obtained with ones reported in literature showed a high 
similarity with a rifampicin RF  0.54 EtOH  3.92 H2O solvate reported by Li in 2010 [92] 
(see Figure 88). This solvate was identified as member of an isostructural series of RF 
solvates that feature highly similar host conformations. In this isosctructural family, guest 
molecules (EtOH, MeOH, and water) were found to be interchangeable and are located within 
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a solvent channel along the α plane of the crystal lattice. Li also identified RF pentahydrate, 
which was published earlier by Gadret et al. [93], as member of this isostructural group and 
verified that samples with mixed guest populations subsequently transform into RF 
pentahydrate, when exposed to ambient humidity. Given the congruence of the XRPD pattern 
as well as conclusions drawn from DVS and DSC results, it is to be assumed that RFaqCryst1 
is another member of this isostructural group. Additionally, x-ray diffractograms of 
RFaqCryst1 also show high similarity with a RF monohydrate, reported by Henwood et al. in 
2001 [90]. In this study, RF was recrystallized from EtOH and vacuum dried. Unfortunately, 
storage conditions of the samples are not reported. So, based on findings of the present study 
(also see previous section), one might assume that solvent of crystallization was removed 
during the drying step and crystals were later re-hydrated, incorporating water from ambient 
humidity. The exact experimental procedure remains unclear, as it was stated that the 
monohydrate became fully amorphous upon drying, which is not in line with the 
manufacturing method reported. Also, identification of the solvate as monohydrate is not 
easily understood, based on TGA/DSC data presented. No effort was made to confirm this 
hypothesis by qualitative solvent analysis (e.g. Karl Fisher analysis). However, in light of the 
manufacturing method and x-ray data presented it is to be assumed that this RF species might 
be another member of this isostructural group.  
Incorporation of water into the crystal lattice was found to vary as a function of ambient vapor 
pressure, which might correspond to different degrees of saturation of positions for solvent 
molecules available in the channel. Loss on initial drying during the DVS experiment (data 
not shown) is in good agreement with loss on drying determined by TGA, so complete 
removal of water from the sample can be assumed. Maximum water uptake determined at 
97% RH was found to be 13.37 % w/w which is equivalent to a molar ratio of RF:H2O of 
1:6.1. But, given the small particle size and corresponding large surface area of the sample, it 
is to be assumed that a certain fraction of this is rather physisorbed than crystal water. Thus, 
RFaqCryst1 could be identical to RF pentahydrate proposed by Gadret et al. Unfortunately, 
the original publication provides single crystal x-ray data only, so direct comparability is 
somewhat limited.  
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Figure 88. X-ray powder diffractograms of RFaqCryst1, RF  0.54 EtOH  3.92 H2O 
(redrawn from [92]), and RF monohydrate (redrawn form[90]). 
Stability studies at accelerated ICH conditions showed that all samples investigated show 
stability of their aerodynamic properties over the entire range of the study. In this study, an 
abbreviated NGI setup, where a glass fiber filter was inserted upstream of S4, was used. S4 
was selected as size cut off, since, starting from this stage, all particles collected are expected 
to be in the dae ≤ five µm range. Additionally, it was expected that smaller particles are more 
prone to undergo processes triggering particle growth, so excluding the fraction of the FPF 
that would impact in S3, was found to be the more conservative approach than also including 
S3.  
Chemical stability of all powder samples was found insufficient under conditions applied. 
Interestingly, RFaqAm1, which was expected to be the most sensitive batch from that series, 
did not show a higher degree of degradation than RFIPAAm1. It is well known that 
amorphous SDr samples of rifampicin undergo degradation [91], so a decrease in RF content 
was to be expected. However, as specific surface areas are expected to be higher in the 
samples spray dried from water and as oxidation to RF-quinone is reported as one of the 
major routes of degradation [89], a more rapid degradation was expected. Also, RFaqCryst1 
showed significant degradation over the six months period of storage. This was unexpected as 
it was assumed that crystalline samples would be stable. As no further characterization of the 
degradation products was performed, the mechanism of degradation remains unclear. One 
might hypothesize that O2 triggered oxidation, or hydrolysis to 3-formyl Rifamycin SV might 
have occurred [89]. As all samples contained significant amounts of water and were not stored 
under an inert atmosphere, it is possible that this might have created a microenvironment 
facilitating both routes of degradation. Ambient air not only provides O2 for oxidation, but 
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also CO2, which might have interacted with the water, providing protons for acid catalyzed 
hydrolyzation. As FPFs of samples spray dried from aqueous solutions were shown to be 
fairly robust to the solid content of the feed solution, it is expected to be feasible to 
incorporate antioxidizing or buffering excipients into the formulation, without decreasing its 
aerosol performance. Especially as it is assumed that, due to the high molecular weight of RF, 
already small amounts might be effective. But, one must keep in mind that during the 
manufacturing process phase separation (RF and antioxidizing agent) might occur, limiting 
the protective effect. It was shown that storage at low temperatures successfully protects all 
formulations from degradation. However, it is not desirable to keep the potential product 
refrigerated, as countries with the highest demand for improved TB therapy often lack 
suitable infrastructure to ensure product stability upon transport and storage (also see 
introduction, 1.4.1). Another approach to prevent degradation would be to keep the dry 
powders protected from ambient gases using inert atmosphere packing. As these formulations 
are intended for use in single use, disposable low cost DPIs, these could be individually 
blistered, and could provide sufficiently high protection of the product.  
 
To summarize, formulations investigated in this section show excellent aerosol properties, 
making them interesting candidates for application using a low-cost disposable DPI. In anti-
infective airways therapy, single use devices are preferred as they minimize the risk of 
infections of medicinal staff, family members, or other groups of persons possibly exposed to 
contaminated inhalers. As of now, the formulations suffer from chemical instability, but 
different approaches have been discussed to optimize either the formulation itself or storage 
conditions applied in a way that would provide a higher stability. The following studies on 
these formulations should focus on improvement of the chemical stability, as well as 
characterization of aerosol performance from devices with dose compartments of higher 
volumes, to investigate what the maximal applicable dose of this formulation is. It is also of 
interest to investigate in vivo deposition of the particles. This is not only relevant in the 
context of developing a novel inhalable TB therapy but also because formulations described 
in this chapter offer an excellent system to test the hypothesis that particle showing a dae 
lower than one µm are being exhaled, which is generally assumed. 
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5 General discussion and outlook 
 
The present work touches on two distinct, but related topics i.e. the development of an 
improved in vitro model to predict aerosol lung deposition in vivo, and the development of a 
particle engineered, excipient free formulation of rifampicin to be used in the context of 
tuberculosis therapy. Aerosol analysis using the improved model was eventually applied to 
formulation candidates investigated, providing more biorelevant assessment of their 
aerodynamic properties. Following, both topics will be discussed separately including a 
discussion of the main findings, their context in literature as well as an outlook. 
 
5.1 Development of a novel, 3D printed induction port for use in cascade impactor 
analysis 
 
Analysis using cascade impaction devices is the most relevant method to describe 
pharmaceutical aerosols. Knowledge of the aerodynamic properties of a formulation is not 
only important in the context of reproducible manufacture, but can also be utilized to predict 
aerosol deposition in vivo. Particles of different aerodynamic diameter, deposit in 
anatomically different locations of the human respiratory system. It is widely accepted that 
particles showing an aerodynamic diameter of one to five µm effectively target the lungs. 
Larger particles are likely to impact in the upper respiratory system, whereas smaller particles 
might be exhaled [16]. The Next Generation Pharmaceutical Impactor is a cascade impaction 
device that was distinctively designed in the early 2000s to meet the needs associated with 
aerosol analysis of pharmaceutical aerosols. Nevertheless, the main focus of the developing 
consortium was on providing highly standardized testing equipment for QC and industrial 
manufacture. As a consequence, the NGI as monographed in USP and Ph.Eur. lacks 
physiological accuracy, which compromises its ability to be used as predictive tool in IVIVC 
[72]. Especially its induction port, which is a tube of uniform cross sectional diameter, a 90° 
bend and tapered ends, is seen as one of the major issues of the NGI, when IVIVC is desired. 
Consequently, much effort has been made to develop more realistic mouth/throat models and 
geometries utilized have been derived from MRT/CT images, observations on patients, or 
191 
5. General discussion and outlook 
 
casts [74–78]. Advanced MT models have been prepared using resin, rubber, or fiber glass 
[75-77], as well as rapid prototyping techniques, such as fused deposition modeling (FDM) 
[78]. Main focus of these studies was on MT deposition, rather than its impact on the 
aerodynamic particle size distribution and the models often times were tested individually, i.e. 
not using the NGI, or another CI. Contrary, the most extensively studied MT model (Alberta 
idealized throat, AIT) is commercially available as a substitute induction port for use with the 
NGI. This model is based on patient data, which have been idealized and compiled into an 
extrathoracic mouth/throat model, based on simple, geometries. It is available in two different 
versions, representing the averaged adult and the averaged child respectively. These models 
are manufactured from stainless steel, and are not intended to be modified in order to adapt 
for pathophysiological alterations of the respiratory tract, special patient populations e.g. pre-
school children, or a completely individualized approach.  
In the present work we presented a novel, modified induction port (mIP) that was based on a 
computer tomographic scan of a trachea that was obtained from an open access database. 
FDM 3D printing technique, which, in context of personalized medicine, had gained a lot of 
attention over the past few years, was used as rapid prototyping technique. It has been shown 
that FDM 3D printing using PLA filament is a suitable technique to produce modified 
induction port models that were found to fully comply with USP and Ph.Eur. requirements in 
terms of air tightness and flow stability. Also it was shown that FDM 3D printing produces 
the models in a reproducible quality. To assess the impact of the material used, all 
formulations investigated were also tested on a 3D printed copy of the regular USPIP, and 
only the nebulized formulation (Sultanol forte) showed a statistically significant increase in 
deposition. Conclusively, it was found that surface properties in this experimental setup play a 
minor role only, which is in good agreement with a study conducted using the AIT, where 
coating the IP’s walls with different materials had been shown to not affect the outcome of the 
aerosol analysis [73]. In order to understand which formulation strategy produces aerosols 
showing increased tracheal deposition, commercial preparations of salbutamol formulated as 
pMDI (with and without VHC), DPI, and solution for nebulization were assessed using the 
novel IP. DPI and nebulized formulations, as well as the pMDI with VHC were found not to 
benefit from alterations of the IP. In the case of the DPI this was due to a decrease in 
preseparator deposition that corresponded to an increase in IP deposition. So, though 
increased IP deposition was observed, cumulative IP and preseparator deposition was found 
unaffected which consequently translated into equivalence of the aerosol characteristics 
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determined, using the USPIP and the mIP respectively. In the case of the nebulized 
formulation, IP deposition was found to be low in all cases, so that the impact of modifying 
the IP was found to be irrelevant in a therapeutic context. Contrary, the pMDI formulation 
assessed showed increased IP deposition using the mIP, which translated into lower fine 
particle fractions (being the fraction of the dose with an aerodynamic diameter ≤ five µm). 
CFD studies confirmed that basing the IP model on physiologically relevant geometries 
produces significantly different airflow patterns, when compared to the regular USP IP, which 
can aid to explain the increased deposition observed. In order to distinguish between 
increased deposition caused by physiological relevant and artificial geometries respectively, 
another modified induction port was designed. This model shows a greater distance of the 
actuator valve from the 90° bend and allows plume expansion. Tests with additional, 
commercially available pMDI formulations showed that different particle populations tend to 
impact in different areas of the MT and that pMDI formulation performance is negatively 
correlated to MT deposition. A specific pMDI formulation strategy - suspending the API 
particles in the propellant - was shown to be more susceptible to MT deposition than solution 
based pMDIs, which show a higher performance in general.  
To assess the suitability of the novel IP model for IVIVC, additional pMDI formulations were 
selected based on availability of in vivo deposition data in literature, and assessed using the 
mIP as well as the mIPext (mIP with USP distal part). It was found that IVIVC is superior 
using the mIP instead of the USPIP. Interestingly, it was also found superior to the one 
achieved using the mIPext, highlighting the need to include an (more sophisticated) oral 
cavity model into the future makes of the model. IVIVC was also found superior, to one 
achieved using the AIT but as this conclusion was based on literature review it must be 
evaluated as indicative only.  
As already mentioned, as a next step in the development of this model, an oral cavity model is 
to be included. Geometries should be derived from CT scans as well, but it is also to be 
investigated if exact geometries of the individual patient are as critical as it was found in the 
case of the trachea, or if an idealized geometry offers the same information for the researcher. 
In later studies the model could be utilized to investigate aerosol deposition in special patient 
populations e.g. children of different age, the elderly, or patients showing pathophysiological 
alterations of the respiratory tract. Additionally, it could also be used to optimize device use in 
clinical practice, as e.g. the effect of different head positions on aerosol deposition could 
easily be investigated without the need to perform clinical trials. As literature e.g. indicates a 
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strong impact of the pMDI spray angle on particle deposition [167], a certain relevance is to 
be expected here. 
 
5.2 Development of excipient free dry powder formulations of RF  
 
Despite all efforts, tuberculosis infection is still one of the leading causes of death in the 
world. It is caused by the gram-negative bacterial species M.tuberculosis and primarily infects 
the lungs, though secondary systemic infections may occur. In routine therapy, four first line 
antibiotics, namely rifampicin, ethambutol, pyrazinamide, and isoniazid are applied and the 
standard therapy includes per oral administration of aforementioned substances over a period 
of at least 26 weeks. In the case of RF, it is often accompanied with unwanted side effects, 
which is related to the high daily doses needed to achieve suitable drug concentrations at the 
site of infection i.e. the lungs. In order to decrease systemic exposure - which is expected to 
limit side effects and increase patients’ adherence - a respirable dosage form of RF is 
desirable. Development of particle engineered dry powder formulations for pulmonary 
therapy started in the early 2000s. Since then, numerous studies have been published focusing 
on different aspects of a potential therapeutic strategy. One approach that has been widely 
investigated is the formulation of micro- and nanoparticulate systems to proactively target 
alveolar macrophages, which host the bacteria in infected tissue. Different classes of 
excipients including PLGA, lipids, chitosan, or modified carbohydrates have been 
investigated as potential matrix forming system but in most cases issues with aerosol 
performance, drug loading, or drug stability are potential drawbacks. Another approach is the 
development of high drug load, excipient free formulations. This approach aims to provide 
high concentrations of the API in the lungs, as the maximum dose applicable using traditional 
formulation strategies, i.e. formulating as interactive blend, is limited to a few mg. Contrary, 
particle engineered formulations can be optimized in a way that delivery of up to about 50 mg 
(and maybe more) per dose becomes accessible. In 2011, Son and McConville had reported a 
first formulation strategy for the manufacture of a high drug load, excipient free formulation 
[91]. In this approach, RF was recrystallized from ethanol and subsequently spray dried, 
which yielded a RF solvate of unique, flake like shape that was characterized as dihydrate and 
showed excellent aerosol properties and good stability. Anyways, from that publication it was 
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unclear how the dihydrate was formed and at which step the water was introduced into the 
system. Two solvent free polymorphs, as well as numerous hydrates and solvates of RF are 
reported in literature and it was hypothesized that recrystallizing RF from other solvents 
might produce particles with enhanced aerosol properties. Thus, one aim of the present work 
was a) to explore, if other common solvents could be utilized in a similar manner as ethanol 
and b) clarify the solid state characteristics of the RF dihydrate. Suitable candidates for 
investigation were screened in an exploratory study, in which RF was recrystallized from 
ethanol, methanol, IPA, acetone, DCM, and water at two API to solvent ratios. Additionally, 
equilibrium saturated solutions of RF in all solvents mentioned were spray dried, as a control. 
Distinct polymorphs (XRPD) were found for samples recrystallized from ethanol, methanol, 
and water. Except of samples spray dried from water, all solutions yielded amorphous, 
spherical, slightly collapsed particles. Contrary, spray drying of watery solutions of RF 
yielded highly collapsed, amorphous particles of exceptionally high fine particle fractions, 
when dispensed from common inhalation devices. Best performing (NGI) formulations 
showing distinct X-ray pattern as well as the best performing amorphous formulations were 
repeated and investigated more detailed.  
DVS, GC, KF, and XRPD experiments revealed that RF samples recrystallized from ethanol 
as well as ones recrystallized from methanol belong to one isostructural series of solvato 
polymorphs, in which guest molecules were found to be inter-changable, depending on the 
ambient conditions applied. This was found in good agreement with literature. In a study 
published by Li [92], RF was recrystallized from several mixtures of solvents and it was 
shown to form different channel solvates. This result has recently been confirmed and 
extended by Wicher et al. [95]. Application of these finding on results obtained investigating 
the samples recrystallized from methanol and ethanol yielded a good model to explain the 
observations made. Based on the results presented in this work in context of the literature 
available, one must conclude that the solvent gravimetrically quantified in the study by Son 
and McConville might be ethanol, water, or - most likely - a mixture thereof. Ethanol would 
be present from the manufacturing process, whereas the water would have been introduced 
from ambient moisture, subsequently replacing the ethanol molecules. Samples recrystallized 
from water were identified as member of another isostructural group of RF solvates and were 
found to be related to a RF  0.54 EtOH  3.92 H2O solvate reported by Li [92], a RF 
pentahyhdrate reported by Gadret et al. [93], and a RF monohydrate reported by Henwood et 
al. [90]. All formulations showed good aerosol properties yielding FPFs from 30 - 40%. It is 
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to be mentioned though that samples were treated in a conservative way in order to maintain 
their original solid state and formulations have not been optimized for aerosol properties, so it 
appears reasonable to assume that significantly higher FPFs could be achieved using this 
formulation strategy. Amorphous control formulations manufactured by spray drying 
solutions of RF in IPA yielded FPFs in the same range. Contrary, spray drying of solutions of 
RF in water produced ultra fine powders, yielding FPFs of up to 90%, using the Handihaler 
DPI. These formulations were also tested using a low cost, low performance, disposable DPI 
surrogate, in order to investigate what minimal requirements are to be met by the DPI, in 
order for these formulations to display acceptable performance. It was shown, that this type of 
formulation demands little performance of the DPIs de-agglomeration engine, supporting the 
hypothesis that it is suitable for application using a low cost, low performance device. 
Additionally, it was found that using this model offered a higher degree of discriminability in 
that high FPF range, when compared to the Handihaler. A similar type of particles had already 
been reported by Chan et al., who spray dried a hydroalcoholic solution of RF. To understand 
why spray drying from water yielded drastically different particles, when compared to e.g. 
ones spray dried from ethanolic solutions of about the same concentration, the mechanism of 
particle formation was investigated using an acoustic levitator. It was found, that in this 
system RF forms a shell at an early stage of droplet evolution that decouples from the liquid 
core and eventually collapses into a highly corrugated, low density particle. The mechanism 
proposed is in good agreement with data published by Chan et al. and other groups using the 
same approach, which had, based on ToF - SIMS and XPS experiments, concluded that RF 
accumulates at the particle surface. Due to their excellent aerosol properties, these particles 
are good candidates for use in a single use disposable DPI product. Additionally, this 
mechanism could be exploited in a platform technology to produce high efficiency aerosols, if 
a physiologically neutral excipient showing similar interfacial behavior could be found. 
Anyways, stability studies revealed that all formulations except the one recrystallized from 
ethanol show limited chemical stability only, though stability of the aerosol performance was 
found to be good. In the case of the amorphous formulations, incorporating protective agents 
might increase their chemical stability. In the case of crystalline formulations, suitable storage 
conditions i.e. refrigerated storage under N2 atmosphere could increase the shelf life of these 
powders. As formulations recrystallized from MeOH or water offer no benefits over 
formulations recrystallized from ethanol but show impaired stability, the RF ethanol/water 
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solvate would be the polymorph of choice to proceed with. Future studies could include 
optimiziation of the particles in terms of aerosolizability and macrophage uptake.  
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8.1 List of mathematical and physical descriptors 
Descriptor Explanation Unit 
Cae Cunningham slip correction factorreference [] 
Cp Cunningham slip correction factor sample [] 
dae Aerodynamic diameter µm 
deq(area) 
 
Diameter of a sphere with equivalent backlight image 
area as the particle of interest. µm 
dgeo Geometric diameter  µm 
EF Emitted fraction % 
FEV1 Forced expiratory volume in one second L/s 
FPF Fine particle fraction % 
FPFemitted Fine particle fraction of the emitted dose  % 
FPFtotal Fine particle fraction of the total dose  % 
FVC Forced vital capacity L 
GSD Geometric standard deviation [] 
KGBW Kilogram bodyweight kg 
LOD Loss on drying % 
MMAD Mass median aerodynamic diameter µm 
NCMH Normal cubic meter per hour m3/h 
RH Relative humidity % 
ρae Density (reference) g/cm3 
ρp Density (particle) g/cm3 
χ Shape correction factor [] 
 
Please note that units presented are not necessarily compliant with the SI system and reflect 
their use in context of this work. 
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8.2 List of abbreviations 
ACI Andersen cascade impactor 
ACT Disposable inhaler model  
AL Acoustic levitation 
aNGI Abbreviated NGI 
API Active pharmaceutical ingredient 
aPSD Aerodynamic PSD 
CFC Chlorofluorocarbon 
CFD Computational fluid dynamics 
CI Cascade impactor 
CLSM Confocal laser scanning microscopy 
COPD Chronic obstructive pulmonary disease 
CT Computer tomography 
CYP Cytochrome P-450 
DSA Drop shape analysis 
DCM Dichloromethane 
DPI Dry powder inhaler 
DSC Differential scanning calorimetry  
DVS Dynamic vapor sorption 
EtOH Ethanol 
FDA US food and drug administration 
FDM Fused deposition modeling 
FI RF form I 
FII RF form II 
HBβCD Highly branched β-cyclodextrin 
HFA Hydrofluoroalkane 
HPLC High performance liquid chromatography  
ICH International Conference on Harmonization 
IgE Immunoglobulin E 
INH Isoniazid 
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IP Induction port 
IPA Isopropyl alcohol 
IVIVC In vitro / in vivo correlation 
MeOH Methanol 
mIP Modified IP 
MOC Micro orifice collector 
MP Microparticle 
MRT Magnetic resonance tomography 
MSLI Multi stage liquid impinger 
MT Mouth/throat 
NCMH Normal cubic meters per hour 
NGI Next Generation Pharmaceutical Impactor 
NP Nanoparticle 
Ph.Eur. European pharmacopoeia 
PLA Poly - (D,L-lactic acid)  
PLGA Poly - (D,L-lactic-co-glycolic acid)  
pMDI Pressurized metered dose inhaler 
PSD Particle size distribution 
PVA Polyvinylalcohol 
QC Quality control 
RF Rifampicin 
Sx Stage x of the NGI 
SAL Salbutamol 
SDr Spray dried 
SEM Scanning electron microscope 
TB Tuberculosis 
TGA Thermogravimetric analysis  
ToF - SIMS Time of flight – secondary ion mass spectrometry  
USP United states pharmacopoeia 
VHC Valved holding chamber 
XPS X-ray photoelectron spectroscopy  
XRPD X-ray powder diffractometry  
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